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Abstract
The epithelial cell-extracellular matrix interface primarily comprises of complex glycans
and glycoconjugates. The widespread distribution of these glycans on the epithelial cell
surface makes them ideal targets for interaction with microbial pathogens. In this thesis, a
framework of integrated approaches was developed to characterize the structure-function
relationships of host cell surface glycans and examine their role in mediating host-
pathogen interactions. The first part of the thesis involves a study of the effect of secreted
bacterial sphingomyelinases on the epithelial cell surface proteoglycan (a large glycan-
protein conjugate), syndecan-1 and on epithelial tight junctions. The findings presented in
this work suggest mechanisms by which sphingomyelinases could enhance bacterial
virulence by regulating epithelial cell function. The second part of the thesis investigates
the glycan binding requirements that govern the human adaptation and transmission of
influenza A viruses by characterizing the molecular interactions between sialylated
glycan-receptors and viral hemagglutinin (HA). The study puts forth the concept that the
topology or shape (going beyond the chemical c2-3 versus a2-6 sialic acid linkage)
adopted by the sialylated glycans is the critical determinant for efficient human
adaptation of these viruses. In conclusion, this thesis provides insights into the molecular
mechanisms of host-pathogen interactions and enables development of improved
strategies for targeted antimicrobial therapies.
Thesis Supervisor: Ram Sasisekharan
Title: Professor of Biological Engineering and Health Sciences and Technology
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Chapter 1
Glycans in host-pathogen interactions.
Summary
Complex polysaccharides or glycans are major components of the cell surface and extra
cellular matrix of epithelial cells. Cell surface glycans and their conjugates play a crucial
role in diverse physiological functions. Besides, these glycans mediate the host-pathogen
interactions of several bacteria, viruses and parasites by interacting with various
microbial glycan binding proteins. An examination of the mechanisms by which glycans
play a role in microbial pathogenesis requires the development of integrated approaches
to characterize the structure-function relationships of the complex cell surface glycans.
The first section of this chapter reviews the current knowledge of the roles of cell surface
glycans and glycoconjugates in promoting microbial pathogenesis. The next section
discusses the integrated approaches developed to study the complex structure of glycans
and their interactions with microbial proteins. The final section describes the design and
development of glycans as therapeutic strategies for microbial infections.
1.1 Glycans
The extracellular matrix (ECM) is a complex milieu comprising primarily of
proteins and polysaccharides. These polysaccharides or glycans are mainly distributed on
the cell surface and cell-matrix interface in the form of conjugates with proteins and
lipids which include glycoproteins, proteoglycans and glycolipids [1, 2]. Glycans are
highly complex and heterogeneous polymers that can be classified on the basis of their
structure as linear or branched sugars. Linear polysaccharides, which mainly include
glycosaminoglycans (GAGs), are either present in free form in the ECM or are O-linked
to proteins to form cell surface glycoconjugates called proteoglycans. The members of
this unbranched family of glycans include heparan sulfate, chondroitin sulfate, dermatan
sulfate, keratin sulfate and hyaluronic acid [3]. Branched glycans, which are the
oligosaccharide components of glycoproteins, may be 0-linked to a Ser/Thr amino acid
residue of the peptide backbone or N-linked to an Asn residue of the peptide [1].
Branched glycans may also be attached to the lipid components of plasma membranes to
form conjugates known as glycolipids [2] (Figure 1.1).
Monosaccharides, which are linked to form either linear or branched sugar chains
by the different glycosidic linkages, constitute the basic building blocks of glycans [2].
The sequential action of several enzymes such glycosidases and glycosyltransferases,
enables the assembly of the glycans from these basic structural units [4]. This non-
template enzymatic biosynthesis of complex polysaccharides contributes to the
microheterogeneity of these biomolecules. Moreover, each of the monosaccharide units
can undergo a variety of chemical modifications, such as sulfation, fucosylation etc,
which add to the diversity of these glycans [1, 3]. This heterogeneous chemical structure
N-linked Proteoglycan Glycolipid 0-linked
glycoprotein glycoprotein
o Glucose O Galactose 0 Mannose U N-Acetylglucosamine * Sialic acid
0 N-Acetylgalactosamine 4 Glucuronic acid $ Iduronic acid * Xylose
Figure 1.1: Examples of cell surface glycans and glycoconjugates. Glycans are classified into two groups
on the basis of their structure - linear sugars and branched sugars. Linear sugars form cell surface
glycoconjugates known as proteoglycans. Branched sugars are further classified based on their covalent
linkages to the core glycoprotein. While N-linked glycans are attached to the asparagine residues in
glycoproteins, 0-linked glycans are bound to serine/threonine residues of the glycoproteins. Branched
glycans are also the major carbohydrate components of glycolipids wherein the glycans are attached to the
lipid components in the plasma membrane.
........ ..................
of glycans and their widespread distribution on the cell surface, make them well
positioned to interact with diverse proteins including growth factors, enzymes, microbial
factors and other ligands at the cell-ECM interface. Through these interactions, glycans
and their conjugates regulate several cellular processes such as cell growth and
differentiation, cell-cell signaling and cell adhesion; and pathophysiological processes
such as tumor invasion and metastasis and immune response. Also, there is an emerging
role for glycans and glycoconjugates in microbial pathogenesis and invasion [5-7].
This chapter reviews the current knowledge of the role of glycans and
glycoconjugates in host-pathogen interactions, by means of their functional interactions
with microbial factors.
1.2 Role of glycans in microbial pathogenesis
Various bacteria, viruses and parasites utilize cell-surface glycans or
glycoconjugates to promote their pathogenesis. In most cases, the microbial factors that
interact with the glycans or glycoconjugates have been identified. Some of the bacterial
strains that interact with glycans and glycoconjugates to enhance their virulence are
Helicobacter Pylori, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus
anthracis, Mycobaterium tuberculosis, Borrelia burgdorferi, Chlamydia trachomatis, and
Bordetella pertussis. The viruses that utilize cell surface glycans and glycoconjugates as
attachment sites to promote cell entry include Influenza A viruses, Herpes simplex virus,
Foot and mouth disease virus, HIV, Cytomegalovirus and Dengue virus. Also, parasites
such as Plasmodium falciparum, Leishmania amazonensi also utilize glycans and
glycoconjugates to invade host cells. The mechanisms by which glycans and
glycoconjugates promote microbial pathogenesis have been the subject of many studies
and are discussed in the following sections.
1.2.1 Bacterial pathogenesis
In order to enhance their virulence, bacterial strains exploit the cell surface
glycans and glycoconjugates by one of the following three mechanisms: (i) By utilizing
glycans and glycoconjugates as attachment sites or receptors for binding to host cells (ii)
By utilizing glycans and glycoconjugates as co-receptors to trigger down-stream
signaling events that promote bacterial invasion and colonization (iii) By ectodomain
shedding of cell surface heparan sulfate proteoglycans to enhance their virulence. These
interactions between the bacterial strains and host cells are mediated by their virulence
factors, which include bacterial adhesins and secretory toxins (Figure 1.2).
Adherence to host cell surface is a crucial first step in the colonization of bacterial
pathogens in host tissues. Several bacterial pathogens produce adhesins, which are glycan
binding proteins that facilitate the attachment of the bacteria to host cell surface
glycoconjugates [8]. One example where the role of the adhesin in bacterial pathogenesis
has been extensively characterized is Helicobacter pylori, the gram negative bacterium
which causes gastritis, peptic ulcers and gastric cancers. Studies have shown that the
adhesin produced by the pathogenic bacteria, blood group antigen binding adhesin
(BabA), specifically recognizes and binds to the Lewisb blood group antigen, with the
oligosaccharide sequence [Fuca 1 -2]Galp1 -3 [Fucal -4]GlcNAcp1 -3 Gal- [9-11]. This
oligosaccharide sequence is extensively expressed on the surface of gastric epithelial
U )j )
S r .) Q screted toxins
A B C D E
Figure 1.2: Glycans in host-pathogen interactions. (A) Glycan binding proteins on the surface of viruses
enable their attachment to host cell surface glycans. Viruses such as influenza A viruses utilize glycans and
glycoproteins as entry receptors to infect host cells. Bacteria exploit cell surface glycoconjugates to
enhance their virulence by three mechanisms. (B) Bacterial strains produce glycan binding proteins called
adhesins that facilitate binding and subsequent invasion of host cells. Examples of strains that use glycans
as entry receptors include H. pylori and E. coli. (C) Bacteria can also utilize cell surface glycoconjugates as
co-receptors for mediating invasion into host cells. For example, during N.gonorrhoeae pathogenesis, the
glycoconjugates serve as the initial binding sites for the bacterial adhesins and this binding event enables
bacterial invasion through a second entry receptor. (D) An alternate mechanism by which bacteria enhance
their virulence is by secreting virulence factors or toxins that trigger accelerated shedding of cell surface
heparan sulfate proteoglycans. Examples of bacterial pathogens that facilitate the release the ectodomains
of proteoglycans include P. aeruginosa and B. anthracis. (E) Several parasites such as P. falciparum and
L. amazonensi utilize glycans as invasion receptors to gain entry into host cells.
.................. ... ......... : : .......... .... .. .. ..... . . ... . .... - - - :... :
cells and thus functions as an entry receptor for this bacterial pathogen [9]. Interestingly,
H. pylori also produces another adhesin, sialic-acid binding adhesin (SabA), which
specifically binds to the glycosphingolipid, sialyl-dimeric-Lewis x antigen [11, 12]. This
sialylated glycolipid is believed to serve as an additional receptor for binding of the
bacteria and thus it plays a role in enhancing bacterial virulence [12].
Bacterial strains produce multiple adhesins which differ in their glycan binding
specificities. Therefore, these adhesins not only facilitate invasion and colonization of the
bacterial strains but also contribute to the determination of the tissue tropism of these
pathogens [8, 13]. For example, Escherichia coli strains are capable of colonizing
intestinal, bladder and kidney epithelium presumably due to the production of multiple
adhesins or fimbriae [14], which recognize specific oligosaccharide components of
glycoprotein and glycolipid receptors expressed in the different tissue-types. The crystal
structures of some of the E. coli fimbrial adhesins with glycans have been solved and this
structural data provides valuable insights into the interaction between the adhesins and
glycans [15].
Certain pathogenic bacteria use glycans and their conjugates as co-receptors for
mediating invasion into host cells. One example is the bacterial pathogen Neisseria
gonorrhoeae which binds to cell surface proteoglycans, particularly the members of the
syndecan family (syndecan-1 and -4). This binding is facilitated by the bacterial adhesin,
OpaA that binds to heparan sulfate side chains of the proteoglycans [16]. However, the
attachment of bacteria to the syndecans has been shown to be insufficient for bacterial
invasion of human epithelial cells. Interestingly, studies have shown that the heparan
sulfate proteoglycans act as co-receptors by binding to OpaA and mediate the entry of the
pathogens into the cells through the integrin receptors in a fibronectin dependant manner
[17].
Shedding of cell surface heparan sulfate proteoglycans is an alternate mechanism
by which bacteria utilize glycoconjugates to promote their pathogenesis [18]. Indeed,
bacterial pathogens such as Pseudomonas aeruginosa and Bacillus anthracis secrete
virulence factors that result in accelerated shedding of the cell surface heparan sulfate
proteoglycan syndecan-1[19-21]. Syndecan-1 shedding is the proteolytic release of the
ectodomains of the proteoglycans mediated by sheddases which are thought to be
members of the metalloproteinase family [22, 23]. Recent studies have shown that this
mechanism of accelerated shedding of syndecan-1 caused by these bacterial virulence
factors enables invasion and colonization of the bacterial pathogens in host epithelium
[19, 21].
Finally, several secreted toxins, which bind to glycoproteins and glycolipids, also
contribute to the pathogenesis of the bacteria. The classic example of this process is the
cholera toxin secreted by Vibrio cholerae, which binds to the Gmi ganglioside, Galpl-
3GalNAcp1-4[Neu5Aca2-3]Galpl-4glcpl-ceramide, expressed on the surface of
enterocytes. The secreted cholera toxin has two subunits A and B, of which B binds to the
oligosaccharide moieties following which subunit A is inserted into the cells. This
process triggers a series of intracellular signaling events that eventually result in the
efflux of water and ions leading to diarrhea [24]. Therefore, even though these secreted
bacterial glycan binding toxins do not mediate pathogen binding to host cells, they can
directly contribute to the pathogenesis of bacterial infections.
1.2.2 Viral pathogenesis
Cell surface glycans and glycoconjugates function as receptors or co-receptors for
several viral surface proteins and thus facilitate the entry of viruses into host cells
(Figure 1.2). The most extensively characterized microbial glycan binding protein is the
influenza A and B virus coat protein, hemagglutinin. The binding of hemagglutinin to
sialylated glycan receptors on host epithelial cell surface is the critical first step in the
entry of the virus into the host epithelial cells. Crystal structures of different subtypes of
influenza A virus hemagglutinin (HA) and sialylated glycans have been solved and the
interaction between the two molecules has been the subject of extensive biochemical
characterization. Such elaborate analyses have shown that HAs isolated from human
viruses preferentially bind to a2-6 linked sialylated glycans (Neu5Aca2-6Galpl-
3GlcNAc), while HAs from avian sources bind to a2-3 linked sialylated glycans
(Neu5Aca2-3Galpl-3GlcNAc) [25, 26]. The cross species transmission of the viruses
from avian to human host is believed to be associated with mutations in the HA that
switch the binding specificity of the HA from a2-3 linked sialylated glycans to a2-6
linked sialylated glycans. Thus, the binding of HA to sialylated glycans not only mediates
the entry of influenza A viruses into host epithelial cells but also determines the host
range of influenza A viruses [27, 28]. Influenza C viruses, on the other hand, express a
protein called hemagglutinin esterase that specifically binds to 9-0-acetyl-neuraminic
acid to gain entry into host cells [29]. It is interesting to note that all types of influenza
viruses (A, B and C) exploit the host cell surface glycans not only for cellular entry but
also during the release of progeny viruses from host cells [30]. In this stage, a viral
surface coat protein with a receptor destroying function (sialidase activity), interacts with
and cleaves the glycans from the cell surface thus facilitating the release of newly formed
viruses. In the case of influenza A and B viruses, this protein is called neuraminidase and
in the case of influenza C viruses the hemagglutinin-esterase itself functions as both the
receptor binding and the receptor cleaving protein [31].
Viruses such as herpes simplex virus 1 (HSV-1) use heparan sulfate
proteoglycans as co-receptors for initial binding. These viruses express five viral
envelope glycoproteins one of which, gC, binds to host cell surface heparan sulfate.
Subsequently, another glycoprotein, gD, binds to its protein receptor on the cell surface
[32]. This results in the interaction of the other viral glycoproteins with the host
membrane ultimately causing a fusion of the viral and the host cell membranes and thus
facilitating viral entry[32, 33]. Studies with another virus, the Human Immunodeficiency
Virus (HIV-1) demonstrated that cell surface heparan sulfate plays the role of the co-
receptor that is responsible for the initial binding event in CD4- T-cells [34, 35]. Further
studies have shown that this binding to heparan sulfate is mediated by the viral surface
glycoprotein, gp120 [34]. Subsequent cellular entry of the virus is facilitated by
chemokine receptors [36].
1.2.3 Pathogenesis ofparasitic infections
Parasites such as Plasmodium falciparum and Leishmania amazonensi rely upon
cell surface glycans to adhere to and invade host cells (Figure 1.2). P. falciparum, the
parasite that causes malaria, invades human erythrocytes utilizing a number of invasion
pathways mediated by complex ligand-receptor interactions [37]. One such mechanism
involves the binding of the parasite to glycophorin A, a sialylated glycoprotein
extensively expressed on the surface of human erythrocytes. Further characterization
revealed that a P. falciparum protein EBA-175 (erythrocyte binding antigen) mediates
invasion by specifically binding to a terminal Neu5Aca2-3Galp- sequence, which is the
major glycan component of glycophorin A [38]. In the case of certain strains, another
sialic acid sialylated glycoprotein, glycophorin B, has been identified as the invasion
receptor [39]. Subsequently, sialic acid independent pathways for invasion have also been
identified [40].
1.2.4 Approaches to examine the role of host glycans in microbial pathogenesis
Defining the biological role of glycans and glycoconjugates in host-pathogen
interactions requires an in-depth characterization of the structure and composition of
glycans on the surface of host cells and an examination of their interactions with diverse
cellular and microbial proteins. This has proven to be a difficult task due to the
challenges involved in the characterization of the structure-function relationships of these
complex carbohydrates. The analysis of the structure of glycans is complicated primarily
due to their extensive diversity and chemical heterogeneity. The presence of
oligosaccharide branches poses additional challenges while dealing with N-linked and 0-
linked glycans. Furthermore, the complexity of developing approaches for synthesis and
amplification of cell surface glycans, limit the availability of material for any structural
characterization [3]. An additional layer of complexity of studying the protein-glycan
interactions, is the inherent multivalent nature of these interactions [41].
The above challenges necessitate the development of integrated approaches to
enable the study of the structure-function relationships of host cell glycans and their
interactions with microbial proteins. These integrated approaches have helped
glycobiologists to elucidate the mechanisms by which glycans regulate the diverse
biological processes, including the pathogenesis of microbes.
1.3 Integrated approaches
Several technologies and tools have been developed to characterize the structure
of these complex glycans and to examine their multivalent interactions with glycan
binding proteins. Approaches that systematically integrate these diverse and yet
complementary set of technologies have greatly enhanced our understanding of glycan
structure-function relationships (Figure 1.3). Such integrated approaches involve a
characterization of the structure and composition of cell surface glycans, an in-depth
analysis of the complex interactions between proteins and defined glycan structures and
the examination of the functional role of these interactions in biological processes
including microbial pathogenesis [3] (Figure 1.3).
1.3.1 Characterization of the structural diversity of glycans
Analysis of structure and composition of the complex glycans has traditionally
been a challenging task. However, the recent advances in development of (i) sensitive
analytical tools and (ii) biochemical approaches have overcome a majority of these
challenges and have enabled the accurate profiling of the glycan components of
glycoproteins, serum, cell surface and even tissues. The analytical techniques used to




Figure 1.3: Development of integrated approaches to study the structure-function relationships of
glycans. Analysis of the role of glycans in host-pathogen interactions requires an in-depth understanding of
the structural features of host cell surface glycans and the functional interactions of microbial glycan
binding proteins with glycans with these unique glycan moieties. Tools such as mass spectrometry (MS)
and lectin histochemical analysis enable the profiling of the glycans on host cells. Biochemical
characterization using techniques such as analysis of co-crystal structures and glycan arrays are critical for
studying the interaction between microbial proteins and glycans. Finally, data from all the above
technologies is integrated using bioinformatics based platforms. Such integrated approaches not only
enable a study of the mechanisms by which glycans mediate host-pathogen interactions but they also
facilitate the development of additional strategies for glycan based therapeutics, vaccines and diagnostics
for infectious diseases.
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sequence of the complex glycans. The biochemical approaches include characterization
of antibodies and lectins that bind to specific di- or tri-saccharide sequences. These
biochemical approaches are extremely useful tools for identification of glycans and their
conjugates, especially on the surfaces of cells and tissues.
Analytical techniques:
Characterization of the cell surface glycans and glycoconjugates is a stepwise process
that requires isolation of the glycans from cell surface or from tissues, purification and
profiling and sequencing of the glycans. Glycans can be released from cell surfaces either
by use of highly specific enzymes, such as PNGase F that releases N-glycans from cell
surface or by chemical methods such as reductive elimination. The released glycans are
then purified and analyzed by one of the several techniques including capillary
electrophoresis (CE), liquid chromatography, mass spectrometry (MS) and nuclear
magnetic resonance spectroscopy (NMR) [1, 2].
Of these techniques, mass spectrometry has emerged as an invaluable tool for
sensitive and high-throughput analyses of the glycan mixtures isolated from cells and
tissues [42]. The MS tools including matrix assisted laser desorption ionization-MS
(MALDI-MS) and electrospray ionization-MS (ESI-MS) provide a mass profile for the
entire set of glycans obtained from cell surfaces and tissues [42, 43]. Using automated
algorithms, each peak in the mass spectra is annotated with the most probable glycan
structures [44, 45]. Further fragmentation of ions using MS/MS techniques can be used to
determine the structure of each glycan in the sample being analyzed. Such profiles can
therefore capture the vast diversity of the cell surface glycans by providing information
about their sequences and branching patterns [42, 46]. When combined with enzymatic
tools, information about glycosidic linkages can also be obtained from these MS
techniques [42].
Furthermore, the different technologies used for separation and sequencing of
glycans can also be integrated to establish the fine structural details of cell surface
glycans. For example, LC-MS or CE-MS techniques are successfully being used for
complete structural characterization of these complex glycans [47, 48].
Biochemical approaches:
Characterization of anti-glycan antibodies and glycan binding proteins, such as
lectins, has greatly facilitated an understanding of the diversity and distribution of
glycans in eukaryotic cells. The use of phage display technology to generate antibodies
against glycan epitopes has helped the characterization of the heterogeneity and
distribution of cell surface glycans, particularly heparan sulfate GAGs [49]. Despite the
advances made in this field, raising antibodies to glycans remains a highly complex task.
Over the last few decades, a lot of attention has been devoted to development of lectins as
tools to study the structure-function relationships of glycans. Lectins are a family of
multivalent proteins that bind specifically to different carbohydrate sub-structures
through their carbohydrate recognition domains [50]. Among the different classes of
lectins, plant lectins have been widely used to characterize the structure of complex
glycans. Over the past few decades, a number of studies have focused on cloning and
expression of recombinant plant lectins and characterization of their glycan binding
specificities [51]. Lectins have emerged as an important tool for glycobiologists as their
glycan binding properties have been exploited for identification, isolation and
purification of glycans. Moreover, histochemical studies with these multivalent proteins
enable an understanding of the cellular distribution of glycans and their conjugates [50-
52]. More recently, lectin microarrays have also been developed to profile glycans in
mammalian cells [53, 54].
These biochemical approaches can also be used in conjunction with the above
mentioned analytical tools to aid in the characterization of glycans. Identification of
different classes of glycans and their separation using lectin affinity chromatography
provides purified glycans for structural and composition analysis. Identification of the
structures and sequences of glycans using the above techniques sheds light on the
specificity of protein-glycan interactions, which in turn increases our understanding of
the regulation of biological functions by glycans.
1.3.2 Characterization ofprotein-glycan interactions
The examination of the interaction between specific glycan structures (identified
from the above approaches) and different glycan binding proteins is critical to decode the
structure-function relationships of glycans. Protein-glycan interactions can be primarily
studied by two approaches (i) molecular analyses of the co-crystal structure data of
protein-glycan complexes and (ii) biochemical analyses by using glycan microarrays.
Such approaches to study protein-glycan interactions provide valuable insights into the
functional role of these interactions in cellular and pathological processes.
Structural characterization:
Given the role of glycans in several biological processes, there is increased
interest in exploring the glycan binding sites of different proteins and the molecular basis
of their interactions with specific oligosaccharide sequences within a complex glycan.
Such a structural analysis requires an in-depth understanding of the conformational
features of the glycan sequences and their role in protein-glycan interactions [55]. The
two commonly used methods for characterizing the molecular aspects of protein-glycan
interactions include X-ray crystallography and NMR. Despite the identification of
numerous proteins that interact with glycans, there is limited crystal structure data
available for protein-glycan complexes [56]. The protein-glycan systems for which the
crystal structures have been most widely characterized are FGF-HSGAG [57], AT III-
pentasaccharide [58] and influenza virus hemagglutinin-sialylated oligosaccharide [25]
complexes. More recently, computational methods are used in conjunction the
experimental structural methods to aid in the characterization of the three dimensional
structure of protein-glycan interactions [56].
An example of a system where such structural analyses have provided valuable
insights into the functional role of the protein-glycan interactions is the influenza A virus
system. Crystal structure studies have led to the identification of the key amino acids,
conserved in all hemagglutinin subtypes, which bind to the sialic acid monosaccharides.
Furthermore, these studies along with computational approaches have also identified the
amino acids within the glycan binding site of each hemagglutinin subtype that recognize
the different sialic acid linkages [25, 26] and have enabled rational drug design for
antiviral therapeutics [59].
Biochemical characterization:
The biochemical characterization of protein-glycan interactions is complicated by
two main issues. The first issue deals with the limited availability of glycans for such
analyses. However, the advances in chemical and chemoenzymatic synthesis of defined
glycan structures and glycoconjugates have overcome this limitation and provided a
platform for the biochemical characterization of protein-glycan interactions [60, 61]. The
second issue deals with multivalency in protein-glycan interactions, which enhances the
affinity of the otherwise weak interaction between these molecules [62]. Multivalency
complicates the study of the biochemical basis of protein-glycan interactions by altering
binding affinities and thus confounds the interpretation of their biological implications
[41]. Moreover, multivalent interactions have complex binding kinetics and require
specialized kinetic models for accurate definition of binding parameters. Therefore,
assays used to study protein glycan interactions should be designed to incorporate this
aspect of multivalency.
Several biochemical approaches have been used to study protein-glycan
interactions including surface plasmon resonance (SPR), isothermal titration
calorimetry(ITC), ELISA assays and affinity chromatography [2]. More recently, solid-
phase glycan microarrays have been developed by the Consortium for Functional
Glycomics for high throughput screening of glycan binding proteins [63]. These
microarrays which have several hundred glycans and glycoconjugates immobilized on
glass surfaces, have become invaluable tools to investigate the glycan binding properties
of diverse mammalian, plant and microbial proteins [64]. In some cases, the glycan
binding specificities of whole viruses have also been investigated [65]. Importantly, in
these assays, the glycan binding proteins are presented in a multivalent fashion in order to
accurately determine the binding specificities of these proteins [64, 65]. The development
of such glycan microarray approaches has particularly provided a wealth of information
on the glycan binding properties of influenza A viruses and their surface protein,
hemagglutinin. Such approaches are critical towards studying the host range of influenza
viruses and for surveillance of currently circulating avian virus strains [65, 66].
1.3.3 Glycomics: Bioinformatics approaches
Integration of the extensive data generated from the above mentioned
technologies is critical for defining the structure function relationships of glycans. The
development of bioinformatics based platforms including relational databases has greatly
enabled the integration of these diverse data sets. Moreover, such systems approaches
also support data mining and pattern recognition tools that enable further exploration of
the relationships between the structural features of the glycans and their functional
interactions with proteins which lead to identification of novel roles of glycans in cellular
and disease processes [1, 67].
1.4 Thesis outline
Using integrated approaches, this thesis aims to determine the role of glycans and
their conjugates, in mediating host-pathogen interactions. Towards this, the functional
interaction of bacterial toxins and viral coat proteins with epithelial cell surface glycans
and glycoconjugates is investigated. The main goals of the thesis are (a) to study the
complex glycans and glycoconjugates expressed on the surface of lung epithelial cells (b)
to study the interaction of microbial factors with these glycans and finally (c) to
investigate the functional role of these glycoconjugates in promoting microbial
pathogenesis by regulating host cell function.
The first part of the work, which is detailed in Chapter 2, studies the mechanisms
by which bacteria and their toxins exploit host epithelial cell glycoconjugates to enhance
their virulence. More specifically, the effect of bacterial sphingomyelinases on two
epithelial cell components: (a) the cell surface heparan sulfate proteoglycan, syndecan-1,
and (b) epithelial tight junctions is examined. Using the sphingomyelinase secreted by the
pathogenic bacteria Staphylococcus aureus as a model system, the role of the proteolytic
cleavage of extracellular domain of syndecan-1 by sphingomyelinases in regulating
epithelial barrier function is investigated.
To further extend this work and gain additional insights into the role of epithelial
cell surface components in microbial pathogenesis, the second part of this thesis aims to
study the role of sialylated glycans expressed on epithelial cell surface in another system
i.e. influenza A virus infection and transmission. Chapter 3 includes a study of the
binding of the influenza A viral coat protein, hemagglutinin (HA), to sialylated glycan
receptors on the epithelial cell surface. This binding event is the first step in the infection
of influenza A viruses. By developing a framework consisting of a set of complementary
approaches, the work presented here, identifies the glycan determinant required for the
human adaptation of influenza virus HA, going beyond the sialic acid linkages. The study
determines that the binding to a2-6 glycans with a characteristic 'umbrella-like' topology
is the critical determinant for efficient human adaptation and human-human transmission
of influenza A viruses. This work is then extended to provide a biochemical
understanding of the differences in human to human transmission of different influenza A
viruses by examining the receptor binding affinities of their HAs. The development of
such a quantitative biochemical framework to explain the differences in the transmission
of the pandemic 1918 viruses is the focus of chapter 4.
The above study enables the development of a structural framework to define
mutations in HA of avian H2N2 viruses that would enable human adaptation of these
viruses. Chapter 5 deals with the examination of the glycan binding properties of the
hemagglutinin from the currently circulating strains of avian H2N2 and the pandemic
human H2N2 viruses. This chapter further discusses the design and experimental
validation of mutations in HA of currently circulating strain of H2N2 that would enable
its high affinity binding to a2-6 glycans with the umbrella-like topology, which is
necessary for its human adaptation. Finally, the conclusions and future implications of
this thesis are presented in chapter 6.
1.5 Conclusions
The development of integrated approaches to study the structure-function
relationships of glycans and glycoconjugates, have greatly improved our understanding
of their role in mediating host-pathogen interactions. Given their widespread role in
mediating host-pathogen interactions, there is great potential for development of glycan
based therapeutics, vaccines and diagnostics for infectious diseases.
Design of glycan based therapeutics usually requires the synthesis of multivalent
conjugates of defined oligosaccharide sequences that bind to the microbial glycan
binding proteins and inhibit the first step of attachment of microbes to host cells. For
example, studies have shown that 3'-sialyllactose oligosaccharides are potent inhibitors
of H. pylori attachment to gastric epithelial cells [68, 69]. Another example is the
synthesis of glycodendrimers of GM1 oligosaccharides that bind to and inhibit the
activity of the cholera toxin, the most lethal toxin of V cholerae [70]. With the
emergence of multidrug resistant pathogens, development of such approaches to inhibit
the microbial glycan binding proteins are promising alternatives to current antimicrobial
therapies.
Carbohydrate-based vaccines have been successfully developed against several
bacterial pathogens including Streptococcus pneumoniae, Haemophilus influenzae,
Neisseria meningitides, and Salmonella typhi [71, 72]. Vaccine strategies using
glycosylphosphatidylinositol (GPI) oligosaccharides conjugated with carrier proteins are
being developed against parasites such as Plasmodium falciparum [72, 73] and
Toxoplasma gondii [72, 74]. Finally, through specific recognition of microbial glycan
binding proteins, glycan arrays can also be used as rapid and reliable diagnostic tools for
detection and identification of microbial pathogens [75, 76].
Further advances in the integration of the diverse technologies to study structure-
function relationships of glycans are critical to uncover novel roles for glycans in host-
pathogen interactions. Such approaches would not only shed light on the molecular
mechanisms of microbial pathogenesis but provide a basis for development of additional
strategies for targeted antimicrobial therapies.
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Chapter 2
The effect of bacterial sphingomyelinases on human
airway epithelial cell components.
Summary
Sphingomyelinases are enzymes that hydrolyze sphingomyelin and are secreted by
several pathogenic bacterial strains. However, the cellular and molecular mechanisms by
which these sphingomyelinases enhance bacterial virulence are unclear. Using the
sphingomyelinase from Staphylococcus aureus (beta toxin) as a model system, this
chapter aims to provide a mechanistic understanding of the effects of bacterial
sphingomyelinases on host epithelial cell function. The specific aim is to investigate the
effect of beta toxin on the epithelial cell components: (i) cell surface heparan sulfate
proteoglycan, syndecan- 1, and (ii) tight junctions. Importantly, this study shows that beta
toxin not only activates the ectodomain shedding of syndecan-1 but also causes barrier
dysfunction in human airway epithelial cells. This study further investigates whether
there is a direct causal relationship between beta toxin activated shedding of syndecan- 1
and epithelial barrier dysfunction via cytoskeletal reorganization.
2.1 Introduction
2.1.1 Bacterial Sphingomyelinases
Sphingomyelinases are enzymes which hydrolyze sphingomyelin, the
sphingophospholipid present in plasma membrane of eukaryotic cells, to produce
ceramide and phosphorylcholine. To date, six classes of sphingomyelinases have been
described [1]. Ceramide generation by sphingomyelinase activity regulates several
cellular signaling pathways and thus plays a role in different cellular and
pathophysiological processes [2, 3].
Sphingomyelinases secreted by pathogenic bacteria are Mg 2 -dependent neutral
sphingomyelinases, homologues of which have also been identified in yeast and
mammalian cells [4]. A variety of gram-positive pathogenic bacterial strains, including
Staphylococcus aureus, Bacillus anthracis, Bacillus cereus secrete sphingomyelinases
[5]. The sequence, structure and catalytic activity of these bacterial enzymes have been
extensively characterized [5-7]. These bacterial sphingomyelinases share sequence
similarity and show hemolytic activity in vitro [5, 7]. A study with S. aureus strains
deficient in beta toxin has indicated a role for this enzyme in enhancing bacterial
virulence [8]. However, the molecular mechanisms by which sphingomyelinases could
function as virulence factors remain largely unknown.
S. aureus and B. anthracis pathogens both cause potentially life-threatening
respiratory infections [9-12]. The epithelial cells of the human airway function as the first
barrier between these bacterial pathogens and underlying tissues. Previous studies have
shown that sphingomyelin is present in the plasma membranes of human epithelial cells,
particularly those of the cornea [13], skin [14], intestines [15] and airways [16]. Thus, it
is possible that these sphingomyelinases enhance the interaction of pathogens such as
S.aureus with airway epithelial cells which contain sphingomyelin as their major
membrane lipid component. More importantly, sphingomyelinases could also act
synergistically with other toxins to promote the pathogenesis of bacterial lung infections.
Therefore, it is important to study the molecular mechanisms by which
sphingomyelinases regulate epithelial cell function. In this chapter, the effect of the S.
aureus sphingomyelinase on the airway epithelial cell surface components syndecan-1
and tight junctions is investigated.
2.1.2 Epithelial barrier: tight junctions
The cell-cell junction complex of human airway epithelial cells comprise of tight
junctions, gap junctions, adherens junctions and desmosomes [17]. Of these, tight
junctions (TJs) are the most apical cell-cell junctions in the polarized epithelial cells and
function as a permeability barrier between the apical and the basolateral surfaces of these
cells [17]. The structural complex of the tight junctions consists of transmembrane
proteins (occludins, claudins and junctional adhesion molecules), cytoplasmic plaque
proteins (zonula-occludens and regulatory proteins) and actin cytoskeletal filaments [17-
19]. The zonula occludens family of the tight junction proteins consists of three proteins
namely, ZO-1, ZO-2 and ZO-3, all of which are proteins containing a PDZ domain [17,
18]. ZO-1 is an important cytoplasmic component of the TJ complex which binds to and
links the transmembrane occludin protein to the actin cytoskeletal filaments [18]. Apart
from their barrier functions in polarized epithelial cells, the TJs are also known to play a
role in other epithelial cell functions [17, 20].
Several bacterial pathogens such as Pseudomonas aeruginosa, Clostridium
difficile, and Helicobacter pylori are known to alter the structure of TJ proteins and
modify the barrier function of these junctions. As a result, the integrity of the epithelial
barrier of human epithelia is compromised and the bacteria and their virulence factors
gain access to the underlying tissues [21]. Several studies have investigated the
mechanisms by which these bacteria disrupt tight junctions and the virulence factors
responsible for the decoupling of the tight junction complex [22-24]. For example,
elastase and type III toxins from P. aeruginosa [23, 25-27] and C. difficile toxins A and B
[22] have been shown to enhance paracellular permeability of epithelial cells.
In this study, the effect of the S. aureus sphingomyelinase on epithelial integrity
in cultured human airway epithelial cells is examined. Such a study requires an
investigation of the effect of the toxin on tight junction structure and function in these
cells. The effect of the toxin on tight junction structure is elaborated by the
immunofluorescence detection of the cytoplasmic tight junction protein ZO-1. Tight
junction function is studied using two commonly used assays - (i) measurement of trans-
epithelial electrical resistance measurements and (ii) paracellular transport of low
molecular weight labeled-dextran, on confluent cell monolayers.
2.1.3 Cell surface heparan sulfate proteoglycans
Heparan sulfate proteoglycans (HSPGs), a major component of the epithelial cell
surface, play an important role in cell-cell and cell-ECM interactions and thus regulate
several cellular and pathological processes. The cell surface HSPGs include two families
of proteoglycans: syndecans and glypicans. The syndecan family consists of four
transmembrane proteoglycans, namely, syndecan-1, -2,-3 and -4. The syndecans are
believed to play a role in the pathogenesis of several bacterial pathogens [28]. There are
two known mechanisms of bacterial interaction with the syndecan family of HSPGs.
Bacteria such as Neisseria gonorrhoeae use heparan sulfate side chains of the syndecan
family as attachment sites and thereby bind to target cells [29]. More recently, studies
have indicated a role for ectodomain shedding of syndecans (syndecan-1, in particular) as
an alternate mechanism for promoting bacterial virulence [30].
Ectodomain shedding is a phenomenon wherein the extracellular domain of the
proteoglycan is proteolytically cleaved and released from the cell surface. Several in vitro
studies have shown that virulence factors secreted by gram positive bacteria such as
Pseudomonas aeruginosa and Staphylococcus aureus accelerate shedding of the HSPG
syndecan-1 [31, 32]. This shedding is thought to be dependant on the activation of
sheddases and intracellular protein tyrosine kinases by the toxins [33]. It is of particular
interest to note that purified sphingomyelinses from S. aureus and B. anthracis have been
shown to activate ectodomain shedding of syndecan- 1 in mouse mammary epithelial cells
[32, 34]. Further, studies in mice have shown that bacterial pathogens such as P.
aeruginosa and B. anthracis exploit ectodomain shedding of host cell syndecan-1 to
promote their pathogenesis [30, 34].
In this chapter the effect of sphingomyelinases on activation of syndecan-1
shedding in human airway epithelial cells is also verified. Furthermore, syndecan-1,
through its cytoplasmic domain, is believed to link the ECM components with actin
cytoskeletal filaments which are also an integral component of the tight junction
complex. Taken together, it is possible that syndecan-1 ectodomain shedding causes
alterations in the structure and function of TJs. This cause-effect relationship is
investigated in the cultured airway epithelial cells using small molecule inhibitors of
sheddases and intracellular protein tyrosine kinases. The following section describes the
results of the study in detail.
2.2 Results and Discussion
2.2.1 Sphingomyelinase from S .aureus causes a loss of tight junction structure in vivo
Work done by our collaborator, Dr. Pyong Woo Park, showed that while the wild
type S. aureus strain 8325-4, efficiently colonizes in mouse lungs, the mutant strain
deficient in beta toxin was unable to colonize in mouse lungs (Unpublished data),
suggesting that the sphingomyelinase plays an important role in bacterial invasion and
colonization in the lung. However, the mechanisms by which these sphingomyelinases
promote bacterial invasion are poorly understood. To determine the role of these bacterial
virulence factors in regulating host epithelial cell function, their effect on epithelial
integrity was first studied. Specifically, the effect of S. aureus and its sphingomyelinase,
beta toxin, on tight junctions in mouse lungs was investigated. Towards this, lung tissue
sections from control and S. aureus infected C57/BL6 mice (kindly provided by Dr.
Pyong Woo Park) were stained with the cytoplasmic tight junction protein ZO-1. Figure
2.1 shows that S. aureus significantly affects tight junction organization as depicted by a
loss of staining of ZO-1 in sections from mice infected with S. aureus. Sections from
untreated control mice on the other hand, had well formed and mature tight junctions as
shown by a continuous and well defined staining pattern of ZO-1 (Figure 2.1). Further,
to determine if the sphingomyelinase secreted by the bacteria also caused a disruption of
tight junction proteins, the effect of this toxin on the distribution of ZO- 1 in mouse lungs
was studied. As shown in Figure 2.1, treatment with beta toxin causes a substantial
decrease in levels of ZO-1 staining as compared to the untreated sections. Further,
stereological analysis of the confocal images shows that the observed differences in ZO-1
staining between treated and control samples are statistically significant (data not shown).
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Figure 2.1: Effect of Staphylococcus aureus and its sphingomyelinase on tight junctions in mouse lung
tissue sections. Control mouse lung tissue sections have well defined tight junctions, as shown by a
continuous ZO-1 staining pattern (green against propidium iodide staining of the nuclei in red). Mice
infected with S. aureus and beta toxin, on the other hand, showed a discontinuous ZO-1 staining pattern.
The white arrows indicate regions with loss of ZO-1 staining. These results indicate that S. aureus and beta
toxin alter the structure of TJ proteins in vivo.
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2.2.2 Sphingomyelinase causes loss of TJ structure and function in culture monolayers
of human airway epithelial cells
To investigate if beta toxin causes loss of structure of the epithelial TJ complex,
in vitro, confluent monolayers of virally transformed human bronchial epithelial cells,
16HBE14o- cells, were incubated with beta toxin for 2 hours at 37*C, fixed and
immunostained using specific monoclonal primary and secondary antibodies for the TJ
plaque protein, ZO-1. ZO-1 is expressed at the plasma membrane surface and is widely
accepted as a marker for TJs. As shown in Figure 2.2, beta toxin incubation of the cells
results in a punctate and discontinuous staining of ZO-1, while the control untreated cells
had mature and well defined tight junctions as indicated by a continuous staining pattern
in these cells.
TJs have two barrier functions: fence and gate functions. The gate function
prevents paracellular permeability and the fence function keeps the epithelial cells
polarized by preventing interactions between components on the apical and basolateral
surfaces [17]. In this study, the effect of beta toxin on the function of TJs was
investigated by recording transepithelial electrical resistance (TEER) measurements of
the monolayers and monitoring of the paracellular transport of labeled tracers. Cells were
seeded in transwell inserts and daily measurements revealed that cells reached the
maximum value of TEER, an average value of around 40 Q cm 2 , between 7 and 9 days
after seeding. So all TEER and paracellular transport assays were performed on day 8.
Cell monolayers were incubated with 5pg/ml of beta toxin at 37*C and TEER
measurements were taken every hour for 5h. The results show that the TEER values on
control cells were 40.26 +/- 2.31 E cm 2 before toxin treatment. Upon treatment with beta
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Figure 22: Effect of beta toxin on tight junction structure in cultured human airway epithelial cells.
HBE cells were treated with 5pg/ml of beta toxin for 2hr at 371C, fixed and immunostained for the tight
junction protein ZO-1. Control cells have well defined tight junctions as elaborated by a continuous ZO-1
staining pattern. Beta toxin treated cells, on the other hand, showed loss of tight junction structure as
evidenced by a punctate ZO-1 staining pattern. The white arrow shows a region of discontinuous TJs.
toxin for two hours, the TEER fell to an average of 13.09+/- 0.8 Q cm 2, which is about
one-third the value on control cell layers which were not exposed to the toxin (Figure
2.3). The TEER values on toxin-treated cells remained significantly lower than the values
on the control cells throughout the 5hr duration of the study. The above result indicates
the loss of epithelial integrity of the monolayer upon exposure to beta toxin.
To study paracellular transport of a low molecular weight FITC-dextran, apical
surfaces of cell monolayers were incubated with different concentrations of the toxin
(2.5-10pg/ml) along with 1 mg/ml of the dextran. Aliquots of media from the basolateral
chamber were taken every hour and the levels of FITC-dextran in these aliquots were
quantified using a fluorescence plate reader. As compared to control untreated cells
(value at 0 pg/ml of toxin), there is about a 3-fold increase in the paracellular transport
upon exposure of cells to purified beta toxin, at a concentration as low as 2.5pg/ml, for
2hr at 37 *C (Figure 2.4A). The paracellular permeability of the labeled tracer increased
to up to 5-fold upon incubation with 10ptg/ml of beta toxin, in comparison with untreated
cells which have intact monolayers. While the paracellular transport of the tracer in
untreated cell monolayers remained almost constant during the duration of the
experiment, the cell inserts treated with 5pg/ml of the toxin showed more than a three-
fold increase in paracellular permeability at the 2hr time point and this permeability
continued to increase with time (Figure 2.4B). It is also important to note that results of
trypan blue exclusion assays showed that the beta toxin did not have any significant
effect on the viability of the cells at the concentration range and the times tested (data not
shown). The above findings together establish that the sphingomyelinase alters structure
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Figure 2.3: Effect of beta toxin on tight junction function in cultured human airway epithelial cells.
Apical surfaces of HBE cells grown in transwell inserts were treated with beta toxin (concentration of
5sg/ml) and transepithelial electrical resistance (TEER) measurements were taken using a volt ohm-meter
before and after the addition of toxin. Exposure to beta toxin for 2hr causes a 3-fold decrease in TEER in
these cultured cells indicating a loss of TJ function as a result of toxin addition. The assay was done in
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Figure 2.4: Effect of purified beta toxin on paracellular permeability in cultured human airway
epithelial cells. Apical surfaces of HBE cells grown in transwell inserts were treated with different
concentrations of beta toxin along with 3KDa FITC-dextran used as a labeled tracer to study paracellular
transport through the cell monolayers. Aliquots of media from the basolateral chamber were collected at
regular time intervals and levels of FITC-dextran were quantified. (A) Shows the paracellular permeability
of HBE cell monolayers incubated with different concentrations of beta toxin (2.5-10pig/ml) for 2hr at 37*C
(B) Compares the paracellular transport of FITC-dextran through untreated and 5pg/ml beta toxin treated
cell monolayers over different time points during the duration of the study. - C * Beta tox 5 pg/n
2.2.3 Beta toxin from S. aureus causes syndecan-1 shedding in human airway
epithelial cells
Previous studies have shown that sphingomyelinases from S. aureus and B.
anthracis enhance ectodomain shedding of syndecan-1 from the surface of normal
murine mammary gland (NMuMg) epithelial cells [32, 34]. To confirm that the S. aureus
sphingomyelinase sheds syndecan-1 in an in vitro human airway cell line, confluent
monolayers of HBE cells were incubated with different concentrations (1-10 tg/ml) of
beta toxin from S. aureus for 2hr at 37*C. The conditioned media was then analyzed for
shed extracellular domains of syndecan-1 using a dot immunoassay. Our results show
that incubation of cells with beta toxin at 5 ptg/ml caused a three-fold increase in the shed
levels of syndecan-1 in the conditioned media as compared with control untreated control
cells (p< 0.02, Student's t-test) (Figure 2.5).
The proteases or sheddases that cleave the extracellular domains of syndecan-1
are thought to be members of the family of metalloproteinases [33]. In order to study the
role of sheddases in regulating beta toxin induced shedding of syndecan-1 the cells were
pre-treated with 5pM of a peptide hydroxamate inhibitor (sheddase inhibitor, SI), GM
6001, which is a broad spectrum inhibitor of the family of metalloproteinases. As
expected, GM6001 significantly inhibited beta toxin accelerated shedding of syndecan-1
(p<0.01, as compared with values from cells treated with beta toxin only) (Figure 2.5),
indicating that beta toxin enhances shedding of syndecan-1 from the surface of human
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Figure 2.5: Effect of beta toxin on ectodomain shedding of syndecan-1 in cultured human airway
epithelial cells. HBE cells were treated with 5pg/ml of beta toxin for 2hr at 37*C in the presence and
absence of GM6001, which is a sheddase inhibitor (SI). The conditioned media from all the samples
(including control untreated cells) were collected and analyzed for syndecan-1 ectodomains using a dot-
immunoassay (see methods for details). Control cells show levels of endogenous shedding of syndecan-1.
Beta toxin treatment of cells causes about a 3-fold increase in the shed levels of syndecan-1 in the
conditioned media as compared with control untreated cells (*: p<0.02, Student's t-test). Pre-treatment of
the cells with GM6001, significantly reduced the beta toxin induced accelerated shedding of syndecan-1
ectodomains into the conditioned media (**: p<0.008, beta toxin versus beta toxin + SI, Student's t-test).
All assays were done in triplicate and the results are shown as mean ± s.d.
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2.2.4 Does Syndecan-1 shedding in HBE cells compromise epithelial barrier
permeability?
The heparan sulfate proteoglycan syndecan- 1 has a highly conserved sequence in
the cytoplasmic domain that binds to PDZ proteins such as syntenin which in turn have
been shown to interact with the actin cytoskeletal filaments [35, 36]. Thus syndecan-1
could regulate the organization of the actin filaments via syntenin. It is likely that the
proteolytic release of the extracellular domains of syndecan-1 could result in the
reorganization of the cytoskeletal filaments and subsequent disruption of the tight
junction complex (Figure 2.6). To dissect out the possible cause-effect relationship
between beta toxin-activated syndecan-1 shedding and barrier dysfunction, human
epithelial cells were pre-treated with different concentrations (5-25 pLM) of the sheddase
inhibitor GM6001 (SI) and paracellular transport of FITC-dextran through the cell
monolayers was monitored. While GM6001 significantly inhibited syndecan-1 shedding
(Figure 2.5), it had no significant effect on the beta toxin-induced increase in paracellular
permeability in cultured HBE cell monolayers at the different concentrations of the toxin
















Figure 2.6: Hypothesis for cause-effect relationship between syndecan-1 shedding and tight junction
disruption. Beta toxin, a sphingomyelinase, causes sphingomyelin hydrolysis in human airway epithelial
cells. Previous reports have shown that beta toxin induced release of syndecan-1 ectodomains is dependant
on sheddases and intracellular protein tyrosine kinases (PTKs). Syndecan-1, a cell surface heparan sulfate
proteoglycan is known to bind to and interact with the actin cytoskeletal filaments via its cytoplasmic
domain. Activation of a PTK by beta toxin could result in the activation of a sheddase, which causes
release of syndecan-1 ectodomains, or could directly regulate the tyrosine phosphorylation of the
cytoplasmic domain of syndecan-1. Changes in phosphorylation state of syndecan-1 could negatively affect
the interaction of the proteoglycan with actin filaments resulting in their reorganization. Actin filaments are
important component of the tight junction complex and any such reorganization could result in the












Figure 2.7: Effect of sheddase inhibitor on beta-toxin induced increase in paracellular permeability of
cultured airway epithelial cells. Apical surfaces of HBE cells grown on transwell inserts were incubated
with either 2.5 or 5pg/ml of beta toxin for 2hr at 374C and FITC dextran, in the presence and absence of
GM6001, a sheddase inhibitor (SI). Aliquots of media from the basolateral chamber were collected at
regular time intervals and levels of FITC-dextran were quantified. Shown is the representative set of data of
incubation of HBE cells with 5pg/ml of beta toxin. As expected, the incubation of cells with toxin resulted
in a significant increase of paracellular permeability as compared with control cells. However, SI was
unable to significantly prevent this toxin induced increase in paracellular transport of labeled tracer. All
assays were done at least in triplicate and the results are shown as mean ± s.d. (*: p< 0.025, **: p>0.1;
Student's t-test).
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Previous studies have indicated that protein tyrosine kinase activity is required for
accelerated shedding of syndecan-1 [32]. The role of PTKs in beta toxin-activated
syndecan-1 shedding in HBE cells was investigated using different protein tyrosine
kinase inhibitors. Tyrphostin A25, the broad spectrum inhibitor of PTKs, did not show
any significant inhibition of syndecan-1 release by beta toxin (data not shown). However,
the inhibitor of Syk family of PTKs, piceatannol, showed significant reduction of toxin-
activated syndecan-1 shedding at an inhibitor concentration range of 10-50 pM (p<0.005,
as compared with shedding values from cells treated with beta toxin only). On the other
hand, pre-treatment of cells with the inhibitor of Src family, PP2, failed to show any
inhibition at the concentration range of 1-20 pM (Figure 2.8A). The above results from
the inhibitor studies indicate that beta toxin activated syndecan-1 shedding is dependant
on the Syk family of PTKs.
It is known that the cytoplasmic domain of syndecan-1 has conserved tyrosine
residues [28]. It is possible that phosphorylation of one or more of these residues not only
regulates syndecan-1 ectodomain shedding but also regulates the interaction between the
cytoplasmic domain of syndecan-1 and the actin cytoskeletal filaments. Changes in the
phosphorylation state of syndecan- 1 could thus affect the epithelial integrity by
controlling the organization of actin filaments (Figure 2.6). To test the above hypothesis,
beta toxin-induced changes in barrier permeability in the presence and absence of these
PTK inhibitors were investigated. As expected, PP2 was unable to inhibit beta toxin
accelerated increase in barrier permeability in HBE cells. Importantly, as shown in
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Figure 2.8: Effect of PTK inhibitors on beta toxin induced ectodomain shedding of syndecan-1 and tight
junction disruption. Apical surfaces of HBE cells were incubated with 5pg/ml of beta toxin for 2hr at
370C, in the presence and absence of PTK inhibitors, such as piceatannol and PP2. (A) Shows shed levels
of syndecan-1 in the conditioned media collected from all samples. As expected, cells treated with beta
toxin had a significantly higher level of shed ectodomains of syndecan-1 in their conditioned media.
Piceatannol, the cell-permeable inhibitor of the Syk family of PTKs, significantly reduced the beta toxin
induced release of syndecan-1 ectodomains. However, PP2, an inhibitor of Src family of PTKs failed to
inhibit beta toxin induced shedding of syndecan-1. (*: p<0.01,beta toxin versus control; **: p< 0.005, beta
toxin + piceatannol versus beta toxin; ***: p> 0.5, beta toxin + PP2 versus beta toxin). (B) Quantifies the
paracellular transport of FITC-dextran through the epithelial cell monolayer. Beta toxin results in
significant loss of epithelial integrity by disrupting the barrier function of TJs. Interestingly, both
piceatannol and PP2 failed to block beta toxin induced tight junction disruption. (*: p5 0.025 Beta tox
versus control; **: p>0.1 beta tox + piceatannol versus beta tox, ***p>O.1 beta tox + PP2 versus beta tox).
................ ..  .
induced barrier dysfunction in these cells (p>O. 1, as compared with permeability on cells
treated with beta toxin only). It is important to note that the inhibitor piceatannol by itself
did not have any significant effect on the paracellular permeability of FITC-dextran in
these cells at all concentrations of the inhibitor tested (Figure 2.10).
In this study, purified S. aureus sphingomyelinase, beta toxin, was used to
investigate the mechanisms by which these sphingomyelinases exploit host epithelial cell
components and promote bacterial pathogenesis. The results demonstrate that beta toxin
accelerates the ectodomain shedding of syndecan-1 from the surface of human airway
epithelial cells and regulates paracellular permeability in these cells by altering the
structure and function of the different TJ proteins. However, the results indicate that
while syndecan-1 shedding is accompanied by TJ disruption in airway epithelial cells
exposed to beta toxin, there is no causal relationship between the two processes.
Given that the main function of these sphingomyelinases is to hydrolyze
sphingomyelin and produce ceramide, this study further investigated the role of ceramide
generation in TJ disruption. To study the effect of ceramide generation on airway
epithelial barrier function, the cells were incubated with beta toxin in the presence and
absence of a monoclonal anti-ceramide antibody, which functions as a ceramide inhibitor.
Preliminary results show a significant decrease in the permeability of FITC-dextran in the
presence of the ceramide antibody (data not shown); indicating that generation of surface
ceramide causes TJ disruption. A recent study reported a similar observation with
intestinal epithelial cells, and suggested that the clustering of ceramide into ceramide
enriched membrane domains was responsible for the loss of intestinal barrier function by
altering the distribution of TJ lipid components [37]. It is possible that ceramide regulates
TJ function in human airway cells using similar a mechanism of redistribution of
membrane lipids. Further investigation is required to elucidate the mechanisms by which
cell surface ceramide generated from bacterial sphingomyelinases regulates paracellular
permeability of human upper airway epithelial cells.
2.2.5 Suramin as an inhibitor of beta toxin induced syndecan-1 shedding and epithelial
barrier dysfunction
A recent study has shown that Suramin, a drug used to treat sleeping sickness, is
able to significantly inhibit B. anthracis sphingomyelinase-activated shedding of
syndecan-1 [34]. The inhibitory effects of Suramin on both accelerated syndecan-1
shedding and TJ disruption caused by S. aureus beta toxin were tested. Suramin was
shown to significantly inhibit beta toxin-activated syndecan-1 shedding in the
concentration range tested (10-50 pM) (Figure 2.9A, p<0.005 as compared with cells
treated with beta toxin only). Interestingly, suramin also showed significant inhibition of
beta-toxin induced paracellular permeability in HBE cells (Figure 2.9B). While, control
experiments with suramin incubation alone showed some reduction in paracellular
permeability as compared with untreated HBE cells at the different concentrations of
suramin tested, statistical analysis of the data shows that this reduction of permeability is
not significant (p-value>0.1, as compared with control untreated cells) (Figure 2.10).
However, the ability of suramin to inhibit several cellular processes by blocking binding
of growth factors to their cellular receptors and regulating activity of protein tyrosine
phosphatases [38, 39] warrants further investigation into the key cellular players involved
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Figure 2.9: Effect of Suramin on beta toxin-induced syndecan-1 shedding and tight junction disruption.
Apical surfaces of HBE cells were incubated with either 2.5 or 5pg/ml of beta toxin for 2hr at 37*C, in the
presence and absence of Suramin at 10 and 50 pM. (A) Shows shed levels of syndecan-1 in the conditioned
media collected from all samples. At both the concentrations of suramin tried, the cell-permeable inhibitor
significantly reduced the beta toxin induced release of syndecan-1 ectodomains. (*: p<0.01, beta tox versus
control; **: p<0.005, Beta tox + Suramin lOpM and beta tox + Suramin 50pM versus Beta tox). (B)
Quantifies the paracellular transport of FITC-dextran through the epithelial cell monolayer. Interestingly,
Suramin significantly blocks beta toxin induced tight junction disruption. (*: p< 0.03 Beta tox versus
control at 2hr; **: p<0.006 beta tox + Suramin 50pM versus beta tox at 2hr and 4hr, ***p<0.047 beta tox +
Suramin 10pM versus beta tox at 2hr and 4hr; ±: p<0.01 beta toxin versus control at 4hr).













Figure 2.10: Effect of inhibitors alone on the paracellular permeability of cultured airway epithelial
cells. Apical surfaces of HBE cells were incubated with lOpM of the PTK inhibitor piceatannol and 10 and
50 pM, respectively, of Suramin. These control experiments showed that the inhibitors by themselves did
not have any significant effect on the paracellular permeability of HBE cells. (*: p>0.1, **: p>0.09, all p-
values were calculated with respect to control cells using Student's t-test).
.... ...............  ..     ..  ..  .. .. . .. .. ..
2.3 Conclusions
In conclusion, the above study demonstrates that bacterial sphingomyelinases
activate proteolytic release of ectodomains of the heparan sulfate proteoglycan syndecan-
1 in human airway epithelial cells. This process of sphingomyelinase-activated syndecan-
1 shedding is accompanied by epithelial barrier dysfunction. However, the findings
indicate that release of syndecan-1 ectodomains does not directly result in loss of
epithelial barrier function in human airway epithelial cells. Previous studies have already
shown the importance of syndecan-1 shedding in the pathogenesis of P. aeruginosa, S.
aureus and B. anthracis [30, 34] infections. Thus, the above findings suggest possible
mechanisms by which sphingomyelinases could enhance bacterial virulence by activating
syndecan-1 shedding and compromising epithelial integrity. With the emergence of
antibiotic resistant bacterial strains, such a study would enable the identification of
potential cellular targets to inhibit bacterial pathogenesis.
2.4 Materials and Methods
2.4.1 Materials:
16HBE14o- cells were a kind gift from Dr. D.C. Gruenert, University of
California, San Francisco. Beta toxin was purchased from Toxin Technology Inc. All the
inhibitors including peptide hydroxamate inhibitors and inhibitors of intracellular protein
tyrosine kinases and protein phosphatases were purchased from EMID Biosciences
(Calbiochem). The primary antibody (rabbit-anti ZO-1), secondary antibody (Alexa Fluor
Goat anti-rabbit) and propidium iodide were purchased from Invitrogen. Transwell plates
were purchased from Coming Inc.
2.4.2 Cell culture experiments:
16HBE14o- cells were grown on fibronectin-coated surfaces and were maintained
in minimum essential medium with 10% FCS. For immunofluorescent detection of TJ
proteins, cells were plated on fibronectin-coated coverslips and were grown to
confluence. For TEER and transport assays, cells were grown in fibronectin-coated
transwell chambers for 8 days. To study the effect of beta toxin on these cells, confluent
monolayers were incubated with 5ptg/ml of beta toxin from Staphylococcus aureus for
2hr at 37'C. For inhibitor studies, cells were pre-treated with the broad spectrum matrix
metalloproteinase (MMP) inhibitor or inhibitors of intracellular protein tyrosine kinases
at indicated concentrations for 90 minutes at 37'C and were then co-incubated with the
inhibitor and toxin for 2hr at 37'C.
2.4.3 Dot immunoassays for syndecan-1 shedding:
16HBE14o- cells were grown to confluence in 6 well plates coated with
fibronectin. Shedding assays were performed as described previously [32, 40]. Briefly,
the cell culture conditioned media was collected (600 p1/well) after incubation of the cell
monolayers with the various test agents and was centrifuged to remove any non-adherent
cells. The supernatant was collected, acidified and the samples were then transferred onto
a cationic nylon membrane using a dot blot apparatus. The membrane was washed with
TBST (TBS with 0.1% Tween-20) and blocked for 1 hr in 5% Blotto (non-fat dry milk in
TBST) at 4*C. The membrane was then incubated overnight in mouse anti- human
syndecan-1 (clone BB4, 1:400 in 5% Blotto) at 4*C. After multiple washes in TBST, the
membrane was incubated for 1 hr in HRP-conjugated goat anti-mouse IgG (1:500 in 5%
Blotto) at room temperature (RT). The levels of shed syndecan- 1 were detected using the
ECL chemiluminiscent kit (Amersham Biosciences) and quantified by densitometry
using a Kodak Gel Imaging System. The results were expressed as arbitrary shedding
units. All experiments were done in triplicate and were repeated at least three times for
consistency.
2.4.4 Immunofluorescence and Confocal Microscopy:
Cells grown on coverslips were incubated for the indicated times with the
different inhibitors and beta toxin, washed extensively and immunostained for ZO-1.
Cells were washed with phosphate buffer saline (PBS) and fixed with 3.7% formaldehyde
for 15 minutes at RT. Non-specific binding was blocked by incubating cells with 0.1M
glycine for 10 minutes at RT. Cells were then permeabilized with 0.1% triton-X for 10
minutes at room temperature and were washed with PBS. Cells were incubated for 90
minutes in rabbit anti-ZO-1 (1:100 in 1% BSA) at 37*C. After washing with PBS, cells
were then incubated for one hour in the dark at 37*C with a rhodamine-conjugated goat
anti-rabbit (1:400 in 1% BSA). Cells were washed and the coverslips were mounted with
SlowFade light antifade kit (Invitrogen) and viewed under confocal microscopy (Zeiss
LSM5 10 laser confocal scanning microscopy).
2.4.5 Immunohistochemistry:
Mouse lung tissue sections were prepared by our collaborator, Dr. Pyong Woo
Park and his colleagues. Briefly, WT C57/BL6 mice were infected intranasally with
1.5x108 or 2x10 8 cfu of S. aureus strain 8325-4 or with purified beta toxin. The animals
were sacrificed 20 h post-infection and the lungs were isolated. The tissues were then
fixed, dehydrated with a series of ethanol washes and embedded in paraffin. The
sectioned tissues (5pm thickness/section) were stored at room temperature until the
subsequent steps of immunohistochemical staining.
For immunohistochemical detection of ZO-1, paraffin embedded lung tissue
sections were first heated in a hybridization oven to 60*C for 30 minutes. Sections were
de-paraffinized by washing in xylene and rehydrated by passing through graded ethyl
alcohols ( a 5 minute wash each in 100%, 90%, 75%, 50% and 25% ethanol) followed by
a wash in water for five minutes. The sections were then incubated in 2mg/ml protease
(Sigma) for antigen retrieval. To prevent non-specific antibody staining, the sections
were blocked in 1% goat serum and were then incubated overnight in rabbit anti-ZO1
(1:50 in 1% goat serum) at 4*C. After washing, the sections were incubated in FITC-
conjugated goat anti rabbit (1:400 in 1% goat serum) for 3 hr at RT. Sections were then
counter stained with propidium iodide (1:100 in TBST) for 20 minutes at RT to visualize
the nuclei and then washed using TBST. Coverslips were mounted onto the slides using a
Slowfade light antifade kit and the sections were viewed using a confocal microscope.
2.4.6 Transepithelial electrical resistance measurements:
HBE cells were seeded on transwell inserts at a density of 105cells/well and were
grown for 8 days. Trans Epithelial Electrical Resistance (TEER) was monitored once
everyday using Millicell-ERS epithelial voltmeter (Millipore Co., Bedford, MA) as per
the manufacturer's instructions. TEER is calculated using the following formula:
TEER = (Rce -Rinsert) *A,
where Rcen: Resistance of the cell layer, Rinsert: Resistance of the blank insert (with no
cells), A: Growing surface area of each well (0.33 cm2).
On day 8, the cells were equilibrated with fresh medium (MEM with 1% FCS) at 37*C
for lhr. Transepithelial electrical resistance measurements were taken before adding the
beta toxin and this is denoted as the Ohr time point. Different wells were then incubated
with varying concentrations of beta toxin at 370C. TEER was monitored on these wells
for every hour up to 5hrs. The results are reported as a percentage of TEER relative to the
values at the Ohr time point. All assays were done in triplicate.
2.4.7. Paracellular transport assays:
HBE cells were seeded on transwell inserts (Costar, Coming Inc) at a density of
105cells/well and were grown for 8 days. On day 8, the cells were equilibrated with fresh
medium (MEM with 1% FCS) at 370C for lhr. 200 g1 of media was added to the apical
chamber in these transwell inserts and 500 pl of media was added to the basolateral
chambers. Transepithelial electrical resistance measurements were recorded before
adding the beta toxin in order to check the integrity of the cell monolayer. Beta toxin at
different concentrations (2.5 -10 pg/ml) along with 0.5 mg/ml of 3KDa of FITC-dextran
(which is used as a tracer) was added to the apical chamber of the cells. 100pl of media
was collected from the basolateral chamber every one hour. The amount of FITC-dextran
in the basolateral media was quantified using a fluorescence plate reader. For inhibitor
studies, the cells were pre-treated with indicated concentrations of inhibitors for 90
minutes at 374C. All assays were done in triplicate and were repeated at least three times
for consistency.
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Chapter 3
Human adaptation of avian influenza A viruses.
Summary
Influenza A viruses are the major cause of the seasonal epidemics and the global
pandemics. The first step in the infection and pathogenesis of these viruses is the binding
of their viral surface hemagglutinin to sialic acid receptors on host epithelial cell surfaces.
The cross species transmission of the influenza A viruses from birds to humans is
believed to be associated with a switch in the receptor specificity from a2-3 to a2-6
sialylated glycans. Using integrated approaches, this study demonstrates that a gain in the
binding of the hemagglutinin to a2-6 sialylated glycans with a distinct structural topology
is critical for the human adaptation of HA. Indeed, hemagglutinin from several human
HINI and H3N2 viruses show high affinity binding to a2-6 sialylated glycans with a
distinct umbrella-like structural topology, while avian viruses do not. This study proposes
the concept that it is the glycan topology and not just the sialic acid linkage per se that is
the key determinant for human adaptation of influenza A virus hemagglutinin.
The work presented in this chapter is in part reproduced with permission from
Nature Biotechnology (2008) 26 (1) 107-113. Copyright 2008 Nature Publishing Group.
3.1 Introduction
3.1.1 Influenza viruses
Influenza viruses are negative sense single-stranded RNA viruses belonging to the
Orthomyxoviridae family [1, 2]. There are three immunological types of influenza
viruses; named as types A, B and C. While all the virus types infect the human host,
influenza A viruses cause most severe illness and are responsible for the annual seasonal
flu epidemics and the more sporadic global pandemics [3, 4]. In a typical year
approximately 15% of the U.S. population is infected, resulting in about 36,000 deaths
and more than 200,000 hospitalizations (www.cdc.gov/flu). Based on the estimated
mortality rate of the 1918 Spanish flu pandemic, epidemiological studies project that a
pandemic in the present would affect roughly 75 million people worldwide.
The genome of influenza A viruses consists of eight RNA segments that encodes
for eleven viral proteins [1, 5-7]. Three of these proteins: hemagglutinin (HA),
neuraminidase (NA), and matrix protein (Ml) are present on the surface of influenza
viruses. The viral coat glycoproteins HA and NA are the antigenic determinants of these
viruses and form the basis for their classification into different serotypes. To date, 16 HA
and 9 NA serotypes have been identified. Other encoded proteins include RNA
polymerase subunits (PB1, PB2, PA), nucleoprotein (NP), nonstructural proteins (NS1
and NS2), a proton-selective ion channel protein (M2) and a newly discovered pro-
apoptotic PB 1 -F2 protein [8].
Evolution of influenza A viruses
Influenza viruses lack a proofreading mechanism in their RNA polymerase, which
causes the synthesis of their new transcripts to be error prone. Accumulations of these
mutations permit development of new serotypes in a process known as antigenic drft.
This antigenic drift helps the virus evade the host immune system by changing the
antigen present on the surface. The segmented nature of the viral RNA allows
reassortment of genes between viruses of different serotypes which results in new
subtypes. This process is called antigenic shift. Antigenic drift is a continuous process
and leads to gradual changes in surface antigens (HA and NA) whereas antigenic shift is
an infrequent occurrence and leads to significant changes in antigen present on the virus
surface [1, 9]. Influenza A viruses occasionally evolve into highly pathogenic and
virulent strains by either acquiring mutations (antigenic drift) or entire gene segments
through reassortment in a host infected by more than one viral strain (antigenic shift).
These highly pathogenic strains yield a high mortality rate in humans and efficiently
transmit from human-to-human which results in a widespread pandemic and serious
global health concern [5, 6, 10, 11]. In the last century, influenza A viruses caused three
pandemics: the 'Spanish flu' of 1918 caused by HINI subtype, the 'Asian flu' of 1957
caused by H2N2 subtype, the 'Hong Kong flu' of 1968 caused by H3N2 subtype.
Cross-species transmission of influenza A viruses
Apart from humans, influenza A viruses infect a variety of animal species
including wild birds, ducks and poultry, pigs, horses, whales and seals [3, 4]. Wild
aquatic birds serve as a natural asymptomatic reservoir for all known subtypes of these
viruses. Occasionally, these viruses are introduced into other species including humans,
swine and domestic birds, from wild bird populations [3, 4, 12, 13] (Figure 3.1). It is of




Figure 3.1: Cross-species transmission of influenza A viruses. Wild birds are natural asymptomatic
reservoirs for influenza A viruses. Occasionally, the viruses are transmitted from these hosts to humans,
pigs, domestic birds such as poultry, horses and sea mammals. Virus strains can be transmitted to humans
directly from either infected domestic birds or pigs.
viruses can also be introduced in pigs by an alternate mechanism of reassortment of gene
segments from avian, swine and human viruses [14, 15]. Currently, two specific subtypes
(HINI and H3N2) circulate in the human population and are responsible for the annual
epidemics. New strains of influenza viruses can be introduced into the human population
through cross species transmission of the viruses from direct contact with infected birds
or pigs [16, 17] (Figure 3.1). More recently, there has been an increase in the number of
strains of avian viruses that directly transmit from birds to the human host. Among the
different subtypes of avian influenza viruses such as H2N2, H5N1, H7N7 and H9N1
currently known to infect humans, the H5N1 or the "bird flu" virus is by far the deadliest
(mortality rate greater than 60%, which is greatly higher than that of the pandemic
strains) [18-22]. Fortunately, these viruses have not yet acquired the ability to efficiently
transmit between humans [23, 24]. Outbreaks have thus far been localized to specific
parts of the world. The H5N1 strains and others have a potential to become a serious
global threat should they mutate to adapt to the human host and achieve efficient human-
human transmission. Therefore, it is important to study the molecular mechanisms that
enable efficient human adaptation and human to human transmission of these viruses.
Influenza A virus infection and replication
The virus infection cycle of influenza A starts with attachment of the virus to the
glycan receptors on the host cells, which is enabled by binding of the antigenic coat
glycoprotein hemagglutinin to host cell surface glycans. The virus is next internalized by
endocytosis, followed by membrane fusion and virus uncoating. Subsequently, the viral
RNA is transported to the nucleus where it undergoes replication and transcription. The
newly synthesized proteins HA and NA are secreted through the Golgi to the cell surface
while other proteins are transported to the nucleus where they associate with the
synthesized transcripts of viral RNA to form virions. These virions then bulge out of the
cell membrane with HA and NA on the surface. The action of the viral neuraminidase,
the antigenic coat glycoprotein which functions as a sialidase, facilitates the release of
these progeny viruses from their host cells which go on to infect other cells [2].
3.1.2 Influenza A virus hemagglutinin
Influenza viruses have long been known for their ability to agglutinate red blood
cells (RBCs) in vitro. Hemagglutinin (HA) is the protein on the influenza virus
responsible for the agglutination-hence its name. The influenza A virus HA is a
transmembrane glycoprotein that exists as a homotrimer with the molecular weight of
220 kDa [25]. HA is a type 1 integral membrane protein with a N-terminal hydrophobic
signal sequence that is cleaved off once the protein is anchored to the membrane, a
transmembrane anchoring domain near its C-terminal, and a short hydrophilic
cytoplasmic tail [26]. HA plays a critical role in the different stages of the viral
pathogenesis. HA functions on the viral surface as a glycan binding protein and enables
virus attachment to host epithelia by binding to sialylated glycan receptors on the host
cell surface, which is the first step in the viral infection cycle [2]. The biosynthesis of HA
occurs as a precursor protein (HAO) that is cleaved by proteases into two subunits - HA1
and HA2. Depending on the HA subtype, these subunits are either separated by one basic
amino acid residue or a polybasic sequence where the cleavage by host tissue proteases
occurs [2, 26, 27]. This proteolytic cleavage of HA plays an important role in the
subsequent steps of the viral pathogenesis. The cleaved HA undergoes a pH dependant
conformational change and the HA2 subunit aids in the fusion of the viral and host
endosomal membranes during post-endocytosis [2, 26, 27]. Through its binding to host
cell glycan receptors, HA also plays a role in determining the host range of influenza A
viruses [4]. Given its critical role in the viral entry into host epithelial cells, it is important
to understand the structure of this glycoprotein, its binding to glycans on host cell surface
and the functional role of this interaction in efficient host species adaptation of the virus.
3.1.3 Glycan receptors for influenza A viruses
While the ability of the virus to agglutinate chicken red blood cells was first observed by
Hirst et al. in 1941 [28], it was only in the 1950s that the identity of the receptor on these
erythrocytes was discovered. Pretreatment of erythrocytes with culture filtrates of Vibrio cholerae
destroyed the ability of these erythrocytes to agglutinate in the presence of influenza viruses [29,
30]. The split product of the enzyme treatment was shown subsequently to be sialic acid [31-33].
Sialic acids are a diverse family of 9-carbon monosaccharides, of which the most abundant
member is N-acetylneuraminic acid. They are negatively charged monosaccharides and are
usually present either at the terminal position of the glycan or linked to another sialic acid [34].
Sialic acid is added on to N- or O-glycans by the sialyltransferase family of enzymes. The
sialyltransferase responsible for the addition of sialic acid depends on the monosaccharide it is
added to and the linkage it is attached with. Sialic acid is linked to the penultimate sugar--usually
a galactose (Gal) in either a2-3 linkage or (x2-6 linkage (Figure 3.2). When sialic acid is added to




Figure 3.2: Linkages associated with avian and human specfcity. Avian respiratory tract and intestines are lined
with glycans containing sialic acid in a2-3 linkage while human respiratory tract contains glycans with sialic acid in a2-
6 linkage leading to a simplistic association between sialic acid linkage and HA receptor specificity.
................................................ . :: ...........
Due to its terminal position, it is the monosaccharide that is most likely to interact with
extracellular molecules including pathogens [35]. Influenza A viruses primarily infect the
respiratory tract in humans and pigs and in birds the primary site of infection is the intestines. The
glycans on the epithelial cell surface that are receptors for these viruses are capped with sialic
acid. Early studies with lectin staining revealed that human tracheal and bronchial epithelia
predominantly express a2-6 sialylated glycans [36]. a2-3 sialylated glycans are extensively
expressed at the site of infection in birds (Figure 3.2). It is believed that pig tracheas express both
a2-3 sialylated glycans and a2-6 sialylated glycans, which probably explains how both avian and
human viruses infect pigs [14].
3.1.4 HA-sialic acid interactions: Crystal Structure Analysis
The earliest HA crystal structure resolved was the HA from the H3N2 strain: A/Hong
Kong/1968 by Wilson et al. [25]. The trimeric HA unit is cylindrical in shape and has a globular
head region that comprises the glycan binding site. Structures of several HA proteins from H1,
H3, H5, H7 and H9 subtypes have been solved along with the co-crystal structures of HA with
(x2-3 and/or a2-6 sialylated oligosaccharides [37-43]. Analysis of these HA-glycan co-crystal
structures indicated the amino acids involved in making contact with the sialylated glycan. In
each case, the position of Neu5Ac sugar was found to be fixed relative to the HA glycan binding
site. Crystal structure studies with HA mutants have shown that the Neu5Ac monosaccharide
interacts with a highly conserved set of amino acids: Tyr98, Serffhrl36, Trpl53, Thr155,
Hisl83, Leu/Ile194 (amino acid numbering is based on H3 HA) across different HA subtypes
anchor the Neu5Ac [27]. It is important to note that while the sialic acid head is required to
anchor the HA, the differences in the binding specificities of different HA subtypes arise from the
interactions of the other non-conserved amino acids in the glycan binding site with the different
glycosidic linkages of Neu5Ac to galactose residue. These glycosidic linkages determine the cis-
or trans- conformation adopted by the glycan in the HA-glycan co-crystal structures. In the HA-
a2-3 co-crystal structures, Neu5Aca2-3Gal (a2-3 motif) adopts a trans conformation. In this
conformation, in addition to the conserved anchor points for sialic acid binding, two critical
residues of HA - Glul90 and Gln226 - are involved in binding to the x2-3 motif. Gln226,
located at the base of the binding site, interacts with the glycosidic oxygen atom of the
Neu5Aca2-3Gal linkage; and Glul90, located on the opposite side of Gln226, interacts with
Neu5Ac and Gal monosaccharides [38, 39, 44]. Conversely, in the HA-a2-6 co-crystal
structures, Neu5Aca2-6Gal (a2-6 motif) adopts a cis conformation. In this conformation, the
critical amino acids of HA involved in stabilizing the glycan interaction are subtype specific, but
are conserved within a subtype. In HI HAs, Lys222 and Asp225 are positioned to interact with
the oxygen atoms of the Gal in the x2-6 motif and Asp190 and Ser/Asn193 interact with
additional monosaccharides GlcNAcpfl-3Gal linked to a2-6 motif. In H3 HAs, on the other hand,
Leu226 and Ser228 are positioned to interact with the ax2-6 motif.
3.1.5 HA-glycan binding: Receptor Specificity
The difference in the receptor specificities of HAs from different species was
demonstrated first by Rogers and Paulson in 1983 by studying their ability to agglutinate
red blood cells (RBCs) [45]. The predominance of a2-3 on chicken and equine RBCs and a2-
6 on turkey and guinea pigs RBCs rendered them suitable for use as tools to probe HA-glycan
binding specificity. RBCs from almost all species possess both a2-3 and a2-6 so the agglutination
method was further modified to include the step of complete desialylation of the RBCs followed
by sialylation by specific a2-3- and a2-6- sialyltransferase, to make the agglutination assay more
reliable when probing sialic acid linkage specificity of the different HAs. More recently, specific
a2-3 and a2-6 sialylated glycans isolated from natural sources have also been used in ELISA-
like assays to determine virus receptor specificity. The advent of the chemoenzymatic synthesis
of glycans and development of the glycan array platform enabled the study of HA specificity to
chemically defined glycans [46, 47]. Glycan arrays developed by the Consortium for Functional
Glycomics (www.functionalglycomics.org) comprise several a2-3 and a2-6 oligosaccharides,
which cover motifs corresponding to both O-linked and N-linked glycans [48-50]. Intact viruses,
recombinantly expressed HAs, and their mutant forms (glycan-binding variants) from Hi, H3,
and H5 subtypes have already been analyzed using these glycan arrays [42, 48, 51]. These studies
have classified binding preference based on the number of distinct ax2-3 and cc2-6 glycans that
have detectable binding signals for a given HA. Results from such binding and agglutination
studies have shown that most avian influenza viruses predominantly bind to sialic acid in
a2-3 linkage, whereas the HAs from human adapted viruses predominantly recognize
sialic acid which is ax2-6 linked to the underlying galactose residue. Most studies focused
on characterizing virus specificity based on sialic acid linkage only, but occasional
studies probed the influence of the internal sugars on the viruses' receptor specificity.
Studies by Gambaryan et al. showed the differences in the binding ability of human
adapted HAs to Neu5Acc2-6Galpl-4GlcNAc and Neu5Aca2-6Galpl-4Glc [52].
Similarly, avian viruses isolated from different species, while showing a common
preference to a2-3 sialylated glycans, differed in their recognition for glycan
modification beyond the Gal residue [53]. Despite these results, the sialic acid linkage
was believed the key determinant of receptor specificity. The crossover of the viruses
from birds to humans was believed to be associated with the ability of HA to switch its
receptor specificity from ax2-3 sialylated glycans to x2-6 sialylated glycans.
3.1.6 HA-glycan binding: Role of receptor specificity in transmission
The ability to completely reconstruct the pandemic 1918 HINI viruses through reverse
genetics offered breakthroughs in the exploration of the roles of the different viral genes--
especially HA-in their virulence and transmissibility [5, 54]. The relationship between the
HA glycan binding specificity and transmission efficiency was demonstrated recently in a
ferret model using the 1918 HIN1 viruses. Ferrets offer reliable animal models to study the
human transmission of influenza viruses due to the predominance of human-like x2-6 glycans in
their upper respiratory tract epithelium [23].In the study by Tumpey et al., a prototypic 1918
pandemic virus SC18 was used along with two other variants. One variant was created by
mutating the Asp225 to Gly225 on the HA to reflect a natural variant A/New York/1/I 8
(NYl8) isolated from an archived lung sample. The second variant AV18 was created by
introducing an additional mutation (Asp190 to Glul 90) on NYl 8 HA to match the conserved
HA sequence of avian HIN viruses. SC18, NY18 and AV18 viruses differed only in their HA
sequence while all other 7 genes of the virus were identical. The mutations in HA led to
differences in their glycan receptor binding preference. SC 18 virus had a preference for a2-6
sialylated glycans; NY18 showed binding to both ax2-3 and o2-6 sialylated glycans and
AV18 bound only to ax2-3 sialylated glycans. In ferrets, only SC18 virus showed efficient
respiratory droplet transmission. While NY18 transmitted inefficiently, AV18 did not
transmit. These findings suggested the possibility that a switch in viruses' HA receptor
specificity from ax2-3 to a2-6 sialylated glycans is imperative for efficient transmission
of these viruses. More specifically, a loss of x2-3 sialylated glycan binding and a gain of
binding to a2-6 sialylated glycans was believed to be associated with efficient human
adaptation and transmission of influenza A viruses. However, in the same study, a
contemporary HINI strain, A/Texas/36/91 (Tx9l) that had a mixed a2-3/2-6 binding was
able to transmit efficiently [55]. Observed differences in the transmissibility of NY18 and Tx9l
despite both having mixed 02-3/A2-6 sialylated glycans binding indicates that the "switch"
framework doesn't adequately explain the role of receptor specificity of HA in human adaptation
and transmission of influenza A viruses. This observation demands a detailed understanding of
HA-glycan interaction, beyond binding to sialylated glycans with a specific linkage, and
the role of such an interaction in virus transmission.
3.1.7 HA-glycan binding: Sialic acid linkage and beyond
These confounding results with respect to the correlation between glycan binding
specificity of HA and transmissibility of the viruses led us to pose the following
questions. First, what is the diversity in the sialylated glycans found in the human upper
respiratory tissues (the physiological human glycan receptors), and could this diversity
account for the specificity in the tissue tropism of the virus? Second, are there nuances of
glycan conformation that might play a role in x2-3 and/or Ca2-6 binding specificity of
HA? Taken together, what are the glycan binding requirements of HA, beyond binding to
sialylated glycans with a specific linkage, necessary for human adaptation? Currently,
avian H5N1 viruses have cx2-3 glycan specificity and also show some a2-6 binding [43,
56], but have not yet been able to transmit from human-to-human. Addressing the above
questions would therefore prove an important step towards not only understanding the
human adaptation of these viruses, but also for effective surveillance of the evolution of
this virus into a potential pandemic human virus. In order to address these questions, we
developed a framework comprising of four complimentary analyses for investigating the
human adapted HA binding to x2-3 and x2-6. A set of such approaches would entail (a)
an investigation of the diversity of the sialic acid structures present in the human upper
airways (b) a detailed analysis of the three dimensional structure of the sialylated glycans
predominantly expressed in human upper airway epithelia (c) a molecular understanding
of HA-glycan interaction going beyond the sialic acid linkages (d) a thorough
biochemical characterization of HA-glycan binding specificities while taking into
account the multivalent nature of these interactions (Figure 3.3). The following sections
discuss each of these approaches in greater detail.
3.2 Results
3.2.1 Diversity of sialylated glycans in human respiratory tissues
The first of the four complementary analyses was to delineate the diversity of
sialylated glycans in the human respiratory tissues as a part of answering a long standing
question on the different types of glycans expressed in these tissues. Towards this, we
used formalin fixed and paraffin embedded normal human tracheal and deep lung tissue
sections. An important first step is the screening of tissue sections by performing
hematoxylin and eosin (H&E) staining and a subsequent histopathological analysis on the
Biochemical analyses
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Figure 3.3: Integrated approaches to study HA-sialylated glycan interacdons. Complementary biochemical,
structural and data mining analyses are integrated to develop a framework that enables identification of the glycan
determinants associated with the human adaptation of HA. The first analysis involves a combination of lectin staining
and MALDI-MS techniques to profile the glycans present on the human upper respiratory tissues. The second
structural analysis examines the structural and conformational features of the sialylated glycans, going beyond the sialic
acid linkages and investigates the interaction between HA and glycans with these structural features by analyzing the
HA-glycan co-crystal structures. Third, the data mining analysis of the existing glycan array data for different HAs
enables correlation of these distinct structural features with binding to HA from different viral strins. The findings
from the above approaches are validated by the final biochemical approach which examines the binding specificity of
HA to pre-defined glycans on an array and to physiological glycans expressed on human upper airway tissue sections.
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tissue sections. Normal human tracheal tissues comprise of a pseudostratified epithelium,
a basement membrane, a lamina propria, sub-mucosa, tracheal smooth muscle and
cartilage (Figure 3.4A). The columnar ciliated cells and the goblet cells are the
predominant epithelial cells on the apical side of the respiratory epithelium (Figure
3.4C). Normal human lung sections consist of alveolar type I and type II cells,
bronchioles and connective tissue (Figure 3.4B). The above histological analysis using
H&E staining is critical to ensure that the sections used are indeed from normal adult
trachea/lung and to look for possible damages to the tissues or evidence of any sub-
clinical lung disease. Tracheal tissue sections from different vendors were subjected to
such a histopathological screening. Interestingly, in tissue sections from one block, we
observed the absence of pseudostratified epithelium, presence of a very thick basement
membrane and evidence of leukocyte accumulation (dark round dots), indicating that the
donor might have had sub-clinical lung disease (Figure 3.4D). In sections from another
block, the respiratory epithelium was separated from the basement membrane indicating
the tissue was damaged. Use of such abnormal tissues sections to study the diversity of
sialylated glycans confounds the interpretation of the results as the expression of sialic
acid and its linkages are known to be affected by disease conditions. Thus, while
procuring respiratory tissue sections, it is extremely important to enquire about the
smoking history of the donor and any clinical history of respiratory disorders. A set of
sections from a third block were normal (Figure 3.4A) and only such pre-screened
normal human tissue sections were used in this study.
The sialylated glycans expressed on the tracheal epithelial cells and on the
alveolar cells in the human deep lung function as receptors for influenza A viruses. So the
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Figure 3.4: Histological screening of human respiratory tissues. (A) Shows the H&E staining of normal
human tracheal tissue section. (B) H&E staining of normal human lung tissue section showing alveolar
type I and type II cells along with bronchioles and blood vessels. (C) Apical surface of the pseudostratified
tracheal epithelium magnified to identify the ciliated and goblet cells. (D) Shows an abnormal human
tracheal tissue. The donor possibly had a sub-clinical lung disease highlighted by the presence of
leukocytes (dark spots), very thick basement membrane lining and lack of a pseudostratified respiratory
epithelium. Only normal tissues as shown in (A) and (B) were used in this study.
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first step was to study the distribution of the different sialic acid linkages in these
different cell types. Towards this, tracheal and lung tissues were incubated with plant
lectins that specifically bind to the sialic acid linkages. The two plant lectins used in this
preliminary study were Sambucus nigra agglutinin (SNA-I), which binds to diverse a2-6
linked sialylated glycans (@2-6) and Maackia amurensis lectin (MAL-II), which binds to
diverse a2-3 (a2-3) linked sialylated glycans. The glycan binding specificity of these
lectins has been characterized using glycan arrays (see Methods). The lectin staining
pattern showed that the apical side of the trachea predominantly expressed a2-6 (Figure
3.5) with minimal expression of a2-3. Interestingly, the region of the tissue section
underlying the respiratory epithelium (or the internal region of the trachea) showed
extensive expression of a2-3 as shown by the MAL-II staining (Figure 3.5). In the deep
lung, on the other hand, SNA-I staining pattern showed minimal expression of a2-6 and
MAL-II staining showed a predominant expression of a2-3 in the alveolar cells (Figure
3.5).
To elaborate on the diversity of the predominantly expressed a2-6 in the upper
respiratory tissues, going beyond the sialic acid linkage, human tracheal tissue sections
were co-stained with Con A/Jacalin and SNA-I/Jacalin (Figure 3.6). As mentioned
earlier, SNA-I broadly binds to diverse a2-6 and hence its binding pattern indicated the
distribution of a2-6. Jacalin, which specifically binds to -Galpl-3GalNAcc- and -
GlcNAcl -3GalNAcca- motifs characteristic of 0-linked glycans, predominantly stained
goblet cells. On the other hand, Con A, which specifically binds to the Mannose sugar
commonly found in high mannose, hybrid and complex type N-linked glycans,





Figure 3.5: Distribution of sialic acid linkages human respiratory tissues. (Top) Shows the lectin staining
of normal human tracheal and alveolar tissues with SNA-I, a lectin that binds to diverse a 2-6 sialylated
glycans. The apical surface of the trachea showed significant SNA-I staining while the alveolar tissue
showed minimal SNA staining. (Bottom) Shows the staining of normal human tracheal and alveolar tissues
with MAL-II, a lectin that binds to diverse a 2-3 sialylated glycans. In contrast to the SNA-I binding, the
alveolar tissue shows significant MAL-II staining while the apical surface showed minimal staining with
MAL-IIl. This data indicates that the cells on the apical surface of the trachea epithelium predominantly
express a 2-6 while the cells in the human deep lung tissues predominantly express a 2-3 glycans.
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Figure 3.6:- Glycan iversity in human upper respiratory tissues. Shows co-staining of tracheal tissue
sections with Con A (red)/Jacalin (green) and SNA-I (red)/Jacalin (green). The localized regions of Jacalin
binding correspond to goblet cells expressing O-linked glycans and the regions of Con A binding
correspond to ciliated cells expressing N-linked glycans on the apical side of the tracheal epithelium. The
extensive binding of SNA-I to both goblet cells (co-stain with Jacalin in yellow) and ciliated cells
respectively shows predominant expression of O-linked and N-linked a2-6 on the apical side. We also
examined the co-staining of MAL-II (red)/Jacalin (green). As expected, MAL-II binds minimally to goblet
and ciliated cells in the apical side of the tracheal epithelium but binds extensively to the internal regions of
the trachea.
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demonstrated a more widespread distribution of N-linked a2-6 as compared to the
localized distribution of O-linked x2-6 on the apical side of the human tracheal
epithelium.
In order to characterize the composition and explore the diversity of the X2-6,
profiling of N-linked sialylated glycans of a representative upper respiratory human
bronchial epithelial (HBE) cell line was performed using MALDI-MS analysis. The
MALDI-MS techniques were specifically modified to better suit the analysis of these
complex acidic glycans. The results showed a substantial diversity in the length and
branching of the a2-6 these upper airway cells (Figure 3.7A). A comparison of
untreated, sialidase A (a broad range enzyme which cleaves terminal sialic acid from
oligosaccharides) treated and sialidase S (an enzyme specific for a2-3 sialylated glycans)
treated samples from HBE cells showed the predominant expression of a2-6 in these
cells as compared to a2-3 (Figure 3.8). Further examination by desialylation (Figure
3.7B) and fragmentation of representative mass peaks using MALDI TOF-TOF
demonstrated that long oligosaccharide branches (with multiple lactosamine repeats)
were supported over multiple short lactosamine branches (Figure 3.7C).
3.2.2 Structural analysis
The observation of extensive diversity of the glycan structures in the human upper
respiratory tissues prompted the second complimentary analysis to examine the
conformational features of these diverse sialylated glycans and their role in HA-glycan
interactions. As mentioned earlier, analyses of all the HA-glycan co-crystal structures
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Figure 3.7: Glycan profiling of representative upper airway cells. (A) MALDI-MS glycan profile of
human bronchial epithelial (HBE) cells using graphical representation (without explicit linkage assignment)
of possible sialylated glycan structures that satisfy the mass peaks (within *3.5 Daltons). HBEs
predominantly express ot2-6 (in comparison with ot2-3) sialylated glycans (Figure 3.8). (B) Desialylation
using Sialidase A and subsequent 2-AB labeling of the N-linked glycans observed in A to deconvolute the
branching pattern from the number of sialic acids. The peaks highlighted in cyan in A and B were further
analyzed using TOF-TOF MS. (C) The MS-MS profile of a representative peak at m/z 2148 shows critical
fragment ions at mlz 548 and 713 and their corresponding counter ions (shown in red) that support the long
oligosaccharide branch (with multiple lactosamine repeats) over multiple short lactosamine branches. MS-
MS profile of m/z 2660 also supports a long oligosaccharide branch (data not shown). Glycans are


















Figure 3.8: MALDI-MS glycan profile of HBE cells after sialidase treatment Shown from top to bottom
are the MALDI-MS glycan profiles respectively of the acidic N-linked glycans isolated form HBE cells in
untreated, Sialidase S (specific for a2, 3 sialylated glycans) pre-treated and Sialidase A pre-treated samples.
The glycan profile of the untreated and Sialidase S treated samples is identical indicating the predominant
expression of a2-6 sialylated glycans on the HBE cells. Treatment with Sialidase A dramatically reduces
















indicated that the orientation of the Neu5Ac sugar (SA) is fixed relative to the HA glycan
binding site. The specificity of HA to a2-3 or c2-6 is therefore governed by interactions
of the HA glycan binding site with the glycosidic oxygen atom and sugars beyond SA.
The conformation of the Neu5Aca2-3Gal linkage is such that the Gal and sugars
beyond Gal (at the reducing end, and in both linear and branched a2-3), occupy a 'cone-
like' region of space, and is governed by the glycosidic torsion angles at this linkage;
hence we define it as a cone-like glycan topology (Figure 3.9 and 3.10). In the cone-like
topology, the HA interactions with the glycans primarily involve contacts with Neu5Ac
and Gal sugars in a three sugar (or trisaccharide) a2-3 motif (Neu5Acx2-3Galpl-
3/4GlcNAc-) and this observation is corroborated by the co-crystal structures [38, 39, 41,
42]. In addition to the two critical amino acids: Glul90 and Gln226, the contacts with ax2-
3 motif and the substitutions such as sulfation and fucosylation of this motif appear to
involve key amino acid positions (Figure 3.9). The variability of the amino acids in these
positions could potentially account for the differential binding specificity of HA to the
diverse x2-3 sialylated glycans (see below). As against the Neu5AcCa2-3Gal linkage, the
presence of the C6-C5 bond obviously provides additional glycan conformational
flexibility in the case of Neu5Aca2-6Gal linkage. This flexibility leads to the aC2-6 motif
adopting both a cone-like topology, as well as a wider region of space as in an
'umbrella'; hence we define it as an umbrella-like glycan topology (Figure 3.9 and
3.10). The umbrella-like topology, therefore spans a wider region on the HA surface than
cone-like topology. In contrast to the cone-like topology, oligosaccharide length and
degree of branching beyond a trisaccharide critically influence HA binding contacts in
the umbrella-like topology. Therefore, the amino acids involved in interactions with the
Umbrelle-like topology
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Figure 3.9: Structural topology of sialylated glycans. (A)The topology of K2-3 and a2-6 is governed by
the glycosidic torsion angles of the trisaccharide motifs-Neu5Acm2-3Gal 0 1-3/4GlcNAc and Neu5Acm2-
6Gal,1-4GlcNAc, respectively. A parameter ( 8 ) -the angle between the C2 atom of Neu5Ac and C1
atoms of the subsequent Gal and GlcNAc sugars in these trisaccharide motifs-characterizes the topology.
Superimposition of the 8 contour and the conformational maps of the ot2-3 and oc2-6 motifs showed that the
oc2-3 motif adopts 100% cone-like topology and ot2-6 motif sampled both the cone-like and umbrella-like
topologies (Figure 3.10). (B) In the cone-like topology sampled by %2-3 and oc2-6, the GlcNAc and
subsequent sugars are positioned along a region spanning a cone. The interactions of HA with the cone-like
topology primarily involves contacts of amino acids at the numbered positions (based on H3 HA
numbering) with Neu5Ac and Gal sugars. On the other hand, in the umbrella-like topology, which is unique
to oc2-6, the GlcNAc and subsequent sugars bend toward the HA binding site (as observed in HA-a2-6
cocrystal structures). Longer w2-6 oligosaccharides (at least a tetrasaccharide) would favor this
conformation as it is stabilized by intra-sugar van der Waals contact between acetyl groups of GlcNAc and
Neu5Ac. HA interactions with sialylated glycans with the umbrella-like topology involve contacts of amino
acids at the numbered positions (based on H3 HA numbering) with GlcNAc and subsequent sugars in
addition to contacts with Neu5Ac and Gal sugars.
.........  .. .  .. .. ... . 
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Figure 3.10: Conformational sampling of cone- and umbrella-like topology by a2-3 and a2-6. A-D show
the conformational (e, W) maps of Neu5Aca2-3Gal, Neu5Aca2-6Gal, Galpl-3GlcNAc and Galp14GlcNAc
linkages respectively. These maps obtained from GlycoMaps DB
(http://www.glycosciences.de/modeling/glycomapsdb/) were generated using ab initio MD simulations
using MM3 force field. The energy distribution is color coded starting from red (representing highest
energy) to green representing lowest energy. The encircled regions 1-5 represent the (9, y) values observed
for the a2-3 and a2-6 oligosaccharides in the HA-glycan co-crystal structures. The trans conformation
(encircled region 1) of Neu5Aca2-3Gal predominates in HA binding pocket with the exception of the co-
crystal structure of A/Aichi/2/68 H3N2 HA with a2-3 where this conformation is gauche (encircled region
2). On the other hand the cis conformation of Neu5Aca2-6Gal (encircled region 3) predominates in HA
binding pocket. The cone-like topology is sampled by encircled regions 1 and 2 and the umbrella-like
topology is sampled by encircled region 3. E-F, show sampling of cone like and umbrella-like topologies
by a2-3 and a2-6 motifs respectively. The regions marked in red in the conformational maps were used as
the outer boundaries to calculate the 0 parameter (angle between C2 atom of Neu5Ac and Cl atoms of
subsequent Gal and GlcNAc sugars) for a given set of (p, W) values. Based on the energy cutoff, the value
of 0 > 1100 was used to characterize cone-like topology and 0 < 1000 was used to characterize umbrella-
like topology. Superimposition of the 0 contour with the conformational energy map indicated that a2-3
motif adopts 100 % cone-like topology since it was energetically unfavorable to adopt umbrella-like
topology. On the other hand, the a2-6 motif sampled both the cone-like and umbrella-like topologies and
this sampling was classified based on the to angle (O-C6-C5-H5) of Neu5Aca2-6Gal linkage.
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umbrella-like topology (key numbered positions shown in Figure 3.9) are not conserved
across the human adapted HI and H3 HAs. Depending upon the HA subtype, a
combination of amino acids at these positions are involved in interacting with a long a2-
6, and this observation is corroborated by the co-crystal structures of HI and H3 with ax2-
6 oligosaccharides [37, 41, 44]. The cone-like topology is therefore characteristic of a2-3
as well as short cx2-6 glycans such as single lactosamine branches. On the other hand, the
umbrella-like topology is unique to a2-6 (Figure 3.9) and is typically adopted by long
glycans with multiple repeating lactosamine units.
Interrogation of the HA-glycan co-crystal structures highlights the fact that the
human adapted HI and H3 HAs have mutated from their presumed avian counterparts to
gain additional contacts with a2-6 in the umbrella-like topology. Defining HA-glycan
interactions based on trans and cis conformations (adopted by a2-3 and a2-6 linkages
respectively) is inadequate as this does not fully capture the structural features and
conformational flexibility of the diverse sialylated glycans observed in human tissues.
However, the cone-like and umbrella-like classification for HA binding fully captures the
structural diversity and conformational plurality of sialylated glycans. Significantly, this
classification is able to distinguish the ci2-3 and a2-6 binding of avian HAs from that of
the a2-6 binding of human adapted HI and H3 HAs.
3.2.3 Data mining analysis
The requirements for HA binding to the cone-like and umbrella-like topology was
further corroborated using the third complimentary novel data mining approach to
analyze the extensive glycan array data available for Hi, H3 and H5 HAs [42, 48]. The
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data mining analysis provided correlations between glycan features (Figure 3.11)
abstracted from the glycans on the array and the HA binding to these glycans. These
correlations are given as rules or classifiers (Figure 3.11) which verify the above
structural constraints. Consistent with these observations, the distinct a2-3 classifiers
(Figure 3.11) indicated that variations around the trisaccharide U2-3 motif primarily
influence the differential x2-3 binding of H1, H3 and H5 HAs. On the other hand, the
length dependent x2-6 classifiers (Figure 3.11) support the critical role of
oligosaccharide length in HA binding to a2-6 in the umbrella-like topology. The Ca2-6
classifier common to the human adapted HI and H3 HAs is consistent with their gain in
ability to bind long a2-6. The glycan binding of wild type (WT) and mutant H5N1 HAs
is however not supported by the long a2-6 classifier although it is supported by both a2-
3 and short a2-6 classifiers (Figure 3.11).
3.2.4. Biochemical analysis of HA-glycan binding
The final complimentary analysis involved corroborating the above findings by
establishing the tissue tropism and binding specificity of human adapted HA to upper
respiratory tissue glycans. Towards this, human tissue binding and direct glycan binding
of recombinant HAs were investigated. The HAs from the hallmark pandemic SC 18 and
the human vaccine strain A/Moscow/10/99 H3N2 (Mos99) were chosen as typical
representative human adapted HI and H3 candidates.
The different subtypes of soluble form of HAs were recombinantly expressed in





UnearTuhput rfac n nn + Berachld)
Influenza HA a2-3 Type a2-6 Type
AfkvkWANwta* (Avl" MIA") ~ }O {t N
sTy" C)
)1ps CI
AiuWck4Wpo&%W)1 (Aen. MS) { OR{ No
(PA CO)
{4-1.core)
Mpe A) ape 9)A/budW22W CMOdfa 111 ..wnw MII
Arusx Cawr t# (Nuihn MINI) No 4 p
(y pA9
Arisa0III (um MINI) W: W1O {'ti
(pe )(Type A6
A4uscn6oes (Humn MXNo) No'4-M>-
(Tpe A)
Figure 3.11: Data mining analysis of HA-glycan interactions. (Top)Examples of the types of glycan
features (e.g., pairs, triplets and quadruplets) abstracted from a representative complex glycan structure. A
comprehensive set of these features was abstracted from the glycans in the glycan array. (Bottom)
Graphical representations of the complex classifier rules for each HA analyzed using the glycan array. The
ai2-3 Type A represents broadest specificity, whereas the Type B and Type C classifiers represent
constraints imposed by structural variations around the trisaccharide ot2-3 motif. The ax2-6 Type A
represents binding to long u2-6, whereas Type B represents binding to short us2-6 (linear or branched). The
core corresponds to either the spacer attached to the reducing end or the trimannosyl core in case of the
single Wc2-6 biantennary glycan on the array. aBinding signals observed for fucosylated o2-3 motif only if it
has GlcNAc [6S]. tinding signals observed only for 6'-sialyl lactose. 'Binding signals also observed for
short 6'-sialyl lactosamine (Type B). dBinding signals are significantly lower than 4x2-3 Type B of H5N1
double mutant. eBinding signals observed only for short 0o2-6 with GlcNAc [6S]. Binding signals just
above background observed for oc2-3 motif with GlcNAc [6S]. *The origin of A/Vietnam/1203/04 is avian
6S
but this viral strain was isolated from an infected human. Keys: U 6-0 sulfated GlcNAc; (9/0) Glc or
GalNAc; I4 Non-fucosylated GlcNAc; Gal without GalNAcpl-4Gal linkage.
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fashion to the synthetic glycans on the array and the physiological glycans on the tissues,
the HA was pre-complexed with primary antibody and labeled secondary antibody in the
ratio of 4:2:1, respectively. The cc2-6 binding specificity of the human adapted HAs was
verified using dose dependent direct binding of the pre-complexed HA to a pre-defined
set of ac2-3 and a2-6 oligosaccharides (Figure 3.12). The binding of SC18 and Mos99
HAs over a range of concentrations to 6'SLN-LN indicated their high affinity binding to
the long x2-6 oligosaccharide. In addition to the long x2-6, Mos99 also bound with high
affinity to the short a2-6 oligosaccharide (6'SLN) and at a relatively lower affinity to the
long a2-3 oligosaccharide (3'SLN-LN-LN).
SC18 and Mos99 HAs showed distinct binding patterns to human respiratory
upper (tracheal) and deep lung (alveolar) tissues (Figure 3.13). Importantly, both HI and
H3 HA showed significant binding to the apical side of tracheal tissue sections. As noted
earlier (Figure 3.6 and 3.7), long branch a2-6 are predominantly expressed on the apical
side of the upper respiratory epithelia. Interestingly, Mos99 showed binding to the
internal region of the trachea and the alveolar sections (which predominantly express a2-
3), consistent with its binding to a2-3 in the direct binding assay. In order to confirm that
the binding was specific to sialic acid, the tissue sections were pre-treated with sialidase
A, an enzyme that cleaves terminal sialic acid residues. There was a substantial reduction
in the binding of SC18 to the sialidase pre-treated tissues indicating that the binding is
indeed sialic acid specific (Figure 3.14). Also, to confirm that the binding of the HAs
was mainly to ax2-6, competition experiments were done with the plant lectin SNA-I
which has a broad specificity to a2-6 and SC18. SNA-I binding to tissues dramatically
reduced the binding of SC18 to the apical side of the trachea indicating that the HAs
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Figure 3.12: Dose dependant direct binding assay of SC18 and Mos99 HAs. The binding specificity of
SC18 and Mos99 HAs was demonstrated with dose-dependent direct binding to defined m2-3 and cx2-6
oligosaccharides. The characteristic binding pattern of SC18 and Mos99 HAs is their binding at saturating
levels to the long oc2-6 (6'SLN-LN) over a range of HA dilution from 40 to 5 ag/ml. The narrow specificity
of SC18 HA correlates with its restrictive tracheal tissue binding. On the other hand, the ability of Mos99
HA to bind to diverse sialylated glycans is consistent with its more extensive binding to tracheal tissue
sections (as compared with SC18). The high affinity binding of SC18 and Mos99 HAs to long o2-6 was
confirmed using another human-adapted H3N2 (A/Wyoming/3/03) HA (Figure 3.16).
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Figure 3.13: Human tissue binding of SC18 and Mos99 HAs. Both SC18 and Mos99 H As show
significant and preferential binding to the apical side of the tracheal tissue (green against as against
propidium iodide staining in red) which predominantly express umbrella-like topology glycans. The
binding of SC18 is restrictive compared to the extensive binding of Mos99.Consistent with the direct
binding results; SC18 shows minimal binding to the alveolar tissue (which express a2-3) as against Mos99
HA which extensively binds to the alveolar tissue sections. The sialic acid specific binding of HA is




Figure 3.14: Sialic acid speciic binding of HA to lung tissue sections. The sialic acid specific binding of
HA to the tracheal tissues is confirmed by minimal to no tracheal staining of the representative SC18 HA
after pretreatment of the tissues with Sialidase A.
SC 8 HA SNA pretreatment + SC18 HA
Figure 3.15: Binding of SC18 HA to a 2-6 sialylated glycans. The a2-6 specific binding of HA to the
tracheal tissues is confirmed by competition experiments done by pre-treating the tissue samples with
SNA-I and then incubating the tissues with SC18 HA. SNA-I pre-treatment significantly reduces SC18
binding (shown in red) to the apical surface of the tissues shown by a decrease in the binding signal in the
samples with SNA-I pre-treatment (right) as compared with control tissue sections (left).
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specifically bind to o2-6 sialylated glycans in human tracheal tissue sections (Figure
3.15).
Another human adapted HA, Wyoming03 (A/Wyoming/3/03), was used to
confirm the high affinity binding of human adapted HAs to long a2-6. Unlike the
precomplexation step included for the binding of SC18 and Mos99, the glycans in the
array and the tissue sections were sequentially incubated with different doses of the full
length Wyoming03 protein followed by incubation with primary and labeled secondary
antibodies. Our results show that Wyoming03 also preferentially binds to long a2-6 with
high affinity in the dose-dependant direct binding assay. Wyoming03 also shows
significant binding to the apical side of the tracheal sections, similar to the binding of
SC18 and Mos99 (Figure 3.16).
Taken together, the above findings show that the human adapted HAs bind
specifically to the long a2-6 (in the umbrella-like topology) that are predominantly
expressed in the human upper respiratory tissues. The a2-3 binding of Mos99 further
suggests that a switch in the glycan binding preference (i.e. losing ability to bind to x2-3)
is not a necessary determinant for human adaptation of HA. Importantly, Tx91, also a
mixed a2-6/a2-3 binding virus that shows HA binding to long a2-6 (Figure 3.11), is
able to efficiently transmit [55]. On the other hand, NY18 another mixed O2-3/2-6
binding virus that does not have HA binding specificity to long c2-6 (Figure 3.11), does
not transmit efficiently [55]. The efficient human adaptation of these viruses is therefore
correlated to HA binding to sialylated glycans of a characteristic umbrella-like topology,
going beyond the specific a2-3 or a2-6 linkage.
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Figure 3.16: Tissue binding and dose dependent direct binding of WyomingO3. To confirm the high
affinity binding of human adapted HI and H3 HA to the long a2-6 sialylated glycans expressed in the
upper respiratory tissues, direct binding and tissue binding studies were performed on Wyoming03, another
human adapted H3N2 HA. Unlike the truncated soluble HA constructs of SC18 and Mos99, the
Wyoming03 is a full length protein and was detected using a ferret polyclonal H3N2 anti-sera primary
antibody. The high affinity binding of Wyoming03 to long a2-6 sialylated glycans is established by the
dose response direct binding (top). Furthermore, the significant binding of Wyoming03 to the apical side of
the tracheal tissue sections (bottom) is similar to that observed with SC18 and Mos99 (Figure 3.13).
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3.2.5 Implications for avian H5N1 viruses
Understanding the glycan binding specificity of influenza A virus HA is critical
for surveillance of the evolution of highly pathogenic strains, such as H5N1, to gain a
foothold in the human population. To study the glycan binding properties of HAs from
H5N1 viruses, the above mentioned dose-dependant direct binding assays and tissue
binding assays were repeated with Viet03O4 (A/Vietnam/03/04) HA. The results of the
direct binding assay showed that the Viet03O4 HA, preferentially bound to a2-3 with
minimal binding to long a2-6 (Figure 3.17). Further, in contrast to the human adapted
HAs, the Viet03O4 HA bound to the diverse a2-3 expressed in the alveolar tissues and
showed minimal binding to the apical side of the trachea (Figure 3.17).
Some strains of the highly pathogenic a2-3 specific H5N1 viruses show mixed
a2-3/a2-6 binding [24, 43] and yet these viruses have shown inefficient transmission in
ferret models [24]. Further examination of the glycan binding properties of representative
H5N1 viruses - A/Vietnam/1203/04 (Viet03O4) and A/Hong Kong/486/97 (HK486)
revealed minimal binding affinity of the viruses to long a2-6 (Figure 3.18). This lack of
high affinity binding to long a2-6 could possibly explain why these H5N1 viruses have
not yet gained a foothold in human population. While additional factors such as the NA
and other viral gene products may play a role in H5N1 viral transmission, a necessary
condition for the human adaptation of its HA is to acquire mutations that would provide
binding specificity to long x2-6. The glycan topology could also play an important role in






T T T Tr
HA Concentration (pugimI)
Figure 3.17: Tissue binding and dose dependent direct binding of VietO304 HA. A, Consistent with
earlier reports 3, 5 of H5N1 virus binding to tissues, the Viet0304 HA (in green against propidium iodide in
red) binds extensively to the diverse and predominant a2-3 expressed in deep lung (alveolar) as against the
upper respiratory (tracheal) tissue sections. B, Shows dose dependent direct binding of Viet03O4 HA.
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Figure 3.18: Dose dependant direct binding assays with H5N1 viruses. In contrast to the dose-dependent
binding profile of the human-adapted SC18 and Mos99 HAs, Viet03O4 and HK486 H5N1 viruses bind with
high affinity to the ot2-3 and minimal affinity to the long o02-6 oligosaccharide. The dose-dependent direct
binding of the whole virus corroborates with the binding of soluble HA protein and the deep lung tissue
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3.3 Discussion
Three related issues have confounded the interpretation of glycan receptor
specificity leading to human adaptation of HA. The first issue arises from the association
of 'human-like receptor' to just the Neu5Aca2-6Gal linkage. This is evident from the use
of short (x2-6 oligosaccharides 6'SL and 6'SLN to define glycan binding specificity of
the H5N1 viruses [24, 43]. These and other earlier studies have predominantly focused on
cc2-3 and ca2-6 linkages, and a switch in the linkage preference. However, since both x2-
3 (short, long, linear and branched) and short a2-6 adopt the cone-like topology as
against the long c2-6 that adopts the characteristic umbrella-like topology, it is the
glycan topology and not just the linkage per se that is the key determinant for human
adaptation of HAs. The second issue deals with the binding specificity of HA-glycan
interactions. Many of the HA glycan array experiments [57] have been performed at a
relatively high HA concentration, without a dose-dependent relationship to establish
specificity. The dose-dependent binding studies presented here enabled us to investigate
the HA-glycan binding affinities and thereby demonstrate long a2-6 binding specificity
of human adapted HAs (Figure 3.12). These studies can be further extended to derive
parameters such as binding affinity constants to quantify the relative glycan binding
affinities of different HAs. The two representative H5N1 viruses showed binding signals
for long x2-6 at the highest viral concentrations. However, the binding affinity for long
a2-6 is minimal compared to the high affinity for ax2-3 over the entire viral concentration
range (Figure 3.18). Interpretation of the glycan binding data at the highest concentration
alone would have led to an erroneous conclusion that these viruses have acquired binding
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to human-like receptors. The third issue deals with the use of chicken red blood cells
agglutination assays. Desialylated and a2-6 resialylated chicken RBCs have been
extensively used in agglutination assays to study ax2-6 binding specificity of WT and
mutant viruses [51, 55, 58]. MALDI-MS glycan profile of chicken RBCs (Figure 3.19)
shows limited abundance of N-linked x2-6 with long branches. Thus, a2-6 resialylation
of these RBCs is unlikely to provide the required human-like receptors defined in the
approach presented in this study.
In light of the present study, employing glycan arrays with long x2-6 would be a
valuable tool for surveillance of the evolution of various Influenza A viral subtypes
leading to human adaptation. Specifically, this can be achieved either by expanding the
diversity of the glycans to include upper respiratory tissue -specific glycans on the
current glycan microarrays, or through the development of a glycan array which includes
representative long a2-6 structures based on those observed in the upper respiratory
tissues. Furthermore, these arrays need to be developed for rapid-dose dependent
analyses of HA binding in order to establish specificity to long cx2-6 structures.
Adaptation studies with the avian viruses using appropriate long a2-6 structures might
provide the needed selection pressure for human adaptation. The ability of H5N1 to bind
cone-like topology glycans with high specificity may explain why selection pressure
strategies based just on glycan linkages have been unsuccessful. Finally, a recent study
reported that the mutations in the glycan binding site of HA (leading to human receptor
binding) could facilitate the generation of antibodies with better neutralizing sensitivity



















Figure 3.19: MALDI-MS analysis of N-linked glycans isolated from chicken RBCs. The MALDI-MS
glycan profile of chicken RBCs shows the lack of predominant expression of sialylated glycans with long
oligosaccharide branches as observed with those expressed in HBEs. The graphical representation (without
explicit linkage assignment) of possible sialylated glycan structures that satisfy the mass peaks (within




binding specificity, therefore offers an opportunity for intervention through vaccine
development to negate the eventuality of a H5N1 pandemic.
3.4 Methods
3.4.1 Lectin staining of human upper respiratory tissues.
Normal human trachea tissue sections (US Biological) were deparaffinized and
rehydrated, followed by blocking endogenous biotin using the streptavidin/ biotin
blocking kit (Vector Labs). Sections were then incubated with FITC labeled Jacalin,
biotinylated Concanavalin A (Con A) and biotinylated Sambuccus nigra agglutinin
(SNA-I) (Vector labs; 10 ig/ml in PBS with 0.05% Tween-20) for 3 hrs. After washing
with TBST (Tris buffered saline with 0.1% Tween-20), the sections were incubated with
Alexa fluor 546 streptavidin (Invitrogen) for 1 hr. Slides were washed with TBST and
viewed under a confocal microscope (Zeiss LSM510 laser scanning confocal
microscopy). All incubations were performed at 22 *C. The glycan array data for the
plant lectins can be accessed from the Consortium for Functional Glycomics (CFG) web
site -
http://www.functionalglycomics.org/glycomics/publicdata/primaryscreen.jsp by selecting
Plant lectins in the "Analyte Category".
3.4.2 MALDI-MS and TOF-TOF MS analysis of N-linked glycans.
Human bronchial epithelial (HBE) cells (16HBE14o-; gift from Dr. D.C.
Gruenert, University of California, San Francisco) were chosen as representative upper
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respiratory ciliated epithelial cells based on the extensive attachment of human adapted
HINI and H3N2 viruses to these cells[59]. These cells were harvested at >90%
confluency with 100 mM citrate saline buffer and the cell membrane was isolated by
homogenization. Washed and pooled RBCs (Rockland Immunochemicals) were lysed by
resuspending in deionized water for 15 minutes and the cell membrane was isolated as
described above. The cell membrane fractions were treated with PNGaseF (New England
Biolabs) and the reaction mixture was incubated overnight at 37 *C. The reaction
mixture was boiled for 10 minutes to deactivate the enzyme and the deglycosylated
peptides and proteins were removed using a Sep-Pak C18 SPE cartridge (Waters). The
glycans were further desalted and purified into neutral (25% acetonitrile fraction) and
acidic (50% acetonitrile containing 0.05% trifluoroacetic acid) fractions using graphitized
carbon solid-phase extraction columns (Supelco) and lyophilized.
MALDI-TOF Analysis: The neutral and acidic fractions were analyzed by MALDI-TOF
MS in positive and negative linear modes respectively with soft ionization conditions
(accelerating voltage 22 kV, grid voltage 93%, guide wire 0.3% and extraction delay time
of 150 ns). Matrices used were as follows: 10 mg/ml 6-aza-thiothymine in ethanol spotted
on perfluorinated Nafion resin for acidic glycans and 40 mg/ml 2,5-dihydroxybenzoic
acid in ethanol for neutral glycans. The peaks were calibrated as non-sodiated species
using external glycan standards. The predominant expression of a2-6 sialylated glycans
was confirmed by treatment of samples using Sialidase A and S. Briefly, the isolated
glycans were incubated with 0.1 U of Arthrobacter ureafaciens sialidase (Sialidase A,
cleaves both a2-3 and ca2-6 sialic acid linkages) or Streptococcus pneumoniae sialidase
(Sialidase S, specifically cleaves a2-3 sialic acid linkage) in a final volume of 100 p.L of
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50 mM sodium phosphate, pH 6.0 at 37 "C for 14 hrs. The glycans were purified as
before and the sialidase treated glycans were analyzed by MALDI-TOF MS.
TOF-TOF Analysis: Sialidase A treated glycans were 2-aminobenzamide (2-AB)
derivatized as described previously [60], purified [61] and lyophilized. MS/MS mass
spectra were acquired on an Applied Biosystems 4700 TOF/TOF Proteomics analyzer,
equipped with delayed extraction and a UV laser (355 nm) controlled by AB 4700 Data
Explorer software. 1 pl of a 5 mg/ml solution of (-cyano-4-hydroxycinnamic acid
prepared in acetonitrile/water mixture (60:40, v/v) was seeded on a standard 192-well
stainless steel MALDI sample plate and allowed to air dry. Subsequently, 1 [1 of 2-AB
labeled glycan sample was spotted on the matrix and allowed to dry. Typically, 1000 -
5000 shots/spectrum was collected in the positive reflector mode for MS/MS spectra.
CID mode (with air as the collision gas) with a chamber pressure of 1-6 x 10-6 Torr and
acceleration voltage of 2 kV was used for glycan fragmentation and internal peptide
standards were used for calibration.
3.4.3 Cloning, baculovirus synthesis, expression and purification of HA.
The soluble form of HA was expressed using the Baculovirus Expression Vector
System (BEVS). Baculoviruses containing SC18 and Mos99 HAs were a gift from Dr.
James Stevens. H5N1 (A/Vietnam/1203/2004; Viet03O4) baculovirus was created from a
pAcGP67-VietO4-HA construct [42] using Baculogold system (BD Biosciences)
according to manufacturer's instructions. The crystal structure of the BEVS expressed
uncleaved HAO from SC 18 [62] is identical to the structure of the SC 18 HA isolated from
the whole virus after bromelain treatment [44]. Studies have also shown that glycan
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binding specificity of BEVS-expressed HAs is in agreement with that of whole viruses
[57]. The baculoviruses were used to infect 500 ml suspension cultures of Sf9 cells
(Invitrogen) cultured in Sf900 II SFM medium (Invitrogen). The infection was monitored
and the cells were harvested 3-4 days post-infection. The soluble form of HA was
purified from the supernatant of the infected cells using the protocol described previously
[62]. Briefly, the supernatant was concentrated using Centricon Plus-70 centrifugal filters
(Millipore) and the soluble HA was recovered from the concentrated cell supernatant by
performing affinity chromatography using Ni-NTA beads (Qiagen). Eluting fractions
containing HA were pooled and dialyzed overnight with a 10 mM Tris-HCl, 50 mM
NaCl buffer (pH 8.0). Subsequently, ion exchange chromatography was performed on the
dialyzed samples using a Mono-Q HR1O/10 column (GE healthcare). The fractions
containing HA were pooled together and subjected to ultrafiltration using Amicon Ultra
100 K NMWL membrane filters (Millipore). The protein was concentrated and
reconstituted in PBS. The purified protein was quantified using Bio-Rad's protein assay
(Bio-Rad).
3.4.4 Binding of H1, H3 and H5 HA to human lung tissues.
Normal human Trachea (US Biological) and lung (US Biomax Inc) tissue sections
were deparaffinized, rehydrated and incubated with 1% BSA in PBS for 30 minutes to
prevent non-specific binding. SC18 and Mos99 were pre-complexed with primary
antibody (mouse anti 6X His tag, Abcam) and secondary antibody (Alexa fluor 488 goat
anti mouse, Invitrogen) in a ratio of 4:2:1, respectively, for 20 minutes on ice. The tissue
binding was performed over different HA concentrations by diluting the pre-complexed
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HA in 1% BSA-PBS. Tissue sections were then incubated with the HA-antibody
complexes for 3 hours at 22 *C. Sections were counterstained with propidium iodide
(Invitrogen; 1:100 in TBST), washed extensively and then viewed under a confocal
microscope (Zeiss LSM5 10 laser scanning confocal microscopy). In the case of sialidase
pretreatment, tissue sections were incubated with 0.2 units of Sialidase A (recombinant
from Arthrobacter ureafaciens, Prozyme) for 3 hours at 370 C prior to incubation with
the proteins.
3.4.5 Tissue binding and dose-dependent direct binding of WyomingO3 and VietO3O4
HA.
The tissue binding and dose dependent direct binding of human adapted HI and
H3 HAs was confirmed using another H3N2 HA (A/Wyoming/3/03; Wyoming03), a full
length HA protein (from Protein Sciences Inc) unlike the truncated soluble constructs.
The tissue sections were prepared as described in the main text. The binding of
Wyoming03 to the tissue was carried out in a sequential fashion by first incubating
with protein (in PBS) for 3 hrs followed by pre-blocking with 2% BSA-PBS for 30 min.
The sections were then incubated with polyclonal ferret H3N2 HA antisera (Center for
Diseases Control) for 3 hrs, washed extensively and incubated with labeled goat- anti
ferret antibody (Rockland Inc.; 1:500 in 2% BSA-PBS) for 60 min. The tissue binding of
H5 HA was performed using the full length version of Viet03O4 and the binding assay
was carried out similar to Wyoming03 using rabbit anti H5N1 HA primary antibody (Pro
Sci Inc.; 1:200 in 2% BSA-PBS) and Alexa flour 488 goat anti-rabbit secondary antibody
(Invitrogen; 1:500 in 2% BSA-PBS). The dose dependent direct binding of Wyoming03
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was carried out sequentially at various HA concentrations (range of 1 - 40 pig/ml) using
the polyclonal ferret H3N2 antisera and HRP-linked goat anti-ferret antibody (Rockland
Immunochemicals). The dose dependent direct binding of Viet03O4 HA was carried out
using the soluble construct (as in the case of SC 18 and Mos99) as described in the main
text.
3.4.6 Dose dependent direct binding of Hi, H3 HA and H5 viruses.
Streptavidin-coated High Binding Capacity 384-well plate (Pierce) was rinsed
with PBS and each well was incubated with 50 pl of 2.4 ptM solution of biotinylated
glycans (3'SLN, 6'SLN, 3'SLN-LN, 6'SLN-LN and 3'SLN-LN-LN) in PBS overnight at
4 "C. LN corresponds to lactosamine (Galpl-4GlcNAc) and 3'SLN and 6'SLN
respectively correspond to Neu5Aca2-3 and Neu5Acax2-6 linked to LN. These glycans
were obtained from the Consortium for Functional Glycomics (CFG). The plate was
subsequently washed with PBS to remove excess glycan and used without further
processing. Appropriate amounts of His tagged HA protein, primary (Mouse anti 6X His
tag IgG, Abcam) and secondary (HRP conjugated goat anti Mouse IgG, Santacruz
Biotechnology) antibodies were mixed in the ratio 4:2:1 and incubated on ice for 20
minutes. The highest HA concentration of 40 jig/ml was chosen based on typical
concentrations used in CFG glycan array analysis [57]. The mixture (pre-complexed HA)
was made up to a final volume of 250 pl with 1% BSA in PBS buffer and 50 pl of pre-
complexed HA was added to each glycan coated well and incubated at 22 *C for 2 h. The
wells were extensively washed with PBS containing 0.05% Tween-20 followed by
washes with PBS.
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Virus stocks (from CDC) were propagated in the allantoic cavity of 10-day-old
embryonated hens' eggs at 37 *C. The allantoic fluids were harvested 24 h post
inoculation and inactivated by treatment with B-propiolactone (BPL; 1/1,000) for 3 days
at 4 *C. Virus binding to the glycan-coated wells was performed as described [43] by
adding appropriate amount of virus to each well after diluting in PBS containing 1%
bovine serum albumin and incubating overnight at 4 *C. After rinsing excess virus with
PBS containing 0.05% Tween-20 and PBS, the wells were incubated with antibody
against the virus (ferret-anti-influenza A raised against A/Hong Kong/213/03 H5N1) for
5h at 4 "C. Following extensive washing of the antibody, the plate was incubated with
HRP-linked goat-anti-ferret antibody (Rockland Immunochemicals) for 2h at 4 *C. After
extensive washes with PBS containing 0.05% Tween-20 and PBS, in all cases, HRP
activity was estimated using Amplex Red Peroxidase Assay Kit (Invitrogen) according to
manufacturer's instructions. Appropriate negative controls were included and all assays
were done in triplicate.
3.4.7 Data mining analysis of glycan microarray data.
The data from glycan microarray screening of HI, H3 and H5 HA were obtained
from the Consortium for Functional Glycomics (CFG) web site -
http://www.functionalglycomics.org/glycomics/publicdata/primaryscreen.jsp. From this
web page, the "Other" option in the "Analyte category" was selected to obtain a list of
microbial lectins screened on the glycan array. The data for all influenza virus HAs were
obtained by sorting this list by investigator and searching the sorted list using "Jim
Paulson" as the investigator name. The principle and methodologies for data mining
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analysis are well established in many fields and involve two main aspects: feature
abstraction and classification. A variety of features including all possible di, tri and
tetrasaccharide combinations present in each glycan in the glycan array were abstracted
(Figure 3.11). The rationale behind choosing these features is based on the binding of
di-, tri- or tetrasaccharides to the glycan binding site of HA. The final dataset comprises
of features from the glycans, as well as the binding signals for each of the HAs screened
on the array. Among the different methods for classification, the rule induction
classification method was utilized. One of the main advantages of this method is that it
generates IF-THEN rules which can be interpreted more easily when compared to the
other statistical or mathematical methods.
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Quantitative Biochemical Rationale for Differences in
Transmissibility of 1918 Pandemic Influenza A Viruses
Summary
The human adaptation of influenza A viruses is critically governed by the binding
specificity of the viral surface hemagglutinin (HA) to long (chain length) a2-6 sialylated
glycan (a2-6) receptors on the human upper respiratory tissues. A recent study
demonstrated that while the 1918 HINI pandemic virus, A/South Carolina/l/1918
(SC18), with oa2-6 binding preference transmitted efficiently, a single amino acid
mutation on HA resulted in a mixed ca2-3 sialylated glycan (c2-3)/a2-6 binding virus
(NYl8) that transmitted inefficiently. In order to define the biochemical basis for the
observed differences in virus transmission, in this study, a biochemical approach has been
developed to quantify the multivalent HA-glycan interactions. Analysis of the molecular
HA-glycan contacts showed subtle changes resulting from the single amino acid
variations between SC 18 and NYl 8. The effect of these changes on glycan binding is
amplified by multivalency resulting in quantitative differences in their long a2-6 glycan
binding affinities. Furthermore, these differences are also reflected in the markedly
distinct binding pattern of SC18 and NYl8 HA to the physiological glycans present in
human upper respiratory tissues. Thus, the dramatic lower binding affinity of NY18 to
long a2-6 glycans, as against a mixed a2-3/6 binding, correlates with its inefficient
transmission. In summary, this study establishes a quantitative biochemical correlate for
influenza A virus transmission.
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The work presented in this chapter is reproduced with permission from Proc Natl
Acad Sci USA. 2008 February 26; 105(8): 2800-2805. Copyright 2008 by The National
Academy of Sciences of the USA.
4.1 Introduction
The "Spanish" influenza pandemic of 1918 caused by the HINI subtype virus
resulted in approximately 20-50 million deaths worldwide (1). The emergence of avian
influenza H5N1 viruses that are able to infect humans (>300 known cases) and produce a
high mortality rate (around 200 deaths) has raised serious global health concerns.
Significantly, adaptation of these viruses for efficient human-human transmission could
result in a new influenza pandemic--a public health disaster of tragic proportions.
The critical step in the host infection of influenza viruses is the binding of their
viral surface hemagglutinin (HA) to sialylated glycan receptors on the epithelial cell
surface of the host organism (2-6). The evolution of pandemic viruses involves crossing
over of avian influenza viruses (natural host) to humans and adaptation to the human host
for subsequent infection and human-human transmission (2, 7). This crossover is
believed to involve mutations in HA that switch its glycan receptor preference from oC2-3
sialylated (c2-3) to c2-6 sialylated (@2-6) glycans found in abundance in human upper
respiratory epithelia (3-5, 8). The human upper respiratory tract ac2-6 receptor adaptation
of HA is a critical step in permitting the viruses to infect and efficiently replicate in these
tissues and leading to rapid human-human transmission (8). Several studies have been
performed to elucidate the distribution of glycans in human upper respiratory tissues (4,
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8-10). We recently demonstrated that human upper airways express a diversity of aX2-6
structures with a predominant expression of long oligosaccharides (11). More
importantly, we observed that both a2-3 and short a2-6 glycan structures obtain a
distinct, narrow cone-like topology while long cc2-6 glycans adopt a flexible umbrella-
like topology. Human adapted HI and H3 HA demonstrated high affinity binding
specificity to long x2-6 glycans that are expressed in the human upper respiratory
epithelium. The classification of HA glycan specificity in terms of the glycan topology
instead of the linkage has permitted us to distinguish the observed a2-3 and ax2-6 binding
of avian HAs from that of the 02-6 binding of human adapted HA. Based on these
observations, we postulated that HA specificity to 02-6 glycan receptors with distinct
topology is the critical determinant for efficient human adaptation of HA.
The relationship between HA mutations which lead to a change in glycan receptor
preference and transmissibility of the prototypic 1918 HIN1 pandemic virus - A/South
Carolina/1/1918 (SC18) - has been investigated using the ferret model (12). Recently,
Tumpey et al demonstrated that the SC18 with a2-6 binding preference transmitted
efficiently but a single amino acid HA mutation (SC 18 + 1 mutation) resulted instead in a
mixed a2-3/a2-6 binding virus (NY18) that transmitted inefficiently (12). Furthermore, a
second HA mutation (NY18 + one mutation) resulted in an a2-3 binding virus (AV18)
that did not transmit. This model system is ideally suited to study transmissibility purely
based on HA mutations, as all other genes are identical in the different viruses. These
remarkable differences in virus transmission as the result of a single amino acid mutation
on HA, in turn raise important questions about HA-glycan specificity in the context of
glycan topology not only for human adaptation but also for efficient transmission.
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In this study, we have developed a quantitative framework to investigate HA-
glycan specificity to explain the observed differences in the transmissibility of the 1918
pandemic influenza A viruses. The differences in the molecular HA-glycan contacts due
to the single amino acid variations were investigated using HI HA - glycan co-crystal
structures (13). The effects of these subtle differences on the multivalent HA-glycan
interactions were captured using a quantitative glycan-binding assay to establish the
relative glycan binding affinities of the HAs. The physiological relevance of the
differences in the HA-glycan binding affinities was investigated using HA binding to
human upper respiratory tissues. Taken together, this approach establishes a quantitative
biochemical correlation between influenza virus HA - glycan binding and virus
transmission.
4.2 Results
4.2.1 Molecular interactions of SC18, NY]8 and A V18 HAs with a2-3 and a2-6
Based on analysis of HA-glycan co-crystal structures, the HA-glycan interactions
are characterized using a cone-like and an umbrella-like glycan topology (11). The x-ray
crystal structure of SC18 HA has been solved (13, 14) but the co-crystal structure of this
HA with sialylated glycans remains unsolved. The structures of NY18 and AV18 HA
were obtained by making the single Asp225Gly (for NY18 HA) and the additional NY18
+ Asp190Glu mutation for AV18 in silico. The co-crystal structures of the related
A/Swine/Iowa/15/30 (ASI30) and A/Puerto Rico/8/34 (APR34) HINI HAs with a2-3
and a2-6 glycans (13) enabled the investigation of molecular interactions between SC18,
NYl 8 and AV18 with x2-3 and a2-6 oligosaccharides.
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The umbrella-like topology is preferred by longer a2-6 oligosaccharides
(tetrasaccharide and higher). The LSTc pentasaccharide (Neu5Acx2-6Galp1-
4GlcNAc1-3Galpl-4Glc) used in the APR34 and AS130 HA - ac2-6 co-crystal
structures represents this long a2-6. Superimposition of these co-crystal structures and
SC 18 HA demonstrated that the contacts with long c2-6 oligosaccharide are divided into
two regions. The base region involves contacts with Neu5Aca2-6Galpl- motif and the
extension region involves contacts with -GlcNAcp1-3Galpl-4Glcpl- motif. A highly
conserved set of amino acids (Tyr95, Ser/Thrl36, Trpl53, Thrl55, Hisl83, Leu/Ile194)
are involved in anchoring the Neu5Ac (Figure 4.1). In the case of APR34 and SC18
HAs, both the backbone carbonyl oxygen and side chain of Asp225 are positioned to
interact with the Gal sugar in the base region. On the other hand, only the carbonyl
oxygen of Gly225 in AS130 HA is positioned to interact with this Gal (Figure 4.1).
Highly conserved Lys222 and Gln226 are also positioned to interact with the base region.
The critical amino acids involved in contacts with the extension region are Asp190 (in
SC18 and AS130 HA), Gln192 and Ser193 (Asn193 in APR34 HA). NY18 HA, the
Asp225Gly mutant of SC18, shares an almost identical glycan binding site with that of
AS130 HA and therefore lacks the extra contact provided by the side chain of Asp225
with Gal in the base region. In contrast, AV18 - the Aspl90Glu/Asp225Gly double
mutant of SC 18-lacks the critical contacts provided by both Asp225 and Asp190 to the
base and extension regions respectively. Among SC 18, NY18 and AV18 HAs, SC18 HA
provides the best contacts with the long ca2-6 in the umbrella-like topology followed by
NY18 HA.
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Figure 4.1: Molecular interactions of SC18, NY18 and AV18 HAs with a2-3 and a2-6. The glycan
binding site on HA is shown with the critical amino acids including the highly conserved Neu5Ac anchors
(Thrl36, Trpl53, Tbr155 and Leul94). Tyr95 and His183 are not shown for clarity. The amino acid
positions are numbered based on HINI HA. A, shows the interaction of the SC18 HA with long a2-6 in
the umbrella-like topology. Lys222, Asp225 and Gln226 provide critical contacts with the base region, and
Asp190, Gln192 and Ser193 provide optimal contacts with the extension region. B, interaction of NY18
HA with the long a2-6 shows the loss of the critical contact of Asp225 with the base region (as observed in
the case of SC18 HA in A). C, interaction of AV18 HA with a2-3 in cone-like topology shows that HA
interactions with cone-like topology involves contacts only with the Neu5Ac and Gal sugars at the base in
contrast to that of the umbrella-like topology of long a2-6. Glul90 and Gln226 in AV18 are positioned to
provide optimal contacts with these sugars. The side chain conformation of Glul90 in AV18 was assigned
based on that of Glul90 in APR34 HA - a2-3 co-crystal structure. D, shows the differences in the key
amino acid positions between SC18, NY18 and AV18 HAs comparing them with the ASI30 and APR34
HAs. The differences in the amino acid contacts with a2-3 and a2-6 are quantified using buried solvent
accessible area calculations.
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Distinct from the umbrella-like topology, the cone-like topology can be adopted
both by a2-3 and ca2-6 (preferentially by short trisaccharide units such as Neu5Aca2-
6Galpl-4Glc (or GlcNAc)). Unlike the two distinct regions of HA contacts found with
the umbrella-like topology, the contacts with the cone-like topology primarily involve
substitutions which center around a trisaccharide Neu5Aca2-3/6Galpl-3/4Glc (or
GlcNAc) motif as observed in the HA - a2-3 co-crystal structures. Specifically, Glul90
and Gln226, which are highly conserved across various avian HAs, are critically involved
in making optimal contacts with the cone-like topology (Figure 4.1). This observation is
corroborated further by the disordered sugars beyond Neu5Ac in the AS130 HA - a2-3
co-crystal structure since Asp instead of Glu at 190 in this HA lacks the contact with the
a2-3. Superimposition of AV18 and APR34 HA, which both contain these critical amino
acids, shows that AV18 HA makes optimal contacts with the cone-like glycan topology.
Both SC18 and NYl8 HAs lack the critical Glul90 residue, and therefore their contacts
with the cone-like glycan topology are less optimal when compared to AV18 HA.
4.2.2 Dose dependent direct HA binding to representative a2-3 and a2-6
oligosaccharides
Novel glycan array platforms have been developed to investigate HA-glycan
interactions (15, 16). These arrays have provided important insights into a2-3 versus a2-
6 binding specificity of various wild type and mutant HAs. In these glycan array studies,
high and low binding signals to the glycans within a single assay using saturating HA
concentrations determine the glycan binding preference for a given HA. It is generally
accepted that the glycan binding affinity for a single binding site on any glycan binding
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Sequential (no precomplex) HA:pAb:sAb pre-complexed
HA concentration at 40 pg/ml
Figure 4.2: Binding assay to capture multivalent HA-glycan interactions. Shown in the figure is
comparison of binding signals between sequential binding assay and precomplexation of HA units with
primary (pAb) and labeled secondary (sAb) antibodies. The conditions of the sequential assay (see
Methods) favor the formation of HA:pAb:sAb in a 1:1:1 ratio. Despite the abundance of the labeled sAb (1
per HA unit) the minimal binding signals observed even at a high HA concentration of 40 pg/ml supports
the low affinity binding of a single glycan to a HA unit (cyan circle). On the other the conditions for
precomplexation of HA:pAb:sAb in a ratio of 4:2:1 favor the spatial arrangement of 4 HA units per
precomplex. This spatial arrangement enhances the glycan binding signals via multivalency as shown by at
least an 8 fold increase in binding to 6'SLN-LN given that there are 4 binding events (each event shown by
a cyan circle) per precomplexed HA unit.
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protein (such as a lectin) is low (typically in the high p.M to mM range). Since each HA
unit is a trimeric protein, there are three glycan binding sites per unit (5). In addition,
multiple HA units assemble on a virus surface. The glycan binding sites within a HA unit
and the spatial arrangement of multiple HA units across a virus surface could play an
important role in multivalent HA-glycan interactions. The concentration of the HA units
relative to the glycans consequently will critically govern HA-glycan binding specificity.
To understand differences in the glycan binding specificity of SC18, NYl8 and
AV18 HAs for a specific spatial arrangement of the HA units and the glycans, systematic
direct HA binding studies on a plate array were performed (see Methods). Minimal
binding signals were observed for SC 18 HA in the sequential ELISA-type binding assay
(Figure 4.2). Given that glycan spacing and HA unit size limits HA binding to only a
single glycan in this assay, the binding signals are consistent with the anticipated weak
affinity of the HA unit to a single glycan. The precomplexation assay with SC18 HA-
where 4 HA units are locked spatially-instead resulted in at least an 8-fold increase in
the binding to the long a2-6 glycan (Figure 4.2). This dramatic increase in the binding
signal underscores the role that the spatial arrangement of multiple HA units play in
enhancing glycan binding.
Dose dependent direct binding assays by serial dilution of the precomplexed
SC18, NY18 and AV18 HAs were performed to establish their relative glycan binding
affinities (Figure 4.3). The cooperativity factor n and the apparent binding constant Kd'
were calculated based on the linearized Hill equation (Figure 4.4) used to model the
binding data (Table 4.1). The typical form of the Hill equation is used to represent the
multivalent binding
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Figure 4.3: Dose dependent direct glycan binding of SC18, NY18 and AV18 HA. A-C, show the binding
signals (expressed as percentage of maximum) of SC18, NY18 and AV18 respectively in the dose-
dependent direct binding assay. SC18 HA shows binding signals only to the long a2-6. At saturating HA
concentrations (40 sg/ml), both SC18 and NY18 HA show identical binding to long a2-6 and NY18 HA
also shows high binding signals to long a2-3. On the other hand, AV18 HA shows a reverse trend (in
comparison to SC18 HA) of high affinity a2-3 binding and minimal a2-6 binding. D, shows comparison of
the long a2-6 (6'SLN-LN) binding of SC18, TX91 and Mos99 HAs with that of NY18 HA. While the long
a2-6 binding signal of NY18 HA approaches that of the other HAs at high concentrations, the binding
curve of NY18 HA over the entire concentration range indicates that it has a dramatically lower long C2-6
binding affinity. Human adapted SC18 and TX91 HINI viruses transmit efficiently in the ferret model
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Y= [HA] (Eqn.1)[HA] n+Kd'
Linearizing Eqn. 1 gives log Y = n * log(HA])- log(Kd) (Eqn. 2)
where y - fractional saturation of the glycan binding sites in the HA units; [HA] -
concentration of HA (in M); n - cooperativity factor; Kd' - apparent binding constant for
the multivalent HA-glycan interactions. The value of y is calculated by normalizing the
binding signals to the saturating binding signal, which represent 100 % occupancy on all
HA, units. An important assumption in the above model is that the glycans in each well
of the plate are in excess of HA. To satisfy this assumption, the binding signals for HA
concentration range from 0.05 to 5 pg/ml was used to calculate n and Kd'. The R-square
value > 0.95 for all the glycan binding data indicates a good fit to the linearized Hill
model. The value of n > 1 reflects the positive cooperativity in the HA-glycan
interactions as a result of the spatial arrangement of multiple HA units and the binding of
a HA unit to a single glycan. While SC 18 HA showed high binding affinity to the single
long a2-6 glycan (Kd' = 5.5 pM), AV18 HA showed the reverse trend with almost no x2-
6 binding and high a2-3 binding affinity (Kd'= 5 pM). On the other hand, while the long
a2-6 binding of NY18 HA was almost identical to that of SC18 HA at saturating HA
concentrations (Figure 4.3), the relative binding affinity to long x2-6 (Kd'= 6 nM) was
significantly lower than that of SC18 HA. These observations correlate with the
differences in molecular interactions of SC18, NY18 and AV18 with aX2-3 and X2-6
oligosaccharides.
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Figure 4.4: Linearized Hill Plot for SC18, NY18, AV18 HA to calculate n and Kd'. A-C, respectively
show the linearized Hill plot of the SC18, NY18 and AV18 HA-glycan binding data obtained by serial
dilution of the precomplexed HA units. The HA concentration range from 0.05 pg/ml to 5 pg/ml was
chosen to satisfy the assumption of glycans being in excess of the HA units (see Methods). The data points
for representative a2-3 (3'SLN-LN) and a2-6 (6'SLN-LN) are shown. The equation is shown along with








Table 4.1: Quantifying the relative a2-3 and a2-6 binding affinities of SC18, NY18 and AV18 HAs.
Relative binding affinities of SC18, NY18 and AV18 HAs to representative long a2-3 and a2-6 glycans.
'n.b.' indicates no binding. The parameters n and Kd' were determined as described in Methods and
elaborated in Figure S2. These parameters were obtained to purely quantify the relative binding affinities
of the HAs and hence their absolute values should be viewed only in this context.
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6'SLN-LN 3'SLN-LN
HIN HAs n Kd' n Ka'
SC18 1.3 5.5 pM n.b. n.b.
NY18 1.2 6.3 nM 1.3 50 pM
AV18 0.9 1 M 1.3 5 pM
4.2.3 Binding of SC18 and NY18 to human upper respiratory tissues
The remarkable differences in the binding affinities of a2-6 and a2-3 (from
above) of SC18 and NYl8 HA render them ideal lectin-like probes to investigate HA
binding to diverse physiological glycans present in human upper respiratory tissues.
Human tracheal sections were used to explore the binding pattern of SC 18 and NYl 8 HA
to the physiological glycans. Although both SC18 and NY18 bind to the apical side of the
trachea (Figure 4.5), the pattern and distribution of the tissue binding of the two HAs
differ significantly. Notably, SC 18 binding to the apical side of the trachea appears more
restricted when compared to the well distributed binding of NY18. NY18 HA also shows
binding to the internal region of the trachea (that are known to express a2-3 glycans),
consistent with its direct binding to a2-3 glycans (Figure 4.3). In order to further
investigate the differences in apical binding of SC18 and NYl8 HAs, co-staining of
tracheal tissues were performed using these HAs and Jacalin (a marker for goblet cells).
This co-staining demonstrated that while SC18 HA predominantly binds to goblet cells
(expressing a2-6); NYl 8 HA showed minimal binding to these cells (Figure 4.6).
4.3 Discussion
Glycan arrays comprising many distinct oligosaccharide motifs have been
employed to investigate the glycan binding of wild type and mutant H1, H3 and H5 HAs
(15-17). Despite these advances, interpretation of glycan receptor specificity that leads to
human adaptation and transmission has remained challenging. This is due, in large part,
to a general notion that glycan-protein interactions are relatively weak and non-specific.
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SC18 HA/ P1 NY18 HA/ P1
Figure 4.5: Binding of SC18 and NY18 HA to human tracheal sections. The apical side of the tracheal
epithelia is indicated by white arrow in all the sections. The binding pattern of SC18 HA is localized around
specific regions on the apical side; on the other hand, NY18 HA shows well distributed apical binding
pattern (HA in green against PI in red). Furthermore, NY18 HA also shows significant staining on the inner
regions of the epithelia which express a2-3 glycans (indicated by MAL-II staining patterns (Chapter 3).
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SC18 HA / Jacalin NY18 HA / Jacalin
Figure 4.6: Human tracheal co-staining of SC18 and NY18 HA with Jacalin. The apical side of the
tracheal epithelia is indicated by white arrow in all the sections. The distinct apical binding patterns of
SC18 and NY18 (in Figure 4.5) are further elaborated by co-staining the HAs (red) with Jacalin (green), a
marker for goblet cells. Representative regions of the apical side are enlarged for clarity. The significant
co-stain of SC18 HA with Jacalin (yellow) indicates that SC18 HA predominantly binds to goblet cells on
the apical side of the epithelia. On the other hand, binding pattern of NY18 HA has minimal overlap with
that of Jacalin indicating that it does not bind to goblet cells on the apical side of tracheal tissue.
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Consequently, the glycan binding specificity for HA has largely been established using
very high protein concentrations. High HA concentration may be useful to establish
binders versus non-binders but it imposes serious limitations on defining appropriate
quantitative measurements to establish relative glycan binding affinities of HA. For
example, at high concentrations, the typically used first order binding kinetics
assumptions (pertaining to HA: glycan ratio) would not be satisfied. To accurately
quantify the relative glycan binding affinities between HAs, it is essential to be at the
'appropriate' HA concentration range. Several key parameters which include the spatial
arrangement of multiple HA units, the surface glycan density, and the ratio of HA to
glycan need to be taken into account when determining the 'appropriate' HA
concentration range for a given glycan array assay. Furthermore, comparing the glycan
binding of different HAs at any single concentration point does not accurately capture the
binding specificity that is established over a concentration range. In this study, the
specific spatial arrangement of the glycans (spacing imposed by biotin-avidin system)
and the HA (imposed by precomplexation of HA units) in tandem with the dose
dependent glycan binding assay was able to overcome these challenges. Most
importantly, the concentration range used to determine the binding affinity parameters (n
and Kd') is such that the glycan is in excess of the HA as would be expected in
physiological conditions. The approach described in this study can be readily extended to
any glycan array platform to quantitatively investigate protein-glycan interactions.
At high HA concentrations, SC18 and NY18 HA display no differences in their
binding to long ac2-6 glycan. The only difference between SC 18 and NY18 at saturating
HA concentrations is the additional binding to a2-3 glycans for NYl8 HA. As the a2-3
145
binding of SC 18, NY18 and AV18 shows inverse correlation with the transmissibility, a
probable conclusion from this data is that the loss of cx2-3 binding specificity is a critical
factor for transmission. However, A/Texas/36/91 (TX91)--a mixed x2-6/A2-3 binding
virus similar to NYl 8-transmitted efficiently in ferrets (12). The dose dependent direct
binding of TX91 and A/Moscow/10/99 H3N2 (Mos99; a mixed (x2-6/A2-3 binding
human adapted H3 HA) compared to that of SC 18 and NYl 8 clearly shows that the high
affinity binding to long a2-6 glycan is a common feature for SC 18, Tx91 and Mos99, but
not for NY18 (Figure 4.3). This common feature of specificity to long a2-6 glycan is
independent of specificity to a2-3 glycans. Thus, this study corroborates the observation
that the high affinity binding to long oc2-6 glycans, which are extensively expressed in the
upper respiratory tissues, is a critical determinant not only for HA human adaptation, but
also for Influenza virus transmission.
The critical role of the long ac2-6 glycans as physiological targets for influenza A
virus infection and transmission also highlights the role of biosynthetic enzymes involved
in synthesizing these glycans in addition to the oc2-6 sialyltransferases. Specifically, the
p4GalTs ( 1-4 galactosyl transferases) and p3GlcNAcTs ($1-3 N-acetyl-glucosaminyl
transferases) are involved in synthesizing multiple lactosamine repeats characteristic of
long x2-6 glycans. The regulation of the expression of these glycosyltransferases would
not only play a critical role in the viral tropism but it would also enable better selection
pressure strategies to understand the evolution of mutations in HA that would lead to
efficient human adaptation and human-to-human transmission.
Differential binding of SC18 and NYl8 to the diverse physiological glycans
present in the human upper respiratory tissues further substantiates the direct binding
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studies. The narrow binding of SC 18 to goblet cells motivates future investigations into
the cellular tropism of human adapted viruses. This observation is consistent with
Matrosovich et al's report (18), where they demonstrated that human adapted HI and H3
virus strains preferentially infect non-ciliated cells and avian viruses preferentially infect
ciliated cells. They also suggested that such differences in the cellular tropism of the
viruses could explain the differences in their efficiency of human-human transmission.
Furthermore, the binding of SC18 HA to goblet cells taken together with its long a2-6
binding specificity correlates with its localized binding to the apical side of the tracheal
tissue and also suggests the expression of long a2-6 glycans in the goblet cells. On the
other hand SNA-I that binds to both short and long a2-6 glycans shows more extensive
apical side tracheal binding (11). Therefore, SC18 HA could potentially be a more
effective lectin-like probe to investigate the distribution of long a2-6 as compared to
SNA-I.
In conclusion, we have shown in this study how quantitative differences in the
HAs binding to long a2-6 glycans correlate with the observed differences in viral
transmission. The study of the 1918 viruses varying only in their HA genes and having
different transmission efficiencies served as good model system to establish this
correlate. Given the potential threat of a pandemic from currently circulating avian H5N 1
viruses, the approach presented here can aid in the screening of H5N1 HA mutants that
could lead to human adaptation and transmission of these deadly viruses.
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4.4 Methods
4.4.1 Cloning, baculovirus synthesis, expression and purification of HA.
The soluble form of HA was expressed using the Baculovirus Expression Vector
System (BEVS). SC18 (A/South Carolina/1/1918; SC18) baculovirus (generated from
pAcGP67-SC18-HA plasmid (14, 15)) was a gift from Dr. James Stevens. pAcGp67-
NY18-HA and pAcGp67-AV18-HA plasmids were generated from pAcGP67-SC18-HA
by [Asp225Gly] and [Aspl90Glu, Asp225Gly] mutations respectively. Mutagenesis was
carried out using QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene). The
primers used for mutagenesis were designed using the web based program, PrimerX
(http://bioinformatics.org/primerx/), and synthesized by IDT DNA technologies
(Coralville, IA). NYl8 and AV18 baculoviruses were created from a pAcGP67-NY18-
HA and pAcGP67-AV18-HA constructs using Baculogold system (BD Biosciences, San
Jose, CA) according to manufacturer's instructions. The baculoviruses were used to infect
300 ml suspension cultures of Sf9 cells (BD Biosciences, San Jose, CA) cultured in BD
BaculoGold Max-XP Insect Cell medium (BD Biosciences, San Jose, CA). These
cultures were monitored for signs of infection and harvested 4-5 days post-infection.
BEVS produces trimeric HA which provides multivalent binding to glycans. The soluble
form of HA was purified from the supernatant of infected cells using the protocol
described previously (14). Briefly, the supernatant was concentrated using Centricon
Plus-70 centrifugal filters (Millipore, Billerica, MA) and the trimeric HA was recovered
from the concentrated cell supernatant using affinity chromatography with columns
packed with Ni-NTA beads (Qiagen, Valencia, CA). Eluting fractions that contained HA
were pooled and dialyzed overnight with a 10 mM Tris-HCl, 50 mM NaCl buffer (pH
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8.0). Ion exchange chromatography was then performed on the dialyzed samples using a
Mono-Q HR1O/10 column (GE healthcare, Piscataway, NJ). The fractions containing HA
were pooled together and subjected to ultrafiltration using Amicon Ultra 100 K NMWL
membrane filters (Millipore, Billerica, MA). The protein was then concentrated and
reconstituted in PBS. The purified protein was quantified using Bio-Rad's protein assay
(Bio-Rad, Hercules, CA).
4.4.2 Dose dependent direct binding of HJNJ HA
To investigate the multivalent HA-glycan interactions a streptavidin plate array
comprising representative biotinylated a2-3 and a2-6 (short and long) was used. The
spatial arrangement of the glycans in the wells of this plate array favors binding to only
one of the three HA monomers in the HA unit. The glycan spacing and the HA unit size
limit binding of the HA unit to a single glycan in the ELISA type binding assay which
involves the sequential application of HA unit, primary and secondary antibodies (see
below). Conversely, the precomplexation of HA units (see below) with primary and
secondary antibodies (HA:primary: secondary = 4:2:1 ratio) facilitates a specific spatial
arrangement of 4 HA units. This precomplexed unit therefore enabled the investigation of
the effects of the relative spatial positioning of multiple HA units on the glycan binding
affinity via multivalency.
Streptavidin-coated High Binding Capacity 384-well plates (Pierce) were loaded to the
full capacity of each well by incubating the well with 50 pl of 2.4 pM of biotinylated
glycans overnight at 4 *C. The biotinylated glycans (3'SLN, 6'SLN, 3'SLN-LN, 6'SLN-
LN and 3'SLN-LN-LN) were obtained from the Consortium of Functional Glycomics
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through their resource request program. LN corresponds to lactosamine (Galpl-
4GlcNAc) and 3'SLN and 6'SLN respectively correspond to Neu5Aca2-3 and
Neu5Acax2-6 linked to LN. Excess glycans were removed through extensive washing
with PBS. For the ELISA-type sequential binding, the glycan-coated wells were
incubated for 2 hrs with HA at a concentration of 40 tg/ml (typical high concentrations
used in glycan array experiments) in PBS containing 1% BSA and subsequently washed
extensively with PBS-Tween followed by PBS. This was followed by incubation with the
primary antibody (Mouse anti 6X His tag IgG) at a concentration of 5 tg/ml in PBS
containing 1% BSA for 3 hrs at room temperature and repeating the above wash steps.
The wells were finally incubated with a 2 pg/ml solution of the secondary antibody (HRP
conjugated goat anti Mouse IgG) for 1 hr at room temperature. In the case of dose
dependent precomplexed HA experiments, a stock solution containing appropriate
amounts of His tagged HA protein, primary antibody (Mouse anti 6X His tag IgG) and
secondary antibody (HRP conjugated goat anti Mouse IgG (Santacruz Biotechnology) in
the ratio 4:2:1 and incubated on ice for 20 min. Appropriate amounts of precomplexed
stock HA were diluted to 250 p1 with 1% BSA in PBS. 50 pl of this precomplexed HA
was added to each of the glycan-coated wells and incubated at room temperature for 2 hrs
followed by the above wash steps. The binding signal was determined based on HRP
activity using Amplex Red Peroxidase Assay (Invitrogen, CA) according to the
manufacturer's instructions. Appropriate negative controls were included and all assays
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Figure 4.7: Capturing multivalent HA-glycan binding at low HA concentrations. A, shows results from
dose-dependent direct binding assay where the precomplexed HA unit is generated for each HA
concentration. The absence of any detectable binding signal below 1 pg/ml supports the notion that binding
kinetics limit the formation of the precomplexed HA units at low HA concentrations. B, shows results from
dose-dependent binding assay where the precomplexed HA unit is generated for the highest concentration
and is serially diluted to the lowest concentration (as reported in Methods section of main text). Unlike in
the case of A, the binding signals are detected for HA concentrations lower than 1 pg/ml supporting the
notion that the precomplexed HA units are formed at low HA concentrations in the serial dilution assay.
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Previously, dose dependent direct binding assays using the above
precomplexation were performed to establish binding specificity of human adapted HAs
to long ca2-6 (11). These assays were performed by incubating different concentrations of
HA with appropriate concentrations of primary and secondary antibodies (to achieve
4:2:1 ratio stated above). However, in this method of precomplexation, the binding
kinetics potentially limit the formation of HA precomplex at low HA concentrations
(below 5 pg/ml). In order to accurately quantify the relative binding affinities, it is
important to be able to measure binding of the precomplex at a lower concentration range
(0.05 to 5 pg/ml) (Figure 4.7). Towards addressing this issue, the binding assay was
modified by preparation of the precomplex at high HA concentration followed by serial
dilution of the stock (as described above).
4.4.3 Binding of Hi HA to human upper respiratory tissues
Formalin fixed and paraffin embedded normal human tracheal tissue sections were
purchased from US Biological. Tissue sections were deparaffinized, rehydrated and pre-
blocked with 1% BSA in PBS for 30 minutes at room temperature (RT). HA-antibody
pre-complexes were generated by incubating recombinant SC18 and NY18 proteins with
primary (mouse anti 6X His tag, Abcam) and secondary (Alexa Fluor 488 goat anti
mouse IgG, Invitrogen) antibodies in a ratio of 4:2:1 respectively for 20 minutes on ice.
The complexes formed were then diluted in 1% BSA-PBS to different final HA
concentrations. Tissue binding studies were performed by incubating tissue sections with
the diluted HA-antibody complexes for 3 hours at RT. To visualize the cell nuclei,
sections were counterstained with propidium iodide (Invitrogen; 1:100 in TBST) for 20
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minutes at RT. For co-staining assays, tissues were deparaffinized, rehydrated and co-
incubated with FITC labeled Jacalin (Vector labs; 10 ptg/ml in PBS with 0.05% Tween 20
(PBST)) and HA-antibody precomplexes (generated as described above using Alexa
Fluor 546 goat anti mouse IgG as secondary antibody and diluted in PBST) for 3 hours at
RT. Sections were then washed and viewed under a Zeiss LSM510 laser scanning
confocal microscope.
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Human adaptation of the hemagglutinin from avian H2N2
viruses
Summary
The H2N2 subtype of influenza A viruses are responsible for the Asian flu pandemic of
1957. Eleven years after this pandemic, these viruses disappeared from the human
population. However, the H2N2 subtype of influenza A viruses have been isolated from
domestic birds in the recent years increasing concerns over the possible transmission of
these viruses from avian to human hosts. The first step in such a cross-species
transmission and an efficient adaptation of influenza A viruses in the human host is the
ability of the viral surface hemagglutinin to gain binding to umbrella-like topology aX2-6
sialylated glycan receptors expressed on the human upper respiratory tissues. While, the
glycan binding properties of hemagglutinin from HINI, H3N2 and H5N1 have been
extensively studied, little attention has been paid to hemagglutinin from H2N2 viruses.
This study describes an extensive biochemical characterization of the glycan binding
properties of a prototypical pandemic H2N2 virus (Alb58) and a representative currently
circulating virus (CkPA04). Further, this study defines mutations in the hemagglutinin of
CkPA04 that enable binding to a2-6 sialylated glycan receptors that adopt the umbrella-
like topology and experimentally validates the glycan binding properties of these mutant
proteins. Such studies provide improved strategies for constant surveillance of the human
adaptation of avian H2N2 viruses.
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5.1 Introduction
Influenza A viruses are responsible for the annual epidemics and the global
pandemics. The 2 0 th century witnessed three major influenza pandemic outbreaks caused
by HINI (Spanish flu, 1918), H2N2 (Asian flu, 1957) and H3N2 (Hong Kong flu, 1968)
subtypes of viruses. H2N2 subtype of influenza A viruses circulated in the human
population between 1957 and 1968 and were replaced by the H3N2 strains which
emerged in humans in 1968 [1, 2]. Estimates from the Centers for Disease Control and
Prevention (CDC) reveal that the Asian flu resulted in about 70,000 deaths in the United
States alone.
Phylogenetic analyses and other studies showed that the H2N2 pandemic viruses
were a result of reassortment of hemagglutinin (HA), neuraminidase (NA) and
polymerase (PB1) genes from circulating H2N2 avian viruses and other gene segments
from HINI human viruses circulating prior to 1957 [2, 3]. While these H2N2 strains
disappeared from the human population in 1968, strains that are antigenically similar to
the pandemic human viruses still circulate in birds [2, 4]. Over the years, there has been a
significant increase in number of H2N2 strains circulating in domestic birds [2, 5]
increasing the risk of human exposure to these avian viruses and re-introduction of the
viruses in the human population. Such a reemergence could lead to a significant global
health threat given, the lack of pre-existing immunity in a huge subset of the human
population that is below the age of forty.
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A key step in the crossover of influenza A viruses from birds to humans is
believed to be associated with the ability of their HA to gain mutations in order to change
their glycan receptor binding preference from x2-3 sialylated (avian receptor) to o2-6
sialylated (human receptor) glycans. Many studies have focused on using avian and
human-adapted HINI and H3N2 HAs and their mutants to demonstrate how specific HA
mutations lead to altering the glycan receptor specificity from avian to human receptors
[6-9]. Using prototypic examples of HAs from human-adapted HINI and H3N2 viruses,
chapters 3 and 4 of this thesis describe that such a switch in the binding preference of the
viral HA from o2-3 to a2-6 sialylated glycans alone does not adequately explain the
human adaptation and transmission of these viruses. Instead, the criterion for efficient
human adaptation of these viruses is the topology or shape (going beyond cL2-3 versus CC-
6 linkage) adopted by the different sialylated glycans. In these studies two distinct
structural topologies for sialylated glycan receptors have been identified. a2-3 and short
ac2-6 sialylated glycan receptors both adopt a cone-like topology. On the other hand, long
a2-6 sialylated glycans, which are tetrasaccharide and longer, adopt a more flexible
umbrella-like topology. Further, the above studies demonstrate that high affinity binding
of the HA to the x2-6 glycans which adopt the umbrella-like topology is the necessary
determinant of the efficient human adaptation and human to human transmission of
influenza A viruses.
Compared to these extensive studies on HINI and H3N2 viruses, there have been
relatively fewer investigations [5, 10] into the glycan receptor binding properties of avian
versus human-adapted H2N2 HAs. The absence of crystal structure data for H2N2 HAs
has further limited the characterization of HA-glycan interactions at the molecular level.
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The potential re-emergence of human-adapted H2N2 viruses necessitates a systematic
investigation of the H2 HA-glycan binding properties. This study encompasses a detailed
structural and biochemical analysis of the glycan-receptor binding specificity of HA from
a representative human pandemic H2N2 virus (A/Albany/6/58; or Alb58) and its
comparison with the HA from a recently circulating avian H2N2 virus
(A/Ck/Pennsylvania/2004; or CkPA04). Further, the work presented in this chapter
includes the design and experimental validation of mutations in CkPA04 HA that lead to
a gain in the binding specificity to c2-6 sialylated glycans with a characteristic umbrella-
like topology (similar to the binding specificity of Alb58 HA). These studies augment the
evolving knowledge on human adaptation of HA from different influenza subtypes. This
study is therefore not only important for anticipating the potential re-emergence of H2N2
but also for understanding the human adaptation of HAs from other subtypes of avian
viruses including H5N1, H7N7 and H9N2.
5.2 Results
5.2.1 Detailed biochemical analysis of glycan receptor specificity of Alb58 HA
Alb58, a prototypical pandemic human virus, was chosen to characterize the
glycan binding properties of this human-adapted H2N2 virus. The HA from Alb58 was
recombinantly expressed and evaluated for its binding to defined glycans in a glycan
array. As described in chapter 4, to quantify the multivalent HA-glycan interactions, a
dose-dependent binding assay using a glycan array comprising of a2-3 sialylated glycans
(3'SLN, 3'SLN-LN and 3'SLN-LN-LN all of which represent the cone-like topology)
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Figure 5.1: Biochemical characterization of glycan binding properties of Alb58 HA. Left, dose dependant
direct binding of HA from the pandemic H2N2 virus strain Alb58. Alb58 HA shows high affinity binding
to long a 2-6. HA also shows significant binding to the a2-3 glycans indicating that Alb58 is a mixed a2-3/
a2-6 binding virus. HA concentration is in pg/ml. Right, tissue binding patterns of Alb58 HA (green) to
normal human tracheal and alveolar tissue (as against PI in red). The HA shows wide spread binding to the
apical surface of the tracheal tissue, as well as the alveolar tissue.
Jacalin/SC18 HA Jacalin/Mos99 HA Jacalin/Alb58 HA
Figure 5.2: Comparison of tissue binding patterns of Alb58 HA with HAs from human adapted SC18
and Mos99 viruses. Shows, co-staining of HAs (red) from SC18, Mos99 and Alb58 with jacalin (green, a
marker for goblet cells) in human tracheal tissues. White arrows show representative regions of co-staining
(yellow) of HA and jacalin indicating binding of these human adapted HAs to goblet cells. The images
were taken at x25 magnification, and representative regions of the apical side are enlarged for clarity.
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and oa2-6 sialylated glycans (6'-SLN, that represents cone-like and 6'-SLN-LN that
adopts umbrella-like topologies) was used. The direct binding of Alb58 HA to the glycan
array using this assay (Figure 5.1) showed that Alb58 HA bound with high affinity to
both short a2-6 (6'-SLN) and long x2-6 (6'-SLN-LN). Quantification of the binding by
calculating binding parameters using the Hill plot provided an apparent Kd' value of 5
pM for binding to 6'SLN-LN, demonstrating a high affinity binding to umbrella-like
topology glycans. It is important to note that the HA from these human viruses also
showed substantial binding to a2-3 sialylated glycans (3'SLN-LN and 3'SLN-LN-LN).
The glycan receptor specificity for Alb58 HA was further characterized by
investigating its binding to physiological glycans expressed in human tracheal (upper
respiratory) and alveolar (deep lung) tissue sections. As described in chapter 3, a
combination of lectin histochemistry and mass spectrometry analysis showed that the
apical surface of the tracheal tissues predominantly express umbrella-like topology a2-6
sialylated glycans while alveolar tissues primarily express a2-3 sialylated glycans.
Application of Alb58 on upper respiratory tracheal tissue sections revealed a significant
binding of the protein to the apical side of the tracheal tissue, suggesting preferential
binding to umbrella-like topology glycans. Moreover, consistent with its binding to a2-3
sialylated glycans in the direct binding assays, Alb58 HA also showed substantial binding
to the alveolar tissue (Figure 5.1).
5.2.2 Comparison of the glycan binding properties ofAlb58 HA with the HAs from two
human adapted viruses SC18 and Mos99
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The glycan binding of Alb58 HA was compared with that of HAs from two
representative human adapted viruses, SC18 (A/H1N1/South Carolina/l/1918) and
Mos99 (A/H3N2/Moscow/10/99), whose dose-dependent direct binding specificities
were established in chapters 3 and 4. This comparison revealed similar binding affinities
of the three human adapted HAs to the umbrella-like topology glycan (Kd' of SC 18 HA
is -5 pM and that of Mos99 HA is -25 pM). Interestingly, the three proteins differed
widely in their binding specificities to a2-3 sialylated glycans. While SC 18 HA showed
minimal binding to these glycans, Mos99 and Alb58 showed substantial binding to the
a2-3 glycans (3'SLN-LN and 3'SLN-LN-LN). Futhermore, detailed comparison of the
binding patterns of these human adapted HA subtypes reveal a substantial binding of all
the HAs to the apical surface of human trachea. More importantly, co-staining results
with the lectin Jacalin show that while SC 18 HA shows a more preferential binding to the
goblet cells, Mos99 HA and Alb58 show widespread binding not only to the goblet cells
but also to the ciliated cells on the apical surface of the tracheal epithelia (Figure 5.2).
5.2.3. Biochemical characterization of the glycan binding properties of currently HA
from circulating avian virus CkPA04
In order to determine the glycan receptor binding properties of Alb58 HA with
that of a HA from the currently circulating avian H2 viruses, a similar detailed
biochemical examination was performed on the CkPA04 HA (Figure 5.3). This HA
showed predominant high affinity binding to the a2-3 glycans on the array consistent
with the glycan receptor specificity of the CkPA04 virus demonstrated previously [5].
The direct binding of this avian H2 virus HA was in stark contrast to the Alb58 HA as it
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Figure 5.3: Biochemical characterization of glycan binding properties of CkPA04 HA. Left, the dose-
dependent direct binding of HA. In contrast to Alb58 HA, CkPA04 HA shows minimal binding to long a 2-
6 while binding with high affinity to a2-3. Right, CkPA04 HA (in green, against PI in red) shows wide
spread binding to the alveolar tissue with minimal binding to the apical surface of tracheal tissues.
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showed minimal binding to the a2-6 glycans on the array (Figure 5.3). Tissue staining
with the CkPA04 HA revealed extensive binding to human alveolar tissues and minimal
binding to the apical side of the tracheal tissues which is consistent with its direct glycan-
binding properties (Figure 5.3). The CkPA04 HA is therefore an ideal avian HA for
defining mutations that would provide it with the binding specificity for human receptors
like that observed for Alb58 HA.
5.2.4 Mutations in CkPA04 HA that optimize its contact with umbrella-like topology
a2-6 glycans
In the absence of H2 HA crystal and HA-glycan co-crystal structures, homology
based modeling was used to obtain the structural complexes of the CkPA04 HA with a2-
3 and Alb58 HA with a2-6 oligosaccharides. Previously, HA-glycan interactions were
characterized based on cone-like and umbrella-like structural topologies of the a2-3 and
a2-6 glycans (Figure 3.9). The residues in CkPA04 HA that appeared to make optimal
contacts with the ac2-3 oligosaccharide (Figure 5.4A) were analogous to those in avian
HAs that interacted with the cone-like topology (Chapter 3). The highly conserved
residues in all the H2 HAs including Ser136, Trp153, Thr155, Glul90 and Leul94 (based
on H3 numbering) are involved in interactions with the Neu5Ac to anchor this sugar in
the binding site of HA. In addition to these conserved residues, Glnl37 is also positioned
to make optimal contact with the Neu5Ac sugar. The residues in position 137 are not as
conserved as the other sialic acid anchoring residues in H2 HA. The residues, Asn186,
Asp 187 and Lys222 are positioned to interact with the Gal and GlcNAc sugars of the x2-
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Figure 5.4: Structural analysis of differences in interactions of CkPA04-a2-3 and Alb58-a2-6
complexes. (A). Shows stereo view of the glycan binding site of CkPA04 (rendered as a cartoon in purple)
in complex with a2-3 oligosaccharide (colored by atom C:yellow; 0: red; N:blue). The sidechain of the
residues making critical contact with the glycan are also shown and colored by atom (C: green; 0: red; N:
blue). (B) Shows stereo view of glycan binding site of Alb58 (rendered as a cartoon in grey) in complex
with a2-6 oligosaccharide (colored by atom C: cyan; 0: red; N: blue). The side chain of the residues
making critical contacts are shown as in A. For the sake of clarity the side chains of only the residue
positions that differ between CkPA04 and Alb58 are shown. (C) Shows the comparison between the buried
surface area of the critical residues making contact with a2-3 in CkPA04 (blue bars) and those making
contact with a2-6 in Alb58 (red bars). The highly conserved residues in H2 HA that interact with Neu5Ac
are not shown. (D) Highlights the differences in the critical residues (in red) that interact with a2-3 and
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fucosylation). The critical interaction with a2-3 is that of Gln226 which appears to make
optimal contact with the glycosidic oxygen atom of the Neu5Acca2-3Gal linkage. This
residue is highly conserved among several avian HAs across different subtypes such as
Hi, H2, H3, H5, etc and has been shown to play a critical role in distinguishing c2-3
versus x2-6 linkage.
The interactions of Alb58 HA with ax2-6 in the structural model of the HA-glycan
complex (Figure 5.4B) are analogous to those observed between human adapted HI HA
and the x2-6 in the umbrella-like topology. In addition to the conserved sialic acid
anchoring residues mentioned above, the key interactions with the base region of the a2-
6 glycan (Neu5Acca2-6Galpl-) involved Arg137, Lys222, Leu226 and Ser228. The
residues interacting with the extension region of the c2-6 glycan (-4GlcNAcpl-3Galpl-
4GlcNAc-) include Lys156, Thr189, Arg192 and Thr193.
The contacts between the specific HA residues and the c2-3 and a2-6 glycans are
quantified by the loss of solvent accessible area upon glycan binding (Figure 5.4C). The
main differences in the critical glycan-binding residues in the CkPA04 - a2-3 and Alb58
- x2-6 structural complexes are in the residue positions 137, 193, 226 and 228 (Figure
5.4D). The differences in these specific positions are consistent with previous studies that
have investigated receptor-binding properties of avian and human H2 viruses[10].
Furthermore, these differences also account for the distinct contacts of the avian and
human H2 HA with the cone-like and umbrella-like topologies of the glycans
respectively. To evaluate the effect of the variations in these critical residues on the
glycan-binding specificity of avian and human H2 HAs, specific mutants on the CkPA04
at these positions were designed as outlined below.
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The first mutant is a double mutation Gln226Leu/Gly228Ser (referred to as LS
mutant) on the CkPA04 HA that is based on the obvious differences in the contact with
the Neu5Ac and the Neu5Ac-Gal linkage highlighted both in chapters 3 and 4 and by
others[10]. The second mutant (Ala193Thr/Gln226Leu/Gly228Ser or TLS mutant) builds
on this double mutation to incorporate the additional Alal93Thr mutation to provide
better contacts with the extension region of the a2-6 glycan in the umbrella-like
topology. The final mutant is a quadruple mutation
(Glnl37Arg/Alal93Thr/Gln226Leu/Gly228Ser or the RTLS mutant) that accounts for all
the key residue changes to make the glycan-binding of CkPA04 resemble as closely as
possible to that of Alb58. These three HA mutants were generated using CkPA04 HA as
a template.
5.2.5 Experimental validation of the glycan binding properties of the CkPA04 mutants
The three CkPA04 HA mutant proteins, LS, TLS and RTLS, were recombinantly
expressed in insect cells using the baculovirus expression system (BEVS). The glycan
binding specificity of these recombinant HAs were characterized using the dose-
dependent direct binding and the tissue binding assays.
The dose-dependent direct binding results (Figure 5.5A-C) showed that when compared
to the CkPA04 HA, the LS, TLS and RTLS mutant proteins showed decreased binding
affinity, albeit notable binding to the a2-3 sialylated glycans, 3'-SLN-LN and 3'-SLN-
LN-LN. All the mutant proteins however showed minimal binding to 3'-SLN. In contrast
with the wild type CkPA04 HA, however, all the mutants showed a significant binding to
both the representative a2-6 sialylated glycans, 6'-SLN and 6'-SLN-LN. More
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importantly, calculation of the binding parameters revealed that the mutant proteins
showed high affinity binding to the 6'SLN-LN glycan with Kd' values in the pM range
comparable with the K' of Alb58 HA for the same glycan (Figure 5.5D). Thus, two
specific mutations, Gln226Leu and Gly228Ser in CkPA04 HA considerably increase its
binding affinity to umbrella-like topology glycans. The additional mutations in positions
137 and 193, further enhance this binding affinity to long a2-6, resulting in binding to
long a2-6 with affinities that are closer to that of the pandemic Alb58 HA. These
observations are consistent with the optimal contacts made by these residue positions
with the umbrella-like topology of the ax2-6 glycans.
Staining of the mutant HAs to the human tissues (Figure 5.6) showed a
widespread binding pattern to the apical surface of the tracheal epithelia. Further, these
mutant proteins also showed binding to alveolar tissues. As shown in chapter 4, the
differences in the HA binding affinities to o2-6 with the umbrella-like topology were
reflected in the distinct staining patterns of the HA in the apical side of the human
tracheal tissues. Given the 8-fold difference in the binding affinity of the LS mutant with
that of Alb58 HA, the binding patterns of the two HAs to the apical surfaces of tracheal
tissues were closely compared by co-staining of the tissue sections with the HAs and
Jacalin (Figure 5.7). This comparison shows that Alb58 binds extensively to the goblet
cells (as well as ciliated cells) in human tracheal tissues. The LS mutant, on the other
hand, showed reduced binding to goblet cells while extensively binding to ciliated cells
on the apical side of the trachea.
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Figure 5.5: Dose-dependent direct glycan binding of CkPA04 mutants LS, TLS and RTLS HA. (A-C)
The binding signals (expressed as percentage of maximum) of LS, TLS, and RTLS, respectively, in the
dose-dependent direct binding assay. All three mutant HAs show high-affinity a2-6 binding while retaining
a2-3 binding. (D) Comparison of the 6'SLN-LN and 3'SLN-LN binding of WT CkPA04, LS, TLS, RTLS
and Alb58 HA. The binding affinities of mutant HAs to long a2-6 (K'd values in the pM range) are








Figure 5.6: Binding of HA from CkPA04 mutants LS, TLS and RTLS to physiological glycans. Top,
Binding of mutant HAs to human tracheal tissues sections. As evidenced by the staining patterns, all
mutant HAs (green) show substantial binding to the apical surface of the trachea. Bottom, shows binding of
these mutant HAs to alveolar tissues. (Magnification: x25.)
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Figure 5.7: Comparison of tracheal tissue binding patterns of Alb58 and LS HAs. The binding patterns
of Alb58 and LS HAs are further elaborated by co-staining of the HAs (red) with jacalin (green). Alb58
shows significant co-staining with jacalin (yellow) indicating extensive binding to goblet cells. Co-staining
pattern of LS HA, on the other hand, shows limited goblet cell binding.
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5.3 Discussion
Despite the threat posed by the potential re-emergence of the currently circulating
avian H2N2 viruses in the human population, few studies have been undertaken to
characterize the receptor binding properties of these viruses. One study by Matrosovich et
al. [10], examined the glycan receptor binding properties of several H2N2 viruses, which
circulated in the human population between 1957 and 1968 and the more recent avian
H2N2 viruses. In this study, the glycan binding specificities of the different H2N2 viruses
was quantified by examining their binding to sialyloligosaccharides which include 3'-
sialyllactose (3'-SL) and 6'-sialyllactosamine (6'-SLN). The study concluded that the
amino acid residues of HA at positions 226 and 228 (based on H3 HA numbering)
critically determined the glycan binding specificities of H2N2 viruses. All HAs from
avian H2N2 viruses had conserved amino acid residues Q226 and G228 and these viruses
showed preferential binding to the ac2-3 linked glycan, 3'-SL. A critical Q226 -- L226
mutation present in most human H2 HA markedly increased the affinity of these viruses
for the a2-6 linked glycan, 6'-SLN and reduced their binding affinity to 3'-SL. An
additional substitution of G228 -- S228 was identified during the analysis of the HA
sequences from later strains of H2N2 viruses. This additional mutation is believed to
enhance the binding of the H2N2 viruses to 6'-SLN. The study thus concluded that the
presence of amino acid mutations L226 and S228 in the HA are critical for binding to o2-
6 linked sialylated oligosaccharide [10].
The above study, however, classified the receptor binding specificities based
solely on binding to the two sialic acid linkages and did not adequately capture the
distinct topologies required for avian and human adaptation of H2 HA. As mentioned
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earlier, sialylated glycans adopt different structural topologies and binding to umbrella-
like topology glycans is the necessary criterion for human adaptation. The synthetic
sialylated oligosaccharides used in the study 3'-SL and 6'-SLN (which is a trisaccharide)
both adopt the cone-like topology. These binding studies do not include a representative
human-like glycan receptor that adopts the more flexible umbrella-like topology. The
absence of binding data to the human glycan receptors that adopt the umbrella-like
topology motivated the detailed investigation of the glycan binding properties of avian
and human adapted H2 HAs as presented in this study.
Using complementary approaches, this study characterizes the glycan binding
properties of the HA from pandemic H2N2 virus (Alb58) and currently circulating avian
H2N2 (ACkPA04) strains. Dose dependant direct binding assays demonstrate that while
HAs from the human H2N2 viruses show high affinity binding to the umbrella-like
topology glycans, the currently circulating avian H2N2 viruses show minimal binding to
these glycans. The glycan binding properties of Alb58 were also compared with HAs
from other human adapted viral subtypes, SC18 and Mos99. The efficient human
adaptation of Mos99 and Alb58 viruses despite their HAs showing a mixed X2-6 / a2-3
glycan binding properties suggests that a switch in binding specificity of HA from a2-3
to x2-6 sialylated glycans may not be a necessary prerequisite for human adaptation.
Instead, the high affinity binding to umbrella-like topology glycans is emerging as a
common factor shared by the different human-adapted virus subtypes (HI, H2 and H3)
and therefore this property is a more appropriate determinant for efficient human
adaptation and transmission of these viruses.
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Development of a detailed structural framework enabled the identification of the
critical amino acid residues in the HA that make contact with these umbrella-like
topology glycans. Based on this analysis three mutant HAs LS, TLS and RTLS were
generated using the avian HA as a template. Interestingly, all three mutants showed high
affinity binding to long a2-6 sialylated glycans that adopt the umbrella-like topology with
binding parameters similar to those of the pandemic Alb58 HA.
Tissue binding analysis with pandemic SC 18 HA showed a predominant binding
of the protein to goblet cells in the apical surface of the tracheal epithelium. This unique
binding pattern of SC18 HA suggests the presence of umbrella-like topology in goblet
cells. Interestingly, Alb58 HA, also shows extensive binding to both ciliated and goblet
cells in the apical surface of human tracheal tissues. However, the LS mutant shows
limited binding to these goblet cells but shows wide spread binding to ciliated cells. The
importance of binding to glycan receptors on the surface of goblet cells in the efficient
infection and transmission of influenza A viruses remains unclear and warrants further
investigation.
It has been demonstrated in chapter 3 that goblet cells predominantly express 0-
linked glycans as opposed to N-linked glycans primarily expressed on the surface ciliated
cells. Therefore, the differences in the goblet cell staining of the LS mutant and Alb58
prompts the expansion of the glycan array to include a2-6 glycan motifs adopting the
umbrella-like topology that are present as a part of O-linked glycans. Technologies are
being developed to print glycans isolated from biological samples [11, 12]. Such glycan arrays
with N- and 0-linked glycans isolated from different cell types would ultimately be valuable tools
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to screen for the cellular tropism of different viruses as well as for surveillance of mutations in
HA leading to human-adapted viruses.
Taken together, the above findings enable extensive characterization of the glycan
binding properties of HAs from avian and human H2N2 viruses. Furthermore, a detailed
structural analysis enables the design and generation of HA mutants that bind to
umbrella-like topology glycans, a necessary determinant for the human adaptation of H2
HA. Such studies are critical for the surveillance of currently circulating avian H2N2
influenza A viruses. Finally, the HA from avian H5N1 and H2N2 viruses are believed
belong to the same clade as HINI and share significant sequence similarity in their
glycan binding domains [13]. Therefore, a study of the mutations in HA of avian H2
viruses that would enable human adaptation of the viruses would provide insights into the
mutations that avian H5N1 virus HAs would need to acquire in order to efficiently adapt
in the human host.
5.4 Methods
5.4.1 Homology based modeling of CkPA04 - a2-3 and Alb58 - a2-6 structural
complexes
Based on the high sequence similarity and the common structural clade [13]of H2
and H5 HAs, the crystal structure of the A/Vietnam/1203/04 H5N1 HA (PDB ID: 2FKO)
was used as a template to model the structure of CkPA04 and Alb58 H2 HAs. Given that
this study is focused on the glycan binding properties of the avian and human H2 HAs,
only the HAI domain of both CkPA04 and Alb58 was modeled using the SWISS-
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MODEL web-based homology-modeling program (URL:
http://swissmodel.expasy.org/SWISS-MODEL.html) [14]. The starting structure of the
CkPA04 - a2-3 and Alb58 - a2-6 glycan complexes was obtained by superimposing the
Ca trace of their glycan binding sites (residues 130 - 230 numbered based on H3 HA)
with that of H5 HA - (x2-3 oligosaccharide (PDB ID: 1JSN) and HI HA - a2-6
oligosaccharide (PDB ID: 1RVT) co-crystal structures respectively. The HA-glycan
contacts in these models were optimized by performing 500 steps of steepest descent
followed by 500 steps of conjugate gradient energy minimization using the AMBER
force-field in the Discover module of Insightll program (Accelrys, San Diego, CA) [15].
The contacts between the specific HA residues and the glycan were quantified by
calculating the difference in the solvent accessible surface area of the residues in the
presence and absence of the glycan using the Solvation module of Insightll (Accelrys,
San Diego, CA).
5.4.2 Cloning, mutagenesis and expression of HA
The Alb58 and CkPA04 plasmids were gifts from Dr. Terrance Tumpey and Dr.
Adolfo Garcia-Sastre, respectively. The human and avian wild type H2N2 HA genes
were subcloned into a pAcGP67A vector to generate pAcGp67-Alb58-HA and pAcGp67-
CkPA04-HA respectively for baculovirus expression in insect cells. Using pAcGp67-
CkPA04-HA as a template the gene was mutated to yield pAcGp67-LS-HA [Gln226Leu,
Gly228Ser], pAcGp67-TLS-HA [Alal93Thr, Gln226Leu, Gly228Ser] and pAcGp67-
RTLS-HA [Glnl37Arg, Alal93Thr, Gln226Leu, Gly228Ser]. The primers for
mutagenesis were designed using PrimerX (http://bioinformatics.org/primerx/) and
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synthesized by IDT DNA technologies (Coralville, IA). The mutagenesis reaction was
carried out using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene, CA)
Alb58, CkPA04, LS, TLS and RTLS baculoviruses were created from their respective
plasmids, using Baculogold system (BD Biosciences, CA) as per the manufacturer's
instructions. The baculoviruses were used to infect 300 ml suspension cultures of Sf9
cells (Invitrogen, Carlsbad, CA) cultured in Sf-900 II SFM medium (Invitrogen,
Carlsbad, CA). The infected cultures were monitored and harvested 4-5 days post-
infection. The soluble trimeric form of HA was purified from the supernatant of infected
cells using modification of the protocol described in the previous chapter. In brief, the
supernatant was concentrated using Centricon Plus-70 centrifugal filters (Millipore,
Billerica, MA) and the trimeric HA was recovered from the concentrated cell supernatant
using affinity chromatography with columns packed with Ni-NTA beads (Qiagen,
Valencia, CA). The fractions containing HA were pooled together and subjected to
ultrafiltration using Amicon Ultra 50 K NMWL membrane filters (Millipore, Billerica,
MA). The protein was reconstituted in PBS and concentrated. The purified protein
concentration was determined using Bio-Rad's protein assay (Bio-Rad, CA).
5.4.3 Dose dependant direct binding assays
To investigate the multivalent HA-glycan interactions a streptavidin plate array
comprising representative biotinylated a2-3 and ac2-6 (short and long) was used. The
glycans included were 3'-SLN, 3'- SLN-LN, 3'SLN-LN-LN, 6'-SLN, all of which adopt
the cone like topology and 6'SLN-LN which adopts the umbrella-like topology. LN
corresponds to lactosamine (Galpl-4GlcNAc) and 3'SLN and 6'SLN respectively
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correspond to Neu5Acca2-3 and Neu5Aca2-6 linked to LN. The biotinylated glycans
were obtained from the Consortium of Functional Glycomics through their resource
request program. Streptavidin-coated High Binding Capacity 384-well plates (Pierce)
were loaded to the full capacity of each well by incubating the well with 50 pl of 2.4 [tM
of biotinylated glycans overnight at 4 'C. Excess glycans were removed through
extensive washing with PBS. To enhance the multivalency in the HA-glycan interactions,
the recombinant HA proteins was pre-complexed with the primary and secondary
antibodies for both the direct and tissue binding assays as described in the previous
chapter. A stock solution containing appropriate amounts of Histidine tagged HA protein,
primary antibody (Mouse anti 6X His tag IgG) and secondary antibody (HRP conjugated
goat anti Mouse IgG (Santacruz Biotechnology) in the ratio 4:2:1 and incubated on ice
for 20 min. Appropriate amounts of precomplexed stock HA were diluted to 250 pl with
1% BSA in PBS. 50 pl of this precomplexed HA was added to each of the glycan-coated
wells and incubated at room temperature for 2 hrs followed by the above wash steps. The
binding signal was determined based on HRP activity using Amplex Red Peroxidase
Assay (Invitrogen, CA) according to the manufacturer's instructions. Appropriate
negative controls were included. The binding parameters, cooperativity (n) and apparent
dissociation constant (Kd'), for H2 HA-glycan binding were calculated using the Hill
equation described in chapter 4.
5.4.4 Tissue binding assays
Formalin fixed and paraffin embedded normal human tracheal and alveolar tissue
sections were purchased from US Biological and US Biomax, respectively. Tissue
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sections were incubated for 30 minutes in a hybridization oven at 60C to melt the
paraffin. Excess paraffin was removed by multiple washes in xylene. Sections were
subsequently rehydrated in a series of ethanol washes. In order to prevent aspecific
binding, sections were pre-blocked with 1% BSA in PBS for 30 minutes at room
temperature (RT). For the generation of HA-antibody precomplexes, the histidine tagged
purified recombinant HAs (Alb58, CkPA04, LS and TLS) were incubated with primary
antibody against his tag (mouse anti 6X His tag, Abcam) and secondary (Alexa Fluor 488
goat anti mouse IgG, Invitrogen) antibody in a ratio of 4:2:1 respectively for 20 minutes
on ice. Tissue sections were incubated with the HA-antibody complexes, diluted to
different final concentrations in 1% BSA-PBS, for 3 hours at RT. Sections were then
incubated with propidium iodide to counterstain the nuclei (Invitrogen; 1:100 in TBST)
for 20 minutes at RT. After thorough washing, sections were mounted and analyzed using
a Zeiss LSM5 10 laser scanning confocal microscope.
In order to further characterize the tissue binding patterns of HA tissue sections,
co-staining of HA with Jacalin was performed to distinguish the binding of HA to goblet
cells from the binding to other cell types on the apical surface of the trachea. Towards
this, tracheal tissue sections were deparaffinized, rehydrated and co-incubated with FITC
labeled Jacalin (Vector labs; 10 ig/ml in PBS with 0.05% Tween 20 (PBST)) and HA-
antibody precomplexes (generated as described above using Alexa Fluor 546 goat anti
mouse IgG as secondary antibody and diluted in PBST) for 3 hours at RT. Sections were
then washed and viewed under a confocal microscope.
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6.1 Thesis contributions and future work
Exploitation of human epithelial cell surface components is an important
virulence mechanism that promotes microbial invasion and pathogenesis. By means of
their interactions with a variety of microbial proteins, epithelial cell surface glycans and
glycoconjugates are key mediators of several host-pathogen interactions. Recent
advances in the analytical and biochemical techniques have greatly enabled the
identification of previously unknown functions of glycans and glycoconjugates in
enhancing microbial virulence. Using approaches that integrate such diverse cutting edge
technologies, this thesis describes the structure-function relationships of glycans and
glycoconjugates and their role in microbial pathogenesis. The following is a summary of
the main contributions made by the different sections of this thesis and a discussion about
the potential future work that this work motivates.
Chapter 2 of this thesis describes the mechanisms by which bacterial
sphingomyelinases exploit cell surface proteoglycans to modulate cellular function and
therefore aid the invasion and colonization of bacterial pathogens. This work
demonstrates that degradation of sphingomyelin and subsequent generation of ceramide
results in the ectodomain shedding of the epithelial cell surface proteoglycan, syndecan-
1, that is accompanied by loss of epithelial integrity. This study has facilitated the
identification of potential cellular targets such as ceramide for development of
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antibacterial therapeutics. Future studies based on this work potentially include the design
and development of inhibitors such as Suramin analogs and ceramide inhibitors to
prevent the sphingomyelinase induced modulation of cellular function. In the era of
emergence of antibiotic resistant superbugs, such approaches could offer promising
alternatives to current antibacterial therapies.
The work presented in chapters 3 and 4 of the thesis redefines the criteria required
for the human adaptation of avian influenza A viruses. Using a framework of integrated
approaches, this study identifies that binding of the viral hemagglutinin to glycans with a
distinct umbrella-like topology is the necessary determinant of efficient human adaptation
of the viruses. Further, these studies are extended to establish a biochemical framework
to explain the differences in the efficiency of transmission of the various strains of
influenza A viruses.
Identification of the glycan determinant required for human receptor specificity of
hemagglutinin has opened up avenues for development of platforms for surveillance of
influenza A viruses. Characterization of the physiological glycans using a combination of
the lectin histochemistry and mass spectrometry technologies presented in this work
provide information on the structural and conformational features of the glycans that
govern the binding of the influenza viruses. Novel glycan array platforms that include
glycans with these critical structural features would serve as invaluable tools for
surveillance of the evolution of currently circulating avian viruses towards human
adaptation. Alternatively, isolation of glycans directly from human upper respiratory
epithelia and development of glycan arrays with these physiological glycans would also
assist in the screening of the receptor binding properties that govern the human
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adaptation and tissue tropism of the different influenza A viruses. Further, an
understanding of the glycan structural features required for the human adaptation of the
viral hemagglutinin could provide improved therapeutic strategies for influenza
infections. For instance, there is potential for development of glycodendrimers that
provide a multivalent display of umbrella-like topology glycans as potent inhibitors of
influenza virus pathogenesis. Such multivalent glycan-based therapeutics could prevent
cellular entry of the viruses by binding to the viral hemagglutinin and inhibiting its
interaction with the cell surface glycans.
Chapter 5 focuses on development of a structural framework for design and
experimental validation of mutations in the hemagglutinin of currently circulating avian
H2N2 viruses that enable gain of human receptor binding specificity. Using biochemical
analyses, this study characterizes the glycan binding properties of the designed HA
mutants as well as HAs of the currently circulating avian viruses and prototypical
pandemic H2N2 viruses. Future studies examining the efficiency of transmission of these
avian, human and mutant viruses in ferret models would further validate the role of
receptor binding specificities of the viral hemagglutinin in the efficient transmission of
the viruses among ferrets. Moreover, such a structural framework provides a basis for
defining mutations in the hemagglutinin of currently circulating avian H5N1, H7N9
viruses that confer human receptor binding specificity. An understanding of these
mutations in avian H5N1 HA provides opportunity not only for effective surveillance of
the human adaptation of these viruses but also for intervention through development of
effective vaccine strategies to prevent the possibility of another influenza pandemic.
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In conclusion, this thesis underscores the function of cell surface glycans and
glycoconjugates as mediators of host-pathogen interactions. This work identifies novel
cellular and molecular mechanisms for bacterial and viral pathogenesis. More
importantly, this study also sets the stage for the development of improved strategies for
management of infectious diseases. The work presented in this thesis thus contributes
towards the advancement of the emerging field of functional glycomics by characterizing




Publications based on this thesis
The work presented in this thesis has led to two publications in peer reviewed journals
which are reproduced in this section with permission.
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0
A switch in specificity of avian influenza A viruses'
hemagglutinin (HA) from avian-like (2-3 sialylated glycans)
to human-like (2-6 sialylated glycans) receptors is believed
J to be associated with their adaptation to infect humansl-4.
We show that a characteristic structural topology-and not the
a2-6 linkage itself-enables specific binding of HA to x2-6
sialylated glycans and that recognition of this topology may
o. be critical for adaptation of HA to bind glycans in the upper
2 respiratory tract of humans. An integrated biochemical,
0 analytical and data mining approach demonstrates that HAs
C from the human-adapted H1N1 and H3N2 viruses, but
2 not H5N1 (bird flu) viruses, specifically bind to long a2-64)
sialylated glycans with this topology. This could explain why
H5N1 viruses have not yet gained a foothold in the human
I population5 ,6 . Our findings will enable the development of
a additional strategies for effective surveillance and potential
Z therapeutic interventions for H5N1 and possibly other
c influenza A viruses.
C
@ Until now, annual influenza outbreaks and epidemics have been
caused by the human-adapted HlNl and H3N2 viruses that circulate
' human populations. However, the ability of H5N1, H7N7 and
H9N2 avian virus subtypes to infect humans has raised concern over
the possibility of a new flu pandemic equal in impact to the 1918
H1N1 Spanish influenza.
The key first step in the infection, transmission and virulence of
these viruses is the binding of HA to sialylated glycans on the epithelial
cell surface3-4-7-9. Transmission from birds to humans is believed to be
closely associated with the ability of the HA to switch its preference
from c2-3 sialylated glycans (a2-3) to a2-6 sialylated glycans (a2-6),
which are extensively expressed in the human upper respiratory
epithelial,,i 0 . Crystal structures of HAs from H1 (human and
swine), H3 (avian and human) and H5 (avian) and their complexes
with c2-3 and/or oc2-6 oligosaccharides have provided molecular
insights into key residues involved in specific HA-glycan inter-
actions2,3,ii-i5 and glycan arrays have been used to investigate the
glycan binding specificity of wild-type and mutant H1, H3 and H5
p
Raman '5, Karthik Viswanathan"'5, S Ragurami,
aranl'3,4
HMs16,17. The relationship between the HA glycan binding specificity
and transmission efficiency has been demonstrated in ferrets, using the
highly pathogenic and virulent 1918 H1N1 viruses18. The reliability of
this animal model for studying human transmission is attributed to
the predominance of human-like m2-6 in the upper respiratory tract
epithelium of ferrets6,9. Switching the receptor binding specificity of
the highly transmissible and pathogenic human H1N1 (A/South
Carolina/1/18; SC18) virus from o2-6 to a2-3 has produced a virus
(AV18) not transmissible in the ferrets18. Although A/New York/l/18
(NY18) H1N1 virus, which shows mixed c2-3/2-6 binding, does not
transmit efficiently, the A/Texas/36/91 (Tx9l) HINI strain-that also
binds to both ot2-3 and a2-6-transmits efficiently18 .
These confounding results with respect to the correlation between
glycan binding specificity of HA and transmissibility of the viruses led
us to pose several questions. First, how diverse are the sialylated
glycan receptors in the human upper respiratory tissues and could this
diversity account for the specificity in the tissue tropism of the virus?
Second, are there nuances of glycan conformation that might play a
role in c2-3 and/or c2-6 binding specificity of HA? Taken together,
what are the glycan binding requirements of HA, beyond binding to
sialylated glycans with a specific linkage, necessary for human adapta-
tion? Currently, avian H5N1 viruses have m2-3 glycan specificity and
also show some c2-6 binding'9,20, but have not yet transmitted
between humans. Answers to these questions would aid the under-
standing of human adaptation of these viruses and facilitate effective
surveillance of the evolution of H5N1 into a potentially pandemic
human virus. To address these issues, we developed a framework
comprising four complementary analyses to investigate binding of
human-adapted HA to a2-3 and x2-6. Integration of these comple-
mentary analyses led to the identification of the necessary glycan
determinant for human adaptation of HA.
The first of the four complementary analyses aimed to delineate the
diversity of sialylated glycans in the human upper respiratory tissues
to answer, in part, a long-standing question on the different types of
a2-6 glycans expressed in these tissues. To elaborate the diversity
of a2-6, which predominate in the upper respiratory tissues8,
human tracheal tissue sections were costained with Concanavalin/
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(ConA)/Jacalin and SNA-I/Jacalin (Fig. la). The glycan binding
specificity of these lectins has been previously characterized using
glycan arrays. As SNA-I binds to diverse a2-6, its binding pattern
indicated the distribution of a2-6. Jacalin, which specifically binds to -
Gals1-3GalNAcx- and -GcNAc1-3GalNAca- motifs, characteristic
of O-linked glycans, predominantly stained goblet cells. On the other
hand, ConA, which specifically binds to mannose commonly found in
high mannose, hybrid and complex type N-linked glycans, predomi-
nantly stained ciliated cells. The lectin binding patterns in Figure la
demonstrated a wide distribution of N-linked c2-6, compared with
the more localized distribution of O-linked x2-6 on the apical side of
the human tracheal epithelium. Matrix-assisted laser desorption/
ionization- mass spectrometry (MALDI-MS) profiling of N-linked
sialylated glycans of a representative upper respiratory epithelial cell
line was performed using techniques that were specifically modified to
better suit the analysis of these complex acidic glycans. The results
showed a substantial diversity (Fig. 1b), as well as predominant
expression of x2-6 (Supplementary Fig. 1 online), in the human
upper respiratory epithelium. Furthermore, desialylation and frag-
mentation of representative mass peaks using MALDI tandem time of
flight (TOF-TOF) (Fig. 1c,d) demonstrated the presence of long
oligosaccharide branches with multiple lactosamine repeats.
The observation of extensive diversity of the glycan structures in the
human upper respiratory tissues prompted the second complementary
analysis, involving examination of the conformational features of these
diverse sialylated glycans and their role in HA-glycan interactions.
Analyses of all the HA-glycan cocrystal structures indicated that the
orientation of the Neu5Ac sugar is fixed relative to the HA glycan
binding site. A highly conserved set of amino acids Y98, S/T136,
W153, H183, L/I194 (numbered based on H3 HA) across different HA
SNA + Jacalin (25 X)































Figure 1 Glycan diversity in human upper respiratory tissues. (a) Costaining of tracheal tissue sections with ConA (red)/Jacalin (green) and SNA-1 (red)/
Jacalin (green). The localized regions of Jacalin binding correspond to goblet cells expressing 0-linked glycans and the regions of conA binding correspond
to ciliated cells expressing N-linked glycans (white arrow) on the apical side of the tracheal epithelium. The extensive binding of SNA-1 to both goblet cells
(costain with Jacalin in yellow) and ciliated cells indicates predominant expression of 0-linked and N-linked 2-6 on the apical side. (b) MALDI-MS glycan
profile of human bronchial epithelial (HBE) cells using graphical representation (without explicit linkage assignment) of possible sialylated glycan structures
that satisfy the mass peaks (within ± 3.5 Daltons). HBEs predominantly express x2-6 (in comparison with a2-3) sialylated glycans (Supplementary Fig. 1).
(c) Desialylation using Sialidase A and subsequent 2-AB labeling of the N-linked glycans observed in b to deconvolute the branching pattern from the
number of sialic acids. The peaks highlighted in cyan in b and c were further analyzed using TOF-TOF MS. (d) The MS-MS profile of a representative peak at
m/z 2148 shows critical fragment ions at m/z 548 and 713 and their corresponding counter ions (shown in red) that support the long oligosaccharide branch
(with multiple lactosamine repeats) over multiple short lactosamine branches. MS-MS profile of m/z 2660 also supports a long oligosaccharide branch (data
not shown). Glycans are represented using the graphical nomenclature adopted by the Consortium for Functional Glycomics (CFG).


















Figure 2 Cone-like (left) and umbrella-like (right)
topologies of 2-3 and a2-6 siaylated glycans.
The topology of a2-3 and a2-6 is governed by
the glycosidic torsion angles of the trisaccharide
motifs-Neu5Ac2-3Galpl-3/4GcNAc and
Neu5Acet2-6Galpl-4GIcNAc, respectively
(Supplementary Fig. 3 online). A parameter
(W)-the angle between the C2 atom of
Neu5Ac and C1 atoms of the subsequent Gal and
GIcNAc sugars in these trisaccharide motifs-
c characterizes the topology. Superimposition of 186,187,
the 0 contour and the conformational maps of 193,
the a2-3 and oc2-6 motifs showed that the 2-3 WON
, motif adopts 100% cone-like topology and c2-6 Gln226
motif sampled both the cone-like and umbrella-
like topologies (Supplementary Fig. 3). In the 193
cone-like topology sampled by a2-3 and
Na2-6, the GIcNAc and subsequent sugars are
E positioned along a region spanning a cone. The interactions of HA with the co
0 positions (based on H3 HA numbering) with Neu5Ac and Gal sugars. On the
GIcNAc and subsequent sugars bend toward the HA binding site (as observed
,~tetrasaccharide) would favor this conformation as it is stabilized by intra-suga
Sinteractions with sialylated glycans with the umbrella-like topology involve corIwith GIcNAc and subsequent sugars in addition to contacts with Neu5Ac and
Ssubtypes are involved in anchoring the Neu5Ac sugar. The specificity
CLof HA to a2-3 or oc2-6 is therefore governed by interactions of the
,2 HA glycan binding site with the glycosidic oxygen atom and sugars
0 besides Neu5Ac.
019
0 The conformation of the Neu5AcoL2-3Gal linkage is such that the
Gal and sugars beyond Gal (at the reducing end, and in both linear
and branched 2-3) occupy a cone-like region of space. Hence, we
Sdefine it as a cone-like glycan topology (Fig. 2). In the cone-like
topology; HA interactions with the glycans primarily involve contacts
with Neu5Ac and Gal sugars in a three-sugar (or trisaccharide) ec2-3
Z motif (Neu5Ac2-3Galli-3/4GcNAc-) and this observation is corro-
borated by the co-crystal structuresl 2 '1 3 . In addition to the two
critical amino acids, E190 and Q226 (Fig. 2), the contacts with the
c2-3 motif and substitutions on this motif, such as sulfation and
fuce lation, appear to involve key amino acid positions (Fig. 2). The4jevariability of the amino acids in these positions potentially accounts
for the differential binding specificity of HA to the diverse 2-3
sialylated glycans (see below). Compared with the Neu5Acc2-3Gal
linkage, the presence of the C6-C5 bond provides additional glycan
conformational flexibility to the Neuan2-6Gal linkage. This enables
the a2-6 motif to adopt a cone-like topology, as well as the potential to
span a wider region of space analogous to the opening of an umbrella.
We thus define the latter conformation-which spans a wider region
on the HA surface than the cone-like topology-as an umbrella-like
glycan topology (Fig. 2). In contrast to the cone-like topology, the
length of the oligosaccharide and its degree of branching beyond a
trisaccharide critically influence HA binding contacts in the umbrella-
like topology. Therefore, the amino acids involved in interactions with
the umbrella-like topology (key numbered positions shown in Fig. 2)
are not conserved across the human-adapted H1 and H3 HAs.
Depending upon the HA subtype, a combination of amino acids at
these positions are involved in interacting with a long c2-6. This
observation is corroborated by the cocrystal structures of Hi and H3
with o2-6 oligosaccharides 3,""-14. Therefore, whereas the cone-like
topology is characteristic of 2-3 as well as short a2-6 glycans such
as single lactosamine branches, the umbrella-like topology is unique to
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ne-like topology primarily involves contacts of amino acids at the numbered
other hand, in the umbrella-like topology, which is unique to a2-6, the
in HA-c2-6 cocrystal structures). Longer a2-6 oligosaccharides (at least a
r van der Waals contact between acetyl groups of GIcNAc and Neu5Ac. HA
itacts of amino acids at the numbered positions (based on H3 HA numbering)
Gal sugars.
Interrogation of the HA-glycan cocrystal structures highlights the
fact that the human-adapted HI and H3 HAs have mutated from their
presumed avian counterparts to gain additional contacts with C2-6 in
the umbrella-like topology. Defining HA-glycan interactions based on
trans and cis conformations (adopted by x2-3 and a2-6 linkages,
respectively) is inadequate as this does not fully capture the structural
features and conformational flexibility of the diverse sialylated glycans
observed in human tissues. In contrast, the cone-like and umbrella-
like classifications for HA binding represent the full extent of the
structural diversity and conformational plurality of sialylated glycans
and are able to distinguish the a2-3 and cx2-6 binding of avian HAs
from that of the 22-6 binding of human-adapted H1 and H3 HAs.
The requirements for HA binding to the cone-like and umbrella-
like topologies were further corroborated using the third complemen-
tary data mining approach, involving analysis of the extensive glycan
array data available for H1, H3 and H5 HAs2, 16. The data mining
analysis provided correlations between glycan features (Fig. 3a)
abstracted from the glycans on the array and the HA binding to
these glycans. These correlations are given as rules or classifiers
(Fig. 3b) that verify the above structural constraints. Consistent
with these observations, the distinct o2-3 classifiers (Fig. 3b) indicated
that variations around the trisaccharide m2-3 motif primarily influence
the differential (x2-3 binding of HI, H3 and H5 HAs. On the other
hand, the length-dependent a2-6 classifiers (Fig. 3b) support the
critical role of oligosaccharide length in HA binding to x2-6 in the
umbrella-like topology. The o2-6 classifier common to the human-
adapted H1 and H3 HAs is consistent with its gain in ability to bind
long a2-6. Although the glycan binding of wild-type and mutant
H5N1 HAs is not supported by the long o2-6 classifier, it is consistent
with both o2-3 and short x2-6 classifiers (Fig. 3b).
The final complementary analysis involved corroborating the above
findings by establishing the tissue tropism and binding specificity of
human-adapted HA to upper respiratory tissue glycans through
investigating human tissue binding and direct glycan binding of
recombinant HAs. The HAs from the hallmark pandemic SC18
and the human vaccine strain A/Moscow/10/99 H3N2 (Mos99) were
chosen as representative human-adapted H1 and H3 candidates.
SC18 and Mos99 HAs showed distinct binding patterns to human
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upper respiratory (tracheal) and deep lung (alveolar) tissues (Fig. 4a).
More importantly, both H1 and H3 HA showed substantial binding
to the apical side of tracheal tissue sections. As noted earlier (Fig. 1),
long-branch a2-6 are predominantly expressed on the apical side of
the upper respiratory epithelia. The OC2-6 binding specificity of
the human-adapted HAs was verified using dose-dependent direct
binding of HA to defined c2-3 and a2-6 oligosaccharides (Fig. 4a).
The binding of SC18 and Mos99 HAs over a range of concentra-
'1. -A A 4u _ U - . _ +1
t ions to 6S14 n t4 te4L r g -a
0 long m2-6 oligosaccharide. In addition to
0 also bound with high affinity to the shori
(6'SLN) and at a relatively lower affinity to t
5 charide (3'SLN-LN-LN).
Taken together, the above findings show
. that the human-adapted HAs bind specifi-
.C cally to the long o2-6 (in the umbrella-like
0 topology), which are predominantly
4 expressed in the human upper respiratory
,0 tissues. The m2-3 binding of Mos99 further
c suggests that a switch in the glycan binding
preference (that is, loss of ability to bind a2-
3) is not a necessary determinant for human
ii adaptation of HA. Tx9l, also a mixed x2-6/
a2-3 binding virus that shows HA binding to
CL long a2-6 (Fig. 3b), is capable of efficient
0 transmission' 8. On the other hand, NY18,
O another mixed a2-3/x2-6 binding virus that
C* does not have HA binding specificity to long
oc2-6 (Fig. 3b), is not transmitted effi-
ciently18. The efficient human adaptation
of these viruses is, therefore, correlated
with HA binding to sialylated glycans of a
z
c Figure 3 Data mining analysis of HA binding
glycan array data. (a) Examples of the types of
g glycan features (e.g., pairs, triplets andquadruplets) abstracted from a representative
"~omplex glycan structure. A comprehensive set of
l'hese features was abstracted from the glycans in
the glycan array. (b) Graphical representations of
the complex classifier rules (Supplementary
Table 1) for each HA analyzed using the glycan
array. The (x2-3 Type A represents broadest
specificity, whereas the Type B and Type C
classifiers represent constraints imposed by
structural variations around the trisaccharide
ct2-3 motif. The c2-6 Type A represents binding
to long a2-6, whereas Type B represents binding
to short oc2-6 (linear or branched). The core
corresponds to either the spacer attached to the
reducing end or the trimannosyl core in case of
the single c2-6 biantennary glycan on the array.
aBinding signals observed for fucosylated 2-3
motif only if it has GlcNAc[6S]. bBinding signals
observed only for 6'-sialyl lactose. cBinding
signals also observed for short 6'-sialyl
lactosamine (Type B). dBinding signals are
significantly lower than a2-3 Type B of H5N1
double mutant. eBinding signals observed only for
short (x2-6 with GlcNAc[6S]. fBinding signals just
above background observed for oc2-3 motif with
GIcNAc[6S]. *The origin of ANietnam/1203/04
is avian but this viral strain was isolated from an
infected human.
he long x2-6, Mos99
tx2-6 oligosaccharide
he long a2-3 oligosac-
characteristic umbrella-like topology, going beyond the specific x2-3
or a2-6 linkage.
Understanding the glycan binding specificity of influenza A virus
HA is critical for surveillance of the evolution of highly pathogenic
strains, such as H5N1, which threaten to gain a foothold in the human
population. Various strains of the highly pathogenic o2-3-specific
H5N1 viruses show mixed o2-3/o2-6 binding54 0 and yet these
viruses have shown inefficient transmission in ferrets5. However,
dose-dependent direct binding studies of representative H5N1
viruses-A/Vietnam/1203/04 (Viet0304) and A/Hong Kong/486/97
(HK486)-showed minimal binding affinity to long o2-6 (Fig. 4b).
The observed initiation of H5N1 infection in tissues predominantly
Pai a T
Pair Terminal (linear) triplet
E Triplet Linear quadruplet
Linear triplet Surface (terminal + branched) quadruplet
Influenza HA a2-3 Type a2-6 Type
A/Duck/Alberta/35/76 (Avian HIN1) OR No
(Type C)
{#~2~ 6/)-i R f~~ ~No
A/Duck/Ukraine/1/63 (Avian H3N8) N O 1111-3/1
(Type C)





(Type A) (Type B)
{a_ 'A -core}
A/Vletn/1203/04 (H5N1*) OR
Gln226Leu/Gly228Ser double mutant J U J {Ji2 Core}
(Type B) (Type B)
A/South Carollna/1/18 (Human HIN1) No (Type A4)
A/Texasl36/91 (Human H1N1) 4 $
(Type Bd) (Type Ae
R10  ORA/New York/1/18 (Human HINI) J~ {41 - J OP Core}
(Type Ca) (Type B*)
A/Moscow/10/99 (Human H3N2) Nof (Type A)
6s0 63-0 sulfated GIcNAc (9/0) Gi or GaINAc 1-4 Nof-fucosylated GIcN1Ac Gal without GaINA01 -4GaI linkage.
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expressing a2-6 (ref. 21) could possibly be explained by the ot2-6
binding at high viral loads. Although additional factors such as the
neuraminidase and other viral gene products may play a role in H5N1
viral transmission, a necessary condition for the human adaptation of
its HA is to acquire mutations that would provide binding specificity
to long ot2-6. The glycan topology could also play an important role in
the balance between the x2-6 binding of HA and cleavage properties
of neuraminidase22,23. Thus, the identification of the ci2-6 sialylated
glycans present on lung tissue can now be used to analyze any
correlation between glycan topology and neuraminidase stalk length
in virulence during human-to-human transmission.
Three related issues have confounded the interpretation of glycan
receptor specificity leading to human adaptation of HA. The first
arises from the association of 'human-like receptors' exclusively
with the Neu5Aca2-6Gal linkage, as evidenced by using short o2-6
oligosaccharides 6'SL and 6'SLN to define glycan binding specificity of
the H5N1 viruses5,20. These and other earlier studies have predomi-
nantly focused on a2-3 and a2-6 linkages, as well as a switch in the
linkage preference. However, as both c2-3 (short, long, linear and
branched) and short a2-6 adopt the cone-like topology as opposed to
long cx2-6, (which adopts the characteristic umbrella-like topology),
glycan topology-and not just linkage per se-is the key determinant
for human adaptation of HAs. The second issue deals with the binding
specificity of HA-glycan interactions. Many HA glycan array experi-
ments" have been performed at a relatively high HA concentration,
without a dose-dependent relationship to establish specificity. Our
dose-dependent binding studies enabled investigation of the
HA-glycan binding affinities and thereby demonstrate the specificity
of human-adapted HAs for binding long OC2-6 (Fig. 4a). These studies
can be further extended to derive parameters such as binding affinity
H1N1 A/South Carolina/1/18 HA (SC18)
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HA concentration (pg/ml)
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H5N1 A/Hong Kong/486/97 (HK486) virus
III
128 64 32 16
Virus titer (HAU)
III Emil ME
Figure 4 Glycan binding specificity of SC18 and Mos99 HAs, as well as H5N1 viruses. (a) Both SC18 and Mos99 HAs show substantial and preferential
binding to the apical side of the tracheal tissue (green against as against propidium iodide staining in red) compared with the alveolar tissue sections,
although binding of SC18 is more restricted than that of Mos99. The sialic acid-specific binding of HA is demonstrated by a substantial reduction in binding
after pretreatment of tissues with Sialidase A (Supplementary Fig. 4 online). Moreover, competition experiments involving SC18 HA and SNA-l showed
dramatic reductions in SC18 HA binding to tracheal sections (data not shown). Further AV18 HA does not bind to tracheal sections (data not shown). The
binding specificity of SC18 and Mos99 HAs was demonstrated with dose-dependent direct binding to defined o2-3 and ot2-6 oligosaccharides (shown on
the right). The characteristic binding pattern of SC18 and Mos99 HAs is their binding at saturating levels to the long a2-6 (6'SLN-LN) over a range of HA
dilution from 40 to 5 pg/ml. The narrow specificity of SC18 HA correlates with its restrictive tracheal tissue binding. On the other hand, the ability of Mos99
HA to bind to diverse sialylated glycans is consistent with its more extensive binding to tracheal tissue sections (as compared with SC18). The high affinity
binding of SC18 and Mos99 HAs to long ot2-6 was confirmed using another human-adapted H3N2 (A/Wyoming/3/03) HA (Supplementary Fig. 5 and
Supplementary Methods online). (b) In contrast to the dose-dependent binding profile of the human-adapted SC18 and Mos99 HAs, Viet03O4 and HK486
H5N1 viruses bind with high affinity to the a2-3 and minimal affinity to the long a2-6 oligosaccharide. The dose-dependent direct binding of the whole virus
corroborates with the binding of soluble HA protein and the deep lung tissue tropism of the H5N1 HA is consistent with its a2 -3 binding specificity
(Supplementary Fig. 6 and Supplementary Methods online). HAU, Virus titer in Hemagglutinating Unit.
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constants to quantify the relative glycan binding affinities of different
HAs. The two representative H5N1 viruses showed binding signals for
long c2-6 at the highest viral concentrations. However, the binding
affinity for long c2-6 is minimal compared to the high affinity for
c2-3 over the entire viral concentration range (Fig. 4b). Interpretation
of the glycan binding data at the highest concentration alone would
have led to an erroneous conclusion that these viruses have acquired
binding to human-like receptors. The third issue concerns the use of
>, chicken red blood cells (cRBC) agglutination assays. Desialylated and
CR02 t2-6 resialylated cRBC have been extensively used in agglutination
0
_ assays to study (x2-6 binding specificity of wild-type and mutant
viruses 8 ,24,25. MALDI-MS glycan profile of cRBC (Supplementary
d Fig. 2 online) shows limited abundance of N-linked a2-6 with long
"0 branches. Thus, (x2-6 resialylation of these cRBC is unlikely to provide
a the required human-like receptors defined in the approach presented
in this study.
b These findings suggest that using glycan arrays with long 2C2-6 will
be valuable for surveillance of the evolution of human adaptation of
a influenza A viral subtypes. Specifically, this can be achieved either by
E expanding the diversity of the glycans to include upper respiratoryJ tissue-specific glycans on the current glycan microarrays, or through
the development of a glycan array that includes representative long
ii oc2-6 structures based on those observed in the upper respiratory
.c tissues. Furthermore, these arrays need to be developed for rapid dose-
0. dependent analyses of HA binding to establish specificity to long 22-6
2 structures. Adaptation studies with the avian viruses using appropriate
O long ct2-6 structures might provide the needed selection pressure for
O human adaptation. The ability of H5N1 to bind cone-like topology
glycans with high specificity may explain why selection pressure
strategies based just on glycan linkages have been unsuccessful. Finally,
a recent study reported that the mutations in the glycan binding site ofC.
2 HA (leading to human receptor binding) could facilitate the genera-
.j tion of antibodies with better neutralizing sensitivity24. A sufficient
z understanding of the avian H5N1 HA mutations leading to long a2-6
c binding specificity offers an opportunity for intervention through
D vaccine development to negate the eventuality of a H5N1 pandemic.
. "*METHODS
ctin staining of human upper respiratory tissues. Normal human trachea
tissue sections (US Biological) were deparaffinized and rehydrated, followed by
blocking endogenous biotin using the streptavidin/biotin blocking kit (Vector
Labs). Sections were then incubated with FITC-labeled Jacalin, biotinylated
conA and biotinylated Sambuccus nigra agglutinin (SNA-I) (Vector labs;
10 pg/ml in PBS with 0.05% Tween-20) for 3 h. After washing with TBST
(Tris-buffered saline with 0.1% Tween-20), the sections were incubated with
Alexa fluor 546 streptavidin (Invitrogen) for 1 h. Slides were washed with TBST
and viewed under a confocal microscope (Zeiss LSM510 laser scanning
confocal microscopy). All incubations were performed at 22 'C. The glycan
array data for the plant lectins can be accessed from the Consortium for
Functional Glycomics (CFG) web site, http://www.functionalglycomics.org/
glycomics/publicdata/primaryscreen.jsp by selecting Plant lectins in the
"Analyte Category."
MALDI-MS and TOF-TOF MS analysis of N-linked glycans. Human bron-
chial epithelial (HBE) cells were chosen as representative upper respiratory
ciliated epithelial cells based on the extensive attachment of human-adapted
H1N1 and H3N2 viruses to these cells'. These cells were harvested at >90%
confluency with 100 mM citrate saline buffer and the cell membrane was
isolated by homogenization. Washed and pooled RBCs (Rockland Immuno-
chemicals) were lysed by resuspending in deionized water for 15 min and the
cell membrane was isolated as described above. The cell membrane fractions
were treated with PNGaseF (New England Biolabs) and the reaction mixture
was incubated overnight at 37 'C. The reaction mixture was boiled for 10 min
to deactivate the enzyme and the deglycosylated peptides and proteins were
removed using a Sep-Pak C18 SPE cartridge (Waters). The glycans were further
desalted and purified into neutral (25% acetonitrile fraction) and acidic (50%
acetonitrile containing 0.05% trifluoroacetic acid) fractions using graphitized
carbon solid-phase extraction columns (Supelco) and lyophilized.
The neutral and acidic fractions were analyzed by MALDI-TOF MS in
positive and negative linear modes, respectively, with soft ionization conditions
(accelerating voltage 22 kV, grid voltage 93%, guide wire 0.3% and extrac-
tion delay time of 150 ns). Matrices used were as follows: 10 mg/mil
6-aza-thiothymine in ethanol spotted on perfluorinated Nafion resin for acidic
glycans and 40 mg/ml 2,5-dihydroxybenzoic acid in ethanol for neutral glycans.
The peaks were calibrated as nonsodiated species using external glycan
standards. The predominant expression of c2-6 sialylated glycans was con-
firmed by treatment of samples using Sialidase A and S. Briefly, the isolated
glycans were incubated with 0.1 U of Arthrobacter ureafaciens sialidase
(Sialidase A, cleaves both c22-3 and a2-6 sialic acid linkages) or Streptococcus
pneumoniae sialidase (Sialidase S, specifically cleaves a2-3 sialic acid linkage) in
a final volume of 100 pl of 50 mM sodium phosphate, pH 6.0, at 37 'C for 14 h.
The glycans were purified as before and the sialidase-treated glycans were
analyzed by MALDI-TOF MS.
Sialidase A-treated glycans were 2-aminobenzamide (2-AB) derivatized, as
described previously26, purified" and lyophilized. MS/MS mass spectra were
acquired on an Applied Biosystems 4700 TOF/TOF Proteomics analyzer,
equipped with delayed extraction and a UV laser (355 nm) controlled by
AB 4700 Data Explorer software. 1 pl of a 5 mg/mI solution of
a-cyano-4-hydroxycinnamic acid prepared in acetonitrile/water mixture
(60:40, vol/vol) was seeded on a standard 192-well stainless steel MALDI
sample plate and allowed to air dry. Subsequently, 1 pl of 2-AB-labeled glycan
sample was spotted on the matrix and allowed to dry. Typically, 1,000-5,000
shots/spectrum were collected in the positive reflector mode for MS/MS
spectra. CID mode (with air as the collision gas) with a chamber pressure of
1-6 x 10-6 Torr and acceleration voltage of 2 kV was used for glycan
fragmentation and internal peptide standards were used for calibration.
Cloning, baculovirus synthesis, expression and purification of HA. The
soluble form of HA was expressed using the Baculovirus Expression Vector
System (BEVS). H5N1 (A/Vietnam/1203/2004; Viet03O4) baculovirus was
created from a pAcGP67-VietO4-HA construct 2 using Baculogold system (BD
Biosciences) according to manufacturer's instructions. The crystal structure of
the BEVS expressed uncleaved HAO from SC18 (ref. 15) is identical to the
structure of the SC18 HA isolated from the whole virus after bromelain
treatment 14. Studies have also shown that glycan binding specificity of BEVS-
expressed HAs is in agreement with that of whole viruses17. H1, H3 and H5
baculoviruses were used to infect 500 ml suspension cultures of Sf9 cells
(Invitrogen) cultured in Sf900 II SFM medium (Invitrogen). The infection was
monitored and the cells were harvested 3-4 d after infection. The soluble form
of HA was purified from the supernatant of the infected cells using the protocol
described previously 5. Briefly, the supernatant was concentrated using Cen-
tricon Plus-70 centrifugal filters (Millipore) and the soluble HA was recovered
from the concentrated cell supernatant by performing affinity chromatography
using Ni-NTA beads (Qiagen). Eluting fractions containing HA were pooled
and dialyzed overnight with a 10 mM Tris-HCI, 50 mM NaCl buffer (pH 8.0).
Subsequently, ion exchange chromatography was performed on the dialyzed
samples using a Mono-Q HR10/10 column (GE Healthcare). The fractions
containing HA were pooled together and subjected to ultrafiltration using
Amicon Ultra 100 K NMWL membrane filters (Millipore). The protein was
concentrated and reconstituted in PBS. The purified protein was quantified
using Bio-Rad's protein assay (Bio-Rad).
Binding of H1, H3 and H5 HA to human lung tissues. Normal human trachea
(US Biological) and lung (US Biomax) tissue sections were deparaffinized,
rehydrated and incubated with 1% BSA in PBS for 30 min to prevent
nonspecific binding. SC18 and Mos99 were precomplexed with primary anti-
body (mouse anti-6 x His tag, Abcam) and secondary antibody (Alexa fluor 488
goat anti-mouse, Invitrogen) in a ratio of 4:2:1, respectively, for 20 min on ice.
The tissue binding was performed over different HA concentrations by diluting
the precomplexed HA in 1% BSA-PBS. Tissue sections were then incubated with
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the HA-antibody complexes for 3 h at 22 'C. Sections were counterstained with
propidium iodide (Invitrogen; 1:100 in TBST), washed extensively and then
viewed under a confocal microscope (Zeiss LSM510 laser scanning confocal
microscopy). In the case of sialidase pretreatment, tissue sections were incubated
with 0.2 units of Sialidase A (recombinant from Arthrobacter ureafaciens,
Prozyme) for 3 h at 37 'C before incubation with the proteins.
Dose-dependent direct binding of H1, H3 HA and H5 viruses. Streptavidin-
coated high binding capacity 384-well plate (Pierce) was rinsed with PBS and
> each well was incubated with 50 pl of 2.4 puM solution of biotinylated glycans
0 (3'SLN, 6'SLN, 3'SLN-LN, 6'SLN-LN and 3'SLN-LN-LN) in PBS overnight at
o 4 'C. LN corresponds to lactosamine (Gals1-4GlcNAc) and 3'SLN and 6'SLN,
respectively, correspond to Neu5Aca2-3 and Neu5Aca2-6 linked to LN. These
glycans were obtained from the Consortium for Functional Glycomics (CFG).3 The plate was subsequently washed with PBS to remove excess glycan and used
without further processing. Appropriate amounts of His-tagged HA protein,
1 primary (mouse anti 6x His tag IgG, Abcam) and secondary (HRP-conjugated
goat anti Mouse IgG, Santacruz Biotechnology) antibodies were mixed in the
o ratio 4:2:1 and incubated on ice for 20 min. The highest HA concentration of
40 tg/ml was chosen based on typical concentrations used in CFG glycan array
analysis 7 . The mixture (precomplexed HA) was made up to a final volume of
C 250 pl with 1% BSA in PBS buffer and 50 pl of precomplexed HA was added to
each glycan-coated well and incubated at 22 'C for 2 h. The wells were
extensively washed with PBS containing 0.05% Tween-20 followed by washes
with PBS.
Virus stocks (from CDC) were propagated in the allantoic cavity of 10-d-old
embryonated hens' eggs at 37 'C. The allantoic fluids were harvested 24 h after
" inoculation and inactivated by treatment with B-propiolactone (BPL; 1/1,000)2 for 3 d at 4 'C. Virus binding to the glycan-coated wells was performed as
described2 0 by adding appropriate amount of virus to each well after diluting in
PBS containing 1% BSA and incubating overnight at 4 'C. After rinsing excess
-C virus with PBS containing 0.05% Tween-20 and PBS, the wells were incubated
with antibody against the virus (ferret-anti-influenza A raised against A/Hong
s Kong/213/03 H5N1) for 5h at 4 'C. After extensive washing of the antibody, the
I plate was incubated with HRP-linked goat-anti-ferret antibody (Rockland
Immunochemicals) for 2 h at 4 'C. After extensive washes with PBS containing
*4 0.05% Tween-20 and PBS, in all cases, HRP activity was estimated using
Z Amplex Red Peroxidase Assay Kit (Invitrogen) according to manufacturer's
o instructions. Appropriate negative controls were included and all assays were
4 done in triplicate.
@
Data mining analysis of glycan microarray data. The data from glycan
e icroarray screening of Hi, H3 and H5 HA were obtained from the
FConsortium for Functional Glycomics (CFG) web site, http://www.functional
glycomics.org/glycomics/publicdata/primaryscreen.jsp. From this web page, the
"Other" option in the "Analyte category" was selected to obtain a list of
microbial lectins screened on the glycan array. The data for all influenza virus
HAs were obtained by sorting this list by investigator and searching the sorted
list using "Jim Paulson" as the investigator name. The principle and meth-
odologies for data mining analysis are well established in many fields and
involve two main aspects: feature abstraction and classification. A variety of
features, including all possible di-, tri- and tetrasaccharide combinations,
present in each glycan in the glycan array were abstracted (Fig. 3a). The
rationale behind choosing these features is based on the binding of di-, tri- or
tetrasaccharides to the glycan binding site of HA. The final data set has features
from the glycans, as well as the binding signals for each of the HAs screened on
the array. The rule-induction classification method was used. One of the main
advantages of this method is that it generates IF-THEN rules, which can be
interpreted more easily when compared to the other statistical or mathematical
methods (Supplementary Table 1 online).
Note: Supplementary information is available on the Nature Biotechnology website.
ACKNOWLEDGMENTS
This work was supported by the National Institute of General Medical Sciences
glue grant U54 GM62116 and National Institutes of Health (NIH) grants
GM57073. The authors thank James Stevens for his generous help in providing
the H1, H3 baculoviruses and H5 HA clones. Human bronchial epithelial
(HBE) cells (16HBE14o-; were a gift from D.C. Gruenert, University of
California, San Francisco. The authors thank the CFG for the glycan array data
and for the supply of glycans for direct binding experiments. The authors
acknowledge Maha Venkataraman and Subu Ramakrishnan at the
Bioinformatics Core of the CFG for their help with data preparation in the data
mining analysis and Dr. Shu-hua Nong for his help with purification of the HA
proteins. Confocal microscopy was performed using the WM Keck Foundation
Biological Imaging Facility at the Whitehead Institute. The MALDI TOF-TOF
analysis was performed at the Barnett Institute of Chemical and Biological
Analysis (Northeastern University, Boston).
Published online at http://www.nature.com/naturebiotechnology/
Reprints and permissions information is available online at http://npg.nature.com/
reprintsand permissions
1. van Riel, D. et al. Human and avian influenza viruses target different cells in the lower
respiratory tract of humans and other mammals. Am. J. Pathol. 171, 1215-1223
(2007).
2. Stevens, J. et al. Structure and receptor specificity of the hemagglutinin from an H5N1
influenza virus. Science 312, 404-410 (2006).
3. Russell, R.J., Stevens, D.J., Haire, L.F., Gamblin, S.J. & Skehel, J.J. Avian and human
receptor binding by hemagglutinins of influenza A viruses. Glycoconj. J. 23, 85-92
(2006).
4. Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the
influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
5. Yen, H.L. et al. Inefficient transmission of H5N1 influenza viruses in a ferret contact
model. J. Viro/. 81, 6890-6898 (2007).
6. Maines, T.R. et al. Lack of transmission of H5N1 avian-human reassortant influenza
viruses in a ferret model. Proc. Nat. Acad. Sci. USA 103, 12121-12126 (2006).
7. Kuiken, T. et al. Host species barriers to influenza virus infections. Science 312,
394-397 (2006).
8. Shinya, K. et al. Avian flu: influenza virus receptors in the human airway. Nature 440,
435-436 (2006).
9. van Riel, D. et al. H5N1 Virus Attachment to Lower Respiratory Tract. Science 312,
399 (2006).
10. Nicholls, J.M., Bourne, A.J., Chen, H., Guan, Y. & Peiris, J.S. Sialic acid receptor de-
tection in the human respiratory tract: evidence for widespread distribution of potential
binding sites for human and avian influenza viruses. Respir. Res. 8, 73 (2007).
11. Eisen, M.B., Sabesan, S., Skehel, J.J. & Wiley, D.C. Binding of the influenza A virus to
cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes
determined by X-ray crystallography. Virology 232, 19-31 (1997).
12. Ha, Y., Stevens, D.J., Skehel, J.J. & Wiley, D.C. X-ray structures of H5 avian and H9
swine influenza virus hemagglutinins bound to avian and human receptor analogs.
Proc. Natl. Acad. Sci. USA 98, 11181-11186 (2001).
13. Ha, Y., Stevens, D.J., Skehel, J.J. & Wiley, D.C. X-ray structure of the hemagglutinin of a
potential H3 avian progenitor of the 1968 Hong Kong pandemic influenza virus.
Virology 309, 209-218 (2003).
14. Gamblin, S.J. et al. The structure and receptor binding properties of the 1918 influenza
hemagglutinin. Science 303, 1838-1842 (2004).
15. Stevens, J. et al. Structure of the uncleaved human H1 hemagglutinin from the extinct
1918 influenza virus. Science 303, 1866-1870 (2004).
16. Stevens, J. et al. Glycan microarray analysis of the hemagglutinins from modern and
pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 355,
1143-1155 (2006).
17. Stevens, J., Blixt, 0., Paulson, J.C. & Wilson, I.A. Glycan microarray technologies:
tools to survey host specificity of influenza viruses. Nat. Rev. Microbiol. 4, 857-864
(2006).
18. Tumpey, T.M. et al. A two-amino acid change in the hemagglutinin of the 1918
influenza virus abolishes transmission. Science 315, 655-659 (2007).
19. Gambaryan, A. et al. Evolution of the receptor binding phenotype of influenza A (H5)
viruses. Virology 344, 432-438 (2006).
20. Yamada, S. et al. Haemagglutinin mutations responsible for the binding of H5N1
influenza A viruses to human-type receptors. Nature 444, 378-382 (2006).
21. Nicholls, J.M. et al. Tropism of avian influenza A (H5N1) in the upper and lower
respiratory tract. Nat. Med. 13, 147-149 (2007).
22. Neumann, G. & Kawaoka, Y. Host range restriction and pathogenicity in the context of
influenza pandemic. Emerg. Infect. Dis. 12, 881-886 (2006).
23. Matrosovich, M., Zhou, N., Kawaoka, Y. & Webster, R. The surface glycoproteins of H5
influenza viruses isolated from humans, chickens, and wild aquatic birds have
distinguishable properties. J. Virol. 73, 1146-1155 (1999).
24. Yang, Z.Y. et al. Immunization by avian H5 influenza hemagglutinin mutants with
altered receptor binding specificity. Science 317, 825-828 (2007).
25. Kumari, K. et al. Receptor binding specificity of recent human H3N2 influenza viruses.
Virol. J. 4, 42-53 (2007).
26. Bigge, J.C. et al. Nonselective and efficient fluorescent labeling of glycans using
2-amino benzamide and anthranilic acid. Anal. Biochem. 230, 229-238 (1995).
27. Grun, C.H. et al. One-step biotinylation procedure for carbohydrates to study
carbohydrate-protein interactions. Anal. Biochem. 354, 54-63 (2006).
NATURE BIOTECHNOLOGY VOLUME 26 NUMBER 1 JANUARY 2008 113

Quantitative biochemical rationale for differences in
transmissibility of 1918 pandemic influenza A viruses
Aravind Srinivasant, Karthik Viswanathant, Rahul Ramant, Aarthi Chandrasekaran t, S. Raguramt, Terrence M. Tumpey*,
V. Sasisekharani, and Ram Sasisekharan*IIll
tDepartment of Biological Engineering, §Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, and ICenter for Cancer
Research, Massachusetts Institute of Technology, Cambridge, MA 02139; and *Influenza Division, National Center for Immunization and Respiratory
Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Mailstop G-16, 1600 Clifton Road NE, Atlanta, GA 30333
Communicated by Robert Langer, Massachusetts Institute of Technology, Cambridge, MA, December 19, 2007 (received for review December 2, 2007)
The human adaptation of influenza A viruses is critically governed
by the binding specificity of the viral surface hemagglutinin (HA)
to long (chain length) a2-6 sialylated glycan (a2-6) receptors on the
human upper respiratory tissues. A recent study demonstrated that
whereas the 1918 H1N1 pandemic virus, A/South Carolina/l/1918
(SCI), with a2-6 binding preference transmitted efficiently, a
single amino acid mutation on HA resulted in a mixed a2-3
sialylated glycan (a2-3)/a2-6 binding virus (NY18) that transmitted
inefficiently. To define the biochemical basis for the observed
differences in virus transmission, in this study, we have developed
an approach to quantify the multivalent HA-glycan interactions.
Analysis of the molecular HA-glycan contacts showed subtle
changes resulting from the single amino acid variations between
SC18 and NY18. The effect of these changes on glycan binding is
amplified by multivalency, resulting in quantitative differences in
their long a2-6 glycan binding affinities. Furthermore, these dif-
ferences are also reflected in the markedly distinct binding pattern
of SC18 and NY18 HA to the physiological glycans present in human
upper respiratory tissues. Thus, the dramatic lower binding affinity
of NY18 to long a2-6 glycans, as against a mixed a2-3/6 binding,
correlates with its inefficient transmission. In summary, this study
establishes a quantitative biochemical correlate for influenza A
virus transmission.
hemagglutinin I multivalency I sialylated glycans
T he Spanish influenza pandemic of 1918 caused by the H1N1subty e virus resulted in ~20 million to 50 million deaths
worldwide (1). The emergence of avian influenza H5N1 viruses that
are able to infect humans (>300 known cases) and produce a high
mortality rate (~200 deaths) has raised serious global health
concerns. Significantly, adaptation of these viruses for efficient
human-human transmission could result in a new influenza pan-
demic, a public health disaster of tragic proportions.
The critical step in the host infection of inf luenza viruses is the
binding of their viral surface hemagglutinin (HA) to sialylated
glycan receptors on the epithelial cell surface of the host
organism (2-6). The evolution of pandemic viruses involves
crossing-over of avian influenza viruses (natural host) to humans
and adaptation to the human host for subsequent infection and
human-human transmission (2,7). This cross-over is believed to
involve mutations in HA that switch its glycan receptor prefer-
ence from a2-3 sialylated (a 2-3) to a2-6 sialylated (a2-6) glycans
found in abundance in human upper respiratory epithelia (3-5,
8). The human upper respiratory tract a2-6 receptor adaptation
of HA is a critical step in permitting the viruses to infect and
efficiently replicate in these tissues, leading to rapid human-
human transmission (8). Several studies have been performed to
elucidate the distribution of glycans in human upper respiratory
tissues (4, 8-10). We recently demonstrated that human upper
airways express a diversity of a2-6 structures with a predominant
expression of long oligosaccharides (11). More importantly, we
observed that both a2-3 and short a2-6 glycan structures adopt
a distinct, narrow cone-like topology, whereas long a2-6 glycans
2800-2805 I PNAS I February 26, 2008 | vol. 105 | no. 8
adopt a flexible umbrella-like topology. Human-adapted H1 and
H3 HA demonstrated high-affinity binding specificity to long
c12-6 glycans that are expressed in the human upper respiratory
epithelium. The classification of HA glycan specificity in terms
of the glycan topology instead of the linkage has permitted us to
distinguish the observed a2-3 and a2-6 binding of avian HAs
from that of the a2-6 binding of human-adapted HA. Based on
these observations, we postulated that HA specificity to a2-6
glycan receptors with distinct topology is the critical determinant
for efficient human adaptation of HA (11).
The relationship between HA mutations, which lead to a
change in glycan receptor preference and transmissibility of the
prototypic 1918 H1N1 pandemic virus [A/South Carolina/1/1918
(SC18)] has been investigated by using the ferret model (12).
Recently, Tumpey et al. (12) demonstrated that the SC18 with
a2-6 binding preference transmitted efficiently but a single
amino acid HA mutation (SC18 + one mutation) resulted
instead in a mixed a2-3/a2-6 binding virus (NY18) that trans-
mitted inefficiently. Furthermore, a second HA mutation (NY18
+ one mutation) resulted in an a2-3 binding virus (AV18) that
did not transmit. This model system is ideally suited to study
transmissibility purely based on HA mutations, as all other genes
are identical in the different viruses. These remarkable differ-
ences in virus transmission as the result of a single amino acid
mutation on HA, in turn, raise important questions about
HA-glycan specificity in the context of glycan topology not only
for human adaptation but also for efficient transmission.
In this study, we have developed a quantitative framework to
investigate HA-glycan specificity to explain the observed dif-
ferences in the transmissibility of the 1918 pandemic influenza
A viruses. The differences in the molecular HA-glycan contacts
caused by the single amino acid variations were investigated by
using H1 HA-glycan cocrystal structures (13). The effects of
these subtle differences on the multivalent HA-glycan interac-
tions were captured by using a quantitative glycan-binding assay
to establish the relative glycan binding affinities of the HAs. The
physiological relevance of the differences in the HA-glycan
binding affinities was investigated by using HA binding to human
upper respiratory tissues. Taken together, this approach estab-
lishes a quantitative biochemical correlation between influenza
virus HA-glycan binding and virus transmission.
Author contributions: A.S., K.V., R.R., and A.C. contributed equally to this work; V.S., R.R.,
and R.S. designed research; A.S., K.V., R.R., A.C., and S.R. performed research; A.S., A.C., and
T.M.T. contributed new reagents/analytic tools; A.S., K.V., R.R., A.C., S.R., T.M.T., and R.S.
analyzed data; and R.R., V.S., and R.S. wrote the paper.
The authors declare no conflict of interest.
Freely available online through the PNAS open access option.
ITo whom correspondence should be addressed. E-mail: rams@mit.edu.
This article contains supporting information online at www.pnas.org/cgi/contentfull/
0711963105/DC1.
0 2008 by The National Academy of Sciences of the USA
www.pnas.org/cgi/doi/10.1073/pnas.0711963105
.......... .... .......................................... ..............
190 192 193 222 225 226
SC18 D Q S K D Q
NYI8 D Q S K G Q
AVI8 E Q S K G Q
AS130 D Q S K G Q
APR E Q N K G Q
Fig. 1. Molecular interactions of SC18, NY18, and AV18 HAs with a2-3 and a2-6. The glycan binding site on HA is shown with the critical amino acids including
the highly conserved Neu5Ac anchors (Thr-136, Trp-153, Thr-155, and Leu-194). Tyr-95 and His-183 are not shown for clarity. The amino acid positions are
numbered based on H1N1 HA. (A) Shown is the interaction of the SC18 HA with long a2-6 in the umbrella-like topology. Lys-222, Asp-225, and Gln-226 provide
critical contacts with the base region, and Asp-190, Gln-192, and Ser-193 provide optimal contacts with the extension region. (B) Interaction of NY18 HA with
the long a2-6 shows the loss of the critical contact of Asp-225 with the base region (as observed in the case of SC18 HA in A). (C) Interaction of AV18 HA with
a2-3 in cone-like topology shows that HA interactions with cone-like topology involves contacts only with the NeuSAc and Gal sugars at the base in contrast to
that of the umbrella-like topology of long a2-6. Glu-190 and Gin-226 in AV18 are positioned to provide optimal contacts with these sugars. The side-chain
conformation of Glu-190 in AV18 was assigned based on that of Glu-190 in APR34 HA-a2-3 cocrystal structure. (D) The differences in the key amino acid positions
between SC18, NY18, and AV18 HAs in comparison with the AS130 and APR34 HAs. The differences in the amino acid contactswith a2-3 and oa2-6 are quantified
by using buried solvent-accessible area calculations [supporting information (SI) Fig. 6].
Results
Molecular Interactions of SCIS, NY18, and AV18 HAs with a2-3 and
a2-6. Based on analysis of HA-glycan cocrystal structures, the
HA-glycan interactions are characterized by using a cone-like and
an umbrella-like glycan topology (11). The x-ray crystal structure of
SC18 HA has been solved (13, 14), but the cocrystal structure of this
HA with sialylated glycans remains unsolved. The structures of
NY18 and AV18 HA were obtained by making the single Asp-
225-Gly (for NY18 HA) and the additional NY18 + Asp-190-Glu
mutation for AV18 in silico. The cocrystal structures of the related
A/Swine/Iowa/15/30 (ASI30) and A/Puerto Rico/8/34 (APR34)
H1N1 HAs with a2-3 and a2-6 glycans (13) enabled the investi-
gation of molecular interactions between SC18, NY18, and AV18
with a2-3 and a2-6 oligosaccharides.
The umbrella-like topology is preferred by longer a2-6 oligo-
saccharides (tetrasaccharide and higher). The LSTc pentasac-
charide [N-acetylneuraminic acid (Neu5Ac) a2-6Gal31-4 N-
acetylglucosamine (GlcNAc) #13-3GalI31-4Glc] used in the
APR34 and ASI30 HA-a2-6 cocrystal structures represents this
long a2-6. Superimposition of these cocrystal structures and
SC18 HA demonstrated that the contacts with long a2-6 oligo-
saccharide are divided into two regions. The base region involves
contacts with the Neu5Aca2-6Gal31- motif, and the extension
region involves contacts with the -GlcNAc31-3Gal#1-4Glc31-
motif. A highly conserved set of amino acids (Tyr-95, Ser/Thr-
136, Trp-153, Thr-155, His-183, Leu/lle-194) are involved in
anchoring the Neu5Ac (Fig. 1). In the case of APR34 and SC18
HAs, both the backbone carbonyl oxygen and side chain of
Asp-225 are positioned to interact with the Gal sugar in the base
region. On the other hand, only the carbonyl oxygen of Gly-225
in ASI30 HA is positioned to interact with this Gal (Fig. 1).
Highly conserved Lys-222 and Gln-226 are also positioned to
interact with the base region. The critical amino acids involved
in contacts with the extension region are Asp-190 (in SC18 and
ASI30 HA), Gln-192 and Ser-193 (Asn-193 in APR34 HA).
NY18 HA, the Asp-225-Gly mutant of SC18, shares an almost
identical glycan binding site with that of ASI30 HA and therefore
lacks the extra contact provided by the side chain of Asp-225 with
Gal in the base region. In contrast, AV18 (the Asp-190-Glu/
Asp-225-Gly double mutant of SC18) lacks the critical contacts
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provided by th Asp-225 and Asp-190 to e base and ext nsionregions, respectively. Among SC18, NY18, and AV18 HAs, SC18HA provides the best contacts with the long a2-6 in theumbrella-like topology followed by NY18 HA.
Distinct from the umbrella-like topology, the cone-like topol-
ogy can be adopted by both a2-3 and a2-6 [preferentially by short
trisaccharide units such as Neu5Aca2-6Gall1-4Glc (or Glc-
NAc)]. Unlike the two distinct regions of HA contacts found
with the umbrella-like topology, the contacts with the cone-like
topology primarily involve substitutions that center around a
trisaccharide Neu5Aca2-3/6Gal1-3/4Glc (or GlcNAc) motif as
observed in the HA-a2-3 cocrystal structures. Specifically,
Glu-190 and Gln-226, which are highly conserved across various
avian HAs, are critically involved in making optimal contacts
with the cone-like topology (Fig. 1). This observation is corrob-
orated further by the disordered sugars beyond Neu5Ac in the
AS130 HA-cr2-3 cocrystal structure because Asp instead of Glu
at 190 in this HA lacks the contact with the a2-3. Superimpo-
sition of AV18 and APR34 HA, which both contain these critical
amino acids, shows that AV18 HA makes optimal contacts with
the cone-like glycan topology. Both SC18 and NY18 HAs lack
the critical Glu-190 residue, and therefore their contacts with the
cone-like glycan topology are less optimal when compared with
AV18 HA.
Dose-Dependent Direct HA Binding to Representative at2-3 and a2-6
Oligosaccharides. Novel glycan array platforms have been developed
to investigate HA-glycan interactions (15, 16). These arrays have
provided important insights into a2-3 versus a2-6 binding specificity
of various WT and mutant HAs. In these glycan array studies, high
and low binding signals to the glycans within a single assay using
saturating HA concentrations determine the glycan binding pref-
erence for a given HA. It is generally accepted that the glycan
binding affinity for a single binding site on any glycan binding
protein (such as a lectin) is low (typically in the high micromolar to
millimolar range). Because each HA unit is a trimeric protein, there
are three glycan binding sites per unit (5). In addition, multiple HA
units assemble on a virus surface. The glycan binding sites within
a HA unit and the spatial arrangement of multiple HA units across
a virus surface could play an important role in multivalent HA-
glycan interactions. The concentration of the HA units relative to
the glycans consequently will critically govern HA-glycan binding
specificity.
To understand differences in the glycan binding specificity of
SC18, NY18, and AV18 HAs for a specific spatial arrangement
of the HA units and the glycans, systematic direct HA binding
studies on a plate array were performed (see Materials and
Methods). Minimal binding signals were observed for SC18 HA
in the sequential ELISA-type binding assay (Fig. 2). Given that
glycan spacing and HA unit size limits HA binding to only a
single glycan in this assay, the binding signals are consistent with
the anticipated weak affinity of the HA unit to a single glycan.
The precomplexation assay with SC18 HA, where four HA units
are locked spatially, instead resulted in at least an 8-fold increase
in the binding to the long a2-6 glycan (Fig. 2). This dramatic
increase in the binding signal underscores the role that the
spatial arrangement of multiple HA units plays in enhancing
glycan binding.
Dose-dependent direct binding assays by serial dilution of
the precomplexed SC18, NY18, and AV18 HAs were per-
formed to establish their relative glycan binding affinities
(Fig. 3). The cooperativity factor n and the apparent binding
constant Kd' were calculated based on the linearized Hill
equation (see Materials and Methods and SI Fig. 7) used to
model the binding data (Table 1). The R2 value >0.95 for all
of the glycan binding data indicates a good fit to the linearized
Hill model. The value of n 1 reflects the positive cooper-
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Fig. 2. Binding assay to capture multivalent HA-glycan interactions. Shown
is a comparison of binding signals between sequential binding assay and
precomplexation of HA units with primary (pAb) and labeled secondary (sAb)
antibodies. The conditions of the sequential assay (see Materials and Meth-
ods) favor the formation of HA/pAb/sAb in a 1:1:1 ratio. Despite the abun-
dance of the labeled sAb (1 per HA unit) the minimal binding signals observed
even at a high HA concentration of 40 gg/ml supports the low affinity binding
of a single glycan to a HA unit (cyan circle). On the other hand, the conditions
for precomplexation of HA/pAb/sAb in a ratio of 4:2:1 favor the spatial
arrangement of four HA units per precomplex. This spatial arrangement
enhances the glycan binding signals via multivalency as shown by at least an
8-fold increase in binding to 6'SLN-LN given that there are four binding events
(each event shown by a cyan circle) per precomplexed HA unit.
arrangement of multiple HA units and the binding of a HA
unit to a single glycan. Whereas SC18 HA showed high binding
affinity to the single long a2-6 glycan (Kd' = 5.5 pM), AV18
HA showed the reverse trend with almost no a2-6 binding and
high a2-3 binding affinity (Ka' = 5 pM). On the other hand,
whereas the long a2-6 binding of NY18 HA was almost
identical to that of SC18 HA at saturating HA concentrations
(Fig. 3), the binding affinity to long a2-6 (Kd' = 6 nM) was
significantly lower than that of SC18 HA. These observations
correlate with the differences in molecular interactions of
SC18, NY18, and AV18 with a2-3 and a2-6 oligosaccharides.
Binding of SC18 and NY18 to Human Upper Respiratory Tissues. The
remarkable differences in the binding affinities of a2-6 and a2-3
(from above) of SC18 and NY18 HA render them ideal lectin-
like probes for investigating HA binding to diverse physiological
glycans present in human upper respiratory tissues. Human
tracheal sections were used to explore the binding pattern of
SC18 and NY18 HA to the physiological glycans. Although both
SC18 and NY18 bind to the apical side of the trachea (Fig. 4),
the pattern and distribution of the tissue binding of the two HAs
differ significantly. Notably, SC18 binding to the apical side of
the trachea appears more restricted when compared with the
well distributed binding of NY18. NY18 HA also shows binding
to the internal region of the trachea (that are known to express
a2-3 glycans), consistent with its direct binding to a2-3 glycans
(Fig. 3). To further investigate the differences in apical binding
of SC18 and NY18 HAs, costaining of tracheal tissues were
performed with these HAs and Jacalin (a marker for goblet
cells). This costaining demonstrated that whereas SC18 HA
predominantly binds to goblet cells (expressing a2-6), NY18 HA
showed minimal binding to these cells (Fig. 5).
Discussion
Glycan arrays comprising many distinct oligosaccharide motifs
have been used to investigate the glycan binding of WT and
mutant H1, H3, and H5 HAs (15-17). Despite these advances,
interpretation of glycan receptor specificity that leads to human
adaptation and transmission has remained challenging. This is
caused, in large part, by a general notion that glycan-protein
Srinivasan et al.
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Fig. 3. Dose-dependent direct glycan binding of SC18, NY18, and AV18 HA. (A-C) The binding signals (expressed as percentage of maximum) of SC18, NY18,
and AV18, respectively, in the dose-dependent direct binding assay. SC18 HA shows binding signals only to the long a2-6. At saturating HA concentrations (40
ykg/ml), both SC18 and NY18 HA show identical binding to long a2-6, and NY18 HA also shows high binding signals to long a2-3. On the other hand, AV18 HA
shows a reverse trend (in comparison with SC18 HA) of high-affinity a2-3 binding and minimal a2-6 binding. (D) Comparison of the long a2-6 (6'SLN-LN) binding
of SC18, TX91, and Mos99 HAs with that of NY18 HA.Whereasthe long a2-6 binding signal of NY18 HA approaches that of the other HAs at high concentrations,
the binding curve of NY18 HA over the entire concentration range indicates that it has a dramatically lower long a2-6 binding affinity. Human-adapted SC18
and TX91 H1N1 viruses transmit efficiently in the ferret model (12). Human-adapted Mos99 H3N2 virus is a vaccine strain.
interactions are relatively weak and nonspecific. Consequently,
the glycan binding specificity for HA has largely been established
by using very high protein concentrations. High HA concentra-
tion may be useful to establish binders versus nonbinders but it
imposes serious limitations on defining appropriate quantitative
measurements to establish relative glycan binding affinities of
HA. For example, at high concentrations, the typically used
first-order binding kinetics assumptions (pertaining to HA/
glycan ratio) would not be satisfied. To accurately quantify the
relative glycan binding affinities between HAs, it is essential to
be at the "appropriate" HA concentration range. Several key
parameters, which include the spatial arrangement of multiple
HA units, the surface glycan density (such as on a plate versus
printed array), and the ratio of HA to glycan need to be taken
into account when determining the appropriate HA concentra-
tion range for a given glycan array assay. Furthermore, compar-
ing the glycan binding of different HAs at any single concen-
tration point does not accurately capture the binding specificity
Table 1. Quantifying the relative a2-3 and a2-6 binding
affinities of SC18, NY18, and AV18 HAs
6'SLN-LN
that is established over a concentration range. In this study, the
specific spatial arrangement of the glycans (spacing imposed by
biotin-avidin system) and the HA (imposed by precomplexation
of HA units) in tandem with the dose-dependent glycan binding
assay was able to overcome these challenges. Most importantly,
the concentration range used to determine the binding affinity
parameters (n and Kd') is such that the glycan is in excess of the
HA as would be expected in physiological conditions. This point
is important for not only HA-glycan interactions, but also for
glycan binding proteins in general. The observations presented
in this study call for the reconsideration of the published results
on glycan specificity based on high protein concentrations. The
SC18HA/l P NY18 HA/ P1
3'SLN-LN
H1N1 HAs n Kd' n Kg
SC18 1.3 5.5 pM n.b. n.b.
NY18 1.2 6.3 nM 1.3 50 pM
AV18 0.9 1 yLM 1.3 5 pM
Relative binding affinities of SC18, NY18, and AV18 HAs to representative
long a 2-3 and a 2-6 glycans. n.b. indicates no binding. The parameters n and
Kd' were determined as described in Materials and Methods and elaborated
in SI Fig. 7. These parameters were obtained to purely quantify the relative
binding affinities of the HAs, and hence their absolute values should be
viewed only in this context.
Fig. 4. Binding of SC18 and NY18 HAto human tracheal sections. The apical
side of the tracheal epithelia is indicated by white arrows. The binding pattern
of SC18 HA is localized around specific regions on the apical side; on the other
hand, NY18 HA shows well distributed apical binding pattern (HA in green
against PI in red). Furthermore, NY18 HA also shows significant staining on the
inner regions of the epithelia that express a2-3 glycans (indicated by MAL-Il-
staining patterns) (data not shown). (Magnification: x25.)
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NY18 HA I Jacalin
Fig. 5. Human tracheal costaining of SC18 and NY18 HA with Jacalin. The
apical side of the tracheal epithelia is indicated by white arrows. The distinct
apical binding patterns of SC18 and NY18 (in Fig. 4) are further elaborated by
costaining the HAs (red) with Jacalin (green), a marker for goblet cells. The
images were taken at x25 magnification, and representative regions of the
apical side are enlarged for clarity. The significant costain of SC18 HA with
Jacalin (yellow) indicatesthat SC18 HA predominantly bindsto goblet cells on
the apical side of the epithelia. On the other hand, the binding pattern of
NY18 HA has minimal overlap with that of Jacalin, indicating that it does not
bind to goblet cells on the apical side of tracheal tissue.
approach described here can be readily extended to any glycan
array platform to quantitatively investigate protein-glycan
interactions.
At high HA concentrations, SC18 and NY18 HA display no
differences in their binding to long a2-6 glycan. The only difference
between SC18 and NY18 at saturating HA concentrations is the
additional binding to a2-3 glycans for NY18 HA. As the a2-3
binding of SC18, NY18, and AV18 shows inverse correlation with
the transmissibility, a probable conclusion from these data are that
the loss of a2-3 binding specificity is a critical factor for transmis-
sion. However, AfIexas/36/91 (TX91), a mixed a2-6/a2-3 binding
virus similar to NY18, transmitted efficiently in ferrets (12). The
dose-dependent direct binding of TX91 and A/Moscow/10/99
H3N2 (Mos99; a mixed a2-6/a2-3 binding human-adapted H3 HA)
compared with that of SC18 and NY18 clearly shows that the high
affinity binding to long a2-6 glycan is a common feature for SC18,
Tx9l, and Mos99, but not for NY18 (Fig. 3). This common feature
of specificity to long a2-6 glycan is independent of specificity to a2-3
glycans. Thus, this study corroborates the observation that the
high-affinity binding to long a2-6 glycans, which are extensively
expressed in the upper respiratory tissues, is a critical determinant
not only for HA human adaptation, but also for influenza virus
transmission.
The critical role of the long a2-6 glycans as physiological
targets for influenza A virus infection and transmission also
highlights the role of biosynthetic enzymes involved in synthe-
sizing these glycans in addition to the a2-6 sialyltransferases.
Specifically, the P4GalTs (,61-4 galactosyltransferases) and
133GlcNAcTs (1-3 N-acetylglucosaminyl transferases) are in-
volved in synthesizing multiple lactosamine repeats characteris-
tic of long a2-6 glycans. The regulation of the expression of these
glycosyltransferases would not only play a critical role in the viral
tropism but it would also enable better selection pressure
strategies to understand the evolution of mutations in HA that
would lead to efficient human adaptation and human-to-human
transmission.
Differential binding of SC18 and NY18 to the diverse physi-
ological glycans present in the human upper respiratory tissues
further substantiates the direct binding studies. The narrow
binding of SC18 to goblet cells motivates future investigations
into the cellular tropism of human-adapted viruses. This obser-
vation is consistent with a report by Matrosovich et aL (18), who
demonstrated that human-adapted H1 and H3 virus strains
SC18 HAI Jacalin
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preferentially infect nonciliated cells and avian viruses prefer-
entially infect ciliated cells. They also suggested that such
differences in the cellular tropism of the viruses could explain
the differences in their efficiency of human-human transmis-
sion. Furthermore, the binding of SC18 HA to goblet cells taken
together with its long a2-6 binding specificity correlates with its
localized binding to the apical side of the tracheal tissue and also
suggests the expression of long a2-6 glycans in the goblet cells.
On the other hand, SNA-I that binds to both short and long a2-6
glycans shows more extensive apical side tracheal binding (11).
Therefore, SC18 HA could potentially be a more effective
lectin-like probe for investigating the distribution of long a2-6 as
compared with SNA-I.
In conclusion, we have shown how quantitative differences in
the HAs binding to long a2-6 glycans correlate with the observed
differences in viral transmission. The study of the 1918 viruses
varying only in their HA genes and having different transmission
efficiencies served as a good model system for establishing this
correlate. Given the potential threat of a pandemic from cur-
rently circulating avian H5N1 viruses, the approach presented
here can aid in the screening of H5N1 HA mutants that could
lead to human adaptation and transmission of these deadly
viruses.
Materials and Methods
Cloning, Baculovirus Synthesis, Expression, and Purification of HA. The soluble
form of HA was expressed by using the baculovirus expression vector system
(BEVS). SC18 baculovirus [generated from pAcGP67-SC18-HA plasmid (14, 15)]
was a gift from James Stevens (Centers for Disease Control). pAcGp67-
NY18-HA and pAcGp67-AV18-HA plasmids were generated from pAcGP67-
SC18-HA by [Asp-225-Gly] and [Asp-190-Glu, Asp-225-Glyl mutations respec-
tively. Mutagenesis was carried out with the QuikChange multi site-directed
mutagenesis kit (Stratagene). The primers used for mutagenesis were de-
signed by using the web-based program, PrimerX (http:/bioinformatics.org/
primerx) and synthesized by IDT DNA Technologies. NY18 and AV18 baculo-
viruses were created from pAcGP67-NY18-HA and pAcGP67-AV18-HA
constructs by using the Baculogold system (BD Biosciences) according to the
manufacturer's instructions. The baculoviruses were used to infect 300-ml
suspension cultures of Sf9 cells (BD Biosciences) cultured in BD BaculoGold
Max-XP Insect Cell medium (BD Biosciences). These cultures were monitored
for signs of infection and harvested 4-5 days postinfection. BEVS produces
trimeric HA, which provides multivalent binding to glycans. The soluble form
of HA was purified from the supernatant of infected cells as described (14).
Briefly, the supernatant was concentrated by using Centricon Plus-70 centrif-
ugal filters (Millipore), and the trimeric HA was recovered from the concen-
trated cell supernatant by using affinity chromatography with columns
packed with Ni-NTA beads (Qiagen). Eluting fractionsthat contained HA were
pooled and dialyzed overnight with a 10 mM Tris-HCI, 50 mM NaCl buffer (pH
8.0). Ion exchange chromatography was then performed on the dialyzed
samples by using a Mono-Q HR10/10 column (GE Healthcare). The fractions
containing HA were pooled together and subjected to ultrafiltration by using
Amicon Ultra 100 K NMWL membrane filters (Millipore). The protein was then
concentrated and reconstituted in PBS. The purified protein was quantified by
using Bio-Rad's protein assay.
Dose-Dependent Direct Glycan Binding of HA. To investigate the multivalent
HA-glycan interactions a streptavidin plate array comprising representative
biotinylated a2-3 and a2-6 (short and long) was used. The spatial arrangement
of the glycans in the wells of this plate array favors binding to only one of the
three HA monomers in the HA unit. The glycan spacing and the HA unit size
limit binding of the HA unit to a single glycan in the ELISA-type binding assay,
which involves the sequential application of HA unit, primary and secondary
antibodies (see below). Conversely, the precomplexation of HA units (see
below) with primary and secondary antibodies (HA/primary/secondary = 4:2:1
ratio) facilitates a specific spatial arrangement of four HA units. This precom-
plexed unit therefore enabled the investigation of the effects of the relative
spatial positioning of multiple HA units on the glycan binding affinity via
multivalency.
Streptavidin-coated high binding capacity 384-well plates (Pierce) were
loaded to the full capacity of each well by incubating the well with 50 pl of 2.4
pM biotinylated glycans overnight at 4'C. The biotinylated glycans [a2-3
sialylated lactosamine (3'SLN), a2-6 sialylated lactosamine (6'SLN), 3'SLN-LN,
........ ....  .............................................................................................................................................................................. .  . ...... ..........  
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6'SLN-LN and 3'SLN-LN-LN] were obtained from the Consortium of Functional
Glycomics (www.functionalglycomics.org) through their resource request
program. LN corresponds to lactosamine (GalI31-4GIcNAc) and 3'SLN and
6'SLN correspond to Neu5Aca2-3 and Neu5Aca2-6 linked to LN, respectively.
Excess glycans were removed through extensive washing with PBS. For the
ELISA-type sequential binding, the glycan-coated wells were incubated for 2 h
with HA at a concentration of 40 pg/ml (typical high concentrations used in
glycan array experiments) in PBS containing 1% BSA and subsequently washed
extensively with PBS-Tween followed by PBS. This process was followed by
incubation with the primary antibody (mouse anti 6x His tag IgG) at a
concentration of 5 jg/ml in PBS containing 1% BSA for 3 h at room temper-
ature and repeating the above wash steps. The wells were finally incubated
with a 2 g/mIl solution of the secondary antibody (HRP-conjugated goat anti
mouse IgG) for 1 h at room temperature. In the case of dose-dependent
precomplexed HA experiments, a stock solution containing appropriate
amounts of His-tagged HA protein, primary antibody (mouse anti 6x His tag
igG) and secondary antibody (HRP-conjugated goat anti mouse igG (Santa
Cruz Biotechnology) in the ratio 4:2:1 and incubated on ice for 20 min.
Appropriate amounts of precomplexed stock HA were diluted to 250 Pl with
1% BSA in PBS. Fifty microliters of this precomplexed HA was added to each
of the glycan-coated wells and incubated at room temperature for 2 h
followed by the above wash steps. The binding signal was determined based
on HRP activity by using Amplex Red Peroxidase Assay (Invitrogen) according
to the manufacturer's instructions. Appropriate negative controls were in-
cluded, and all assays were performed in triplicate.
Previously, dose-dependent direct binding assays using the above precom-
plexation were performed to establish binding specificity of human-adapted
HAs to long a2-6 (11). These assays were performed by incubating different
concentrations of HA with appropriate concentrations of primary and sec-
ondary antibodies (to achieve the 4:2:1 ratio stated above). However, in this
method of precomplexation, the binding kinetics potentially limit the forma-
tion of HA precomplex at low HA concentrations (<5 pg/ml). To accurately
quantify the relative binding affinities, it is important to be able to measure
binding of the precomplex at a lower concentration range (0.05 to 5 pg/ml) (SI
Fig. 8). Toward addressing this issue, the binding assay was modified by
preparation of the precomplex at high HA concentration followed by serial
dilution of the stock (as described above).
To quantify the binding affinity (for the above precomplexation assay),
binding parameter Kd' is defined and calculated based on the following
model. The typical form of the Hill equation is used to represent the multi-
valent binding
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from US Biological. Tissue sections were deparaffinized, rehydrated, and
preblocked with 1 % BSA in PBS for 30 min at room temperature. HA-antibody
precomplexes were generated by incubating recombinant SC18 and NY18
proteins with primary (mouse anti 6x His tag; Abcam) and secondary (Alexa
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BSA-PBS to different final HA concentrations. Tissue binding studies were
performed by incubating tissue sections with the diluted HA-antibody com-
plexes for 3 h at room temperature. To visualize the cell nuclei, sections were
counterstained with propidium iodide (PI) (Invitrogen; 1:100 in TBST) for 20
min at room temperature. For costaining assays, tissues were deparaffinized,
rehydrated, and coincubated with FITC-labeled Jacalin [Vector Labs; 10 ptg/ml
in PBS with 0.05% Tween 20 (PBST)] and HA-antibody precomplexes (gener-
ated as described above with Alexa Fluor-546 goat anti-mouse IgG as second-
ary antibody and diluted in PBST) for 3 h at room temperature. Sections were
then washed and viewed under a Zeiss LSM510 laser scanning confocal
microscope.
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